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SUMMARY 
 Local recurrence of malignant brain tumor, glioblastoma multiforme (GBM) is seen 
as one of the major reasons for the limited improvement in mean survival rate of patients 
despite post-operative aggressive chemotherapy. Hence, sustained drug administration at 
high therapeutic levels and deeper penetration of the drug into the tumor are paramount to 
ensuring substantial improvements in clinical outcomes. Even though, polymeric local 
drug delivery systems developed over the years have attempted to address this therapeutic 
challenge, sufficient drug penetration and sustainability issues still remain as they are 
controlled by transport properties of the drug, type of polymeric carrier and geometry of 
the implant. In this study, we have developed biodegradable micro/nano-structured 
implants delivering paclitaxel that are able to provide highly sustainable therapeutic 
paclitaxel levels to the tumor site and evaluated the efficacy of the implants. 
Additionally, a cell microencapsulation system was developed for delivering anti-
angiogenic PEX protein to treat GBM and evaluated bio-molecular mass transport across 
the microcapsule membrane.  
 
 The chemotherapeutic drug paclitaxel possessing favorable transport properties in the 
brain/tumor tissue was encapsulated in two types of poly(D,L-lactic-co-glycolic) acid 
(PLGA) based implants. Firstly, paclitaxel-loaded PLGA was micro/nano-structured into 
fibers diameters ranging from micron to nanometer using electrospinning technique. The 
dependence of fiber diameter on the drug release was observed and hence nanofibers 
demonstrated higher drug release rate. However drug release was near zero-order with 
small initial burst unlike other devices due to the multilayered structure.  Secondly, 
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paclitaxel-loaded PLGA microspheres were entrapped in calcium cross-linked alginate 
matrix (beads) using electrospray technique and ionotropic gelation.  Drug release from 
the beads was dependent on the gelation time, gelling bath concentration and microsphere 
loading as they controlled the disintegration. The presence of alginate matrix as a barrier 
resulted in negligible initial burst, but a near zero-order release profile. Both the fiber and 
bead implants were therapeutically efficacious in treating C6 glioma both at in vitro 
cellular level and in vivo subcutaneous tumor level.  
 
 Out of the fiber and bead implants, four formulations (F2, F3, H80, and M80) were 
screened based on the in vitro release profiles for the subsequent pharmacokinetic and 
anti-tumor efficacy evaluation in an intracranial nude mice xenograft model of GBM. 
Enhanced, therapeutic paclitaxel penetration (~1 µM) in the mouse brain up to 5 mm 
from the implant site even after 42 days post-implantation from F3 and H80 was 
confirmed and deduced to be diffusion/elimination controlled. F3 and H80 demonstrated 
significant (~30 fold) tumor inhibition and significantly low tumor proliferation index 
after 41 days of treatment in comparison to sham and placebo controls.  
 
 In another study, microcapsules with calcium cross-linked alginate core and genipin-
chitosan membrane shell (GCA) were fabricated using an electrospray process followed 
by chitosan co-acervation and genipin cross-linking. The primary objective however, was 
analyzing the effects of the membrane characteristics and microcapsule size on bio-
molecular mass transport across these microcapsules using mathematical models based 
on the balance of bio-molecular chemical potential. Compared to other microcapsules, 
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the GCA microcapsules possess greater perm-selectivity for they allow diffusion of small 
molecules and proteins but completely exclude large antibodies. These results elucidate 
the implications of controlling membrane properties and microcapsule size to realize 
favorable transport phenomena of bio-molecules. 
 
 In summary, the micro/nano-structuring of polymeric implants using EHDA 
technique could enhance the paclitaxel availability at the implant surface resulting in 
deeper drug penetration in the tumor tissue and hence these implants could be potential 
drug delivery devices for local chemotherapy to treat malignant brain tumors. 
Additionally, GCA microcapsules possessing greater perm-selectivity and capsular 
integrity could be used to encapsulate terminally differentiated cells to express and 
release proteins with anti-angiogenic and anti-tumoral properties to treat brain tumors.  
  
Keywords: Paclitaxel-PLGA micro/nano-fibers, alginate hydrogel, microspheres, 
malignant glioma, local chemotherapy, local anti-angiogenic therapy, drug/protein 
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1.1 Background and Motivation 
 The interdisciplinary domain constituting chemical engineering, materials science and 
pharmaceutical science is popularly termed as “drug delivery”. This technology has 
exhibited myriad possibilities and promises in the realm of cancer therapy. The 
traditional cancer treatment still comprises surgical removal of the tumor in most cases. 
This is typically followed by systemic injection of anti-cancer drugs to kill the tumor 
which is termed as “systemic chemotherapy”. Depending on the drugs, such a treatment 
is often aimed at inhibiting tumor cell proliferation, invasion, migration or recurrence. 
Another direction of tackling the tumor is to cut down its blood supply. This is often 
achieved by attacking the endothelial cells surrounding the tumor there by preventing the 
growth of blood vessels or “angiogenesis” by using drugs, proteins or genes. Such a 
therapy is termed as “anti-angiogenic therapy”. Thus, the combination of chemotherapy 
and anti-angiogenic therapy promises to be more effective than single modality therapy.   
 
 Efficacy of systemic chemo/anti-angiogenic therapy is often challenged by the limited 
delivery of therapeutic agents to the target site and inability to reach therapeutic levels of 
concentration. These limitations could be due to various factors such as the presence of 
physiological barriers, lack of specificity and rapid drug clearance. More importantly, 
modern clinical pharmacology necessitates that the tumor gets sustainable exposure to 
therapeutic agents over a prolonged period of time to prevent disease or tumor recurrence 
and aid in patient recovery. The use of drugs at very high concentrations to achieve 
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efficacy could result in unavoidable systemic toxicities and hence calls for a crucial 
control of drug levels below toxicity limits. An engineering solution to overcome the 
limitations of systemic therapies was addressed by a novel treatment modality known as 
“local therapy”. Contrary to systemic administration, local chemo- or anti-angiogenic 
therapy is performed by implanting biodegradable polymeric drug delivery devices 
encapsulating the therapeutic agents at the target site. This allows continuous release of 
agents at therapeutic concentration levels directly to the target site (usually tumor area). 
Local chemotherapy has outweighed its limitation (invasiveness) and hence 
biodegradable polymer matrices are widely used to encapsulate various drugs/proteins 
with the possibility of tailoring release rate through controlled polymer degradation.  
 
 Drug delivery to the brain represents one of the most challenging areas of research to 
date. Specifically, local chemotherapy to treat malignant brain tumors has been addressed 
in this research thesis from an engineering/materials science perspective. The reasons for 
choosing drug delivery to treat brain tumors are varied but highly critical. Firstly, 
malignant brain tumors (gliomas) represent approximately 32% of all primary central 
nervous system (CNS) neoplasms (CBTRUS, 2005-2006; Reardon et al., 2006) and GBM 
is the most common type. GBM being characterized by aggressive proliferation of 
undifferentiated cells, pervasive invasion into distant healthy brain tissue and a high 
penchant to recur is among the most recalcitrant tumors to be treated efficiently. 
Secondly, the presence of the blood-brain-barrier (BBB) deters the penetration of most 
chemotherapeutic agents into the brain resulting in inefficacious treatments. 
Consequently, an estimated worldwide annual mortality of nearly 42,000 is caused by 
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malignant gliomas alone (Parkin et al., 2001) in spite of access to state-of-the-art 
imaging, neurosurgery, radiotherapy and chemotherapy. Patients diagnosed with GBM 
have a median survival time of around 3 months and most of them die within 6 months to 
2 years post diagnosis (Ohgaki et al., 2004; Ohgaki et al., 2005).  Unfortunately the 
efforts to improve survivability of GBM patients through systemic chemotherapy has 
been hampered by the presence of tight capillary cellular junctions of the BBB,  rapid 
drug elimination and neurotoxicity from high drug doses. Consequent efforts focused on 
overcoming the BBB limitation and an ingenious solution to bypass the BBB by locally 
implanting polymeric drug delivery devices to achieve sustained drug release for 
extended periods of time was developed. However, the need to develop polymeric drug 
delivery implants that possess features such as easy intracranial application, near-constant 
drug release for extended time periods facilitating high drug penetration into the tumour 
bed, slow sustained drug release resulting in low systemic and local toxicity, and bio-
compatibility still remains to be addressed. The critical factors that decide the efficacy of 
such implants are properties of the encapsulated drug, type of polymer and geometry of 
the implant. Properties of the encapsulated drug such as its molecular weight, diffusivity 
in the brain tissue and drug elimination constant are keys to determining the penetration 
distance of the drug in the brain tissue, whereas drug cytotoxicity is crucial to treatment 
efficacy. Selection of the polymer as the implant material is critical because of the 
desired properties such as biocompatibility, controllable degradation and cross-linking 
ability. The geometry of the implant and surface area to volume ratio play key roles in 
determining polymer degradation and drug release kinetics. In case of implants delivering 
anti-angiogenic proteins, there is an increasing need to protect the activity of the protein, 
Chapter 1                                                                                                          Introduction                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
4 
prevent protein denaturation and provide physiological, therapeutic concentration 
sustainably. Such protein delivery can be attained by cell microencapsulation where in 
cells (expressing the protein of interest) encapsulated in microcapsules provide 
physiologically active protein delivery. Nevertheless various challenges such as efficient 
immunoisolation, selection of suitable cell line, optimal mass transfer and mechanical 
stability of the implants, still exist in the development of such microcapsules.   
  
 The need for improved treatment efficacy in GBM patients and the inadequacy in 
clinically potential, local chemo/anti-angiogenic therapy implants led us take up this 
important research. In particular, an effort to develop implants for GBM chemotherapy 
and anti-angiogenic therapy applications was made in this study. For chemotherapy, two 
types of implants were developed to deliver paclitaxel, a well known chemotherapeutic 
agent. For anti-angiogenic therapy, a microcapsule system (GCA) comprising of calcium 
cross-linked alginate core and permeable genipin cross-linked chitosan membrane shell 
was developed to encapsulate terminally differentiating QM7 cells expressing PEX 
protein, an endogenous inhibitor of glioma angiogenesis, cell proliferation and migration.  
 
1.2 Objectives  
Specific objectives of this study are:  
Biodegradable implants for GBM chemotherapy:  
• To develop paclitaxel-loaded PLGA implants in the form of micro/nano-fibers using 
electrospinning process.  
 Physicochemical characterization of the implants. 
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 Study on the effect of PLGA co-polymer and fiber size on the in vitro 
paclitaxel release.    
 Study on the implant efficacy in terms of in vitro cytotoxicity against C6 
glioma cells.  
 Study on the implant efficacy in terms of in vivo C6 glioma subcutaneous 
tumor inhibition in mice.  
• To develop alginate hydrogel matrix entrapping paclitaxel-loaded PLGA 
microspheres in the form of beads using electrospray process in dripping mode. 
 Physicochemical characterization of the implants. 
 Study on the effect of microsphere loading, gelling bath concentration and 
gelation time on bead disintegration and in vitro paclitaxel release.    
 Study on the implant efficacy in terms of in vitro cytotoxicity against C6 
glioma cells.  
 Study on the implant efficacy in terms of in vivo C6 glioma subcutaneous 
tumor inhibition in mice. 
• To comprehensively evaluate the fiber and bead implants in an in vivo intracranial 
model in mice.  
 Comparative study of simulation and experimental data for the understanding 
and evaluation of pharmacokinetics of paclitaxel (delivered from the implants) 
in mouse brain.  
 Evaluation of therapeutic efficacy of the implants (with optimal 
pharmacokinetics) in treating an intracranial human glioblastoma xenograft 
model in mice.     
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Microcapsule implants for GBM anti-angiogenic therapy: 
• To develop PEX protein delivering GCA microcapsule system. 
 Study of the effect of genipin cross-linking time and microcapsule size on the 
mechanical stability and membrane permeability characteristics.  
 Study of bio-molecular mass transport across the genipin-chitosan membrane 
of the GCA microcapsule through kinetics experiment and modelling.   
 
Overall, the work was aimed at providing efficient and strategic drug/protein delivery 
implants for neurosurgeons to treat malignant brain tumors. 
 
1.3 Structure of the Thesis 
The report is divided into 8 chapters. Chapter 1 gives a brief introduction, motivation and 
objectives of the thesis. Chapter 2 provides a thorough literature review relevant to the 
topic. Chapter 3 reveals the research approach employed. The following two chapters 
give accounts on the development of two kinds of implants for GBM chemotherapy; 
Development, characterization and evaluation of paclitaxel-loaded PLGA micro/nano-
fiber implants are described in Chapter 4. Chapter 5 focuses on the development, 
characterization and evaluation of alginate hydrogel matrix entrapping paclitaxel-loaded 
PLGA microspheres. Chapter 6 contains the pharmacokinetic and therapeutic efficacy 
evaluation of the two implants in a complex and clinically relevant in vivo intracranial 
model. Chapter 7 discusses the development of GCA microcapsules followed by 
membrane and mechanical stability characterization and their effects on bio-molecular 
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transport. Chapter 8 consolidates the conclusions and proposes improvements along with 
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2.1 Malignant Glioma: What and how bad is it? 
 Neoplasms of the brain derived from the glial cells are generally termed as gliomas. 
Glioblastoma multiforme (GBM) represents the most common and aggressive type of 
malignant glioma and is classified as Grade IV by the World Health Organization 
(Kleihues et al., 2000). It is characterized by a diffusely infiltrating spread of 
undifferentiated cells arising in the lobar white matter or in the deep gray matter of the 
brain (Ohgaki et al., 2005). The following characteristics of GBM present critical 
treatment challenges: 1) tumor localization in the brain; 2) aggressive proliferation; 3) 
pervasive invasion into brain parenchyma; 4) high penchant to recur; 5) limited response 
to conventional therapy due to intrinsic resistance; 6) limited brain revival capacity; 7) 
presence of BBB restricting drug delivery; 8) edema and intracranial pressure due to 
tumor capillary leakage; 9) undesired neurotoxicity of anti-cancer agents (Chamberlain, 
2006). As a result, an estimated annual mortality of nearly 42,000 worldwide is caused by 
malignant gliomas alone (Parkin et al., 2001).  
 
2.2 Treatment Options for GBM 
2.2.1 Standard Therapy  
 Currently, standard therapy for GBM still remains conventional consisting of a gross-
total surgery of accessible tumor as depicted in Figure 2.1. A distinct demarcation of 
tumor from normal brain tissue never exists because of the invasive nature of GBM. Thus 
surgical resection does not completely remove the tumor and prevent recurrence in most 
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cases. Another reason for partial tumor de-bulking is the proximity of healthy brain 
tissue.   
 
Figure 2.1 Various therapeutic modalities for GBM (adapted from Raza et al., 2005). 
 
Although repeated resection could improve survival rate and remove hypoxic tissue, 
other factors such as insufficient clinical trials and bias in patient selection prevents the 
evaluation of its benefits (Chang et al., 2006). Until recently, surgery was followed by 
adjuvant therapies such as systemic chemotherapy and radiotherapy to improve the 
survival rate of the patients. However, the ubiquitous nature of GBM to recur has 
rendered a multitude of these therapeutic modalities largely inefficacious (Behin et al., 
2003). For instance, the median survival of patients with GBM with surgical intervention 
alone is 6 months with an extension to 9 months by an additional radiotherapy (Lesniak, 
2005).  
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2.2.2 Systemic Chemotherapy  
 An adjuvant therapeutic modality where in potent chemotherapeutic drugs are 
injected systemically (into the blood stream as shown in Figure 2.1) to bring about 
cytotoxic effects on the tumor cells. Different drugs act on the tumor cells differently 
depending on their mechanism of action. Chemotherapy generally brings about mitotic 
arrest of the tumor cells at a particular growth phase. However, systemic chemotherapy 
of most anticancer agents such as carmustine (Green et al., 1983; Walker et al., 1980), 
doxorubicin (von Holst et al., 1990), carboplatin (Poisson et al., 1991), 4-
hydroperoxycyclophosphamide (4-HC) (Longee et al., 1990), paclitaxel (Prados et al., 
1996; Chamberlain et al., 1999; Chang et al., 2001), 5-fluorouracil (Cvitkovic et al., 
1993), methotrexate (Dukic et al., 2000), etc have failed multiple clinical trials with no 
improvement in the patient survival rate. The limited clinical success of systemic 
chemotherapy to treat malignant gliomas can be attributed to the following: 1) The 
presence of three physiological barriers: the BBB, the blood-cerebrospinal fluid-barrier 
(BCB) and the blood-tumor-barrier (BTB); 2) rapid drug elimination; 3) systemic and 
neurotoxicity effects due to high drug dose; 4) intrinsic drug resistance; 5) tumor 
heterogeneity.  
 
 The BBB is the most important barrier constituting tight junctions of endothelial 
cells. The continuous lipid layer formed by the tight junctions of the BBB restricts 
penetration of large, charged, lipid-insoluble molecules from the bloodstream into the 
brain. Unfortunately most of the chemotherapeutic drugs possess the above properties 
and are thus prevented from penetrating the BBB to enter the brain parenchyma (Lesniak 
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2005). Additionally, the presence of P-glycoprotein (Pgp), a drug efflux transporter 
protein on the cerebral endothelium results in significant efflux barrier effects by 
excluding drugs from entering the CNS (Kemper et al., 2003). The BCB consisting of 
tightly bound choroid epithelial cells are reported to be strengthened by an organic acid 
transport system that prevents/controls the diffusion/penetration of molecules within the 
interstitial fluid (Lesniak 2005). Furthermore, the BTB made up of abnormally dilated, 
leaky and tortuous tumor microvasculature increases interstitial pressure resulting in an 
increase in net flow of fluid or edema that further inhibits diffusion/penetration of 
chemotherapeutic agents from the bloodstream to the brain parenchyma (Roose et al., 
2003). Secondly, systemic chemotherapy has shown serious limitations due to rapid 
elimination of the drugs and low selectivity. Typically, a chemotherapeutic drug 
administered intravenously would be eliminated from the body by transcapillary 
elimination and enzymatic or hydrolytic degradation (Fung et al., 1998) resulting in low 
drug levels at the target site. The non-targeting nature of systemic chemotherapy also 
contributes to the low drug levels. Finally, the use of high-dose chemotherapeutic drugs 
to overcome the rapid elimination and reach therapeutic local drug levels has resulted in 
serious systemic and neurological toxicities. For instance, patients receiving high dose 
carmustine developed serious toxicity such as cerebral oedema and visual loss (Shapiro et 
al., 1992). Another study reported systemic toxicities (thromboembolic) after intra-
arterial administration of cisplatin (Mortimer et al., 1992). Intravenous high dose 
paclitaxel administration in patients also resulted in central neurotoxicity (Chang et al., 
2001). Malignant gliomas exhibit marked cellular and genetic heterogeneity apart from 
possessing striking heterogeneity in cell surface protein expression and molecular defects 
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which make these tumors highly resistant to mono-therapeutic modalities (Reardon et al., 
2006). Unfortunately all these drawbacks have either hindered the delivery of 
chemotherapeutic agents locally in therapeutic levels and sustainably or resulted in 
inefficacious treatments. Strategies aimed at overcoming these limitations have since then 
become a major focus of brain tumor research.  
 
2.2.3 Alternative Routes for Chemotherapy  
 Glioma tumor heterogeneity and the resultant drug resistance have been partially 
addressed using medical approaches such as identifying critical molecular targets and 
treatment modalities. However, till today the most critical factor affecting the success of 
any kind of therapy is the barrier posed by the BBB and hence various medical, 
pharmaceutical and engineering approaches have been developed. Some of the innovative 
approaches include: 1) Increasing the drug permeability through the BBB; 2) Disrupting 
the BBB; and 3) Bypassing the BBB. To enhance the drug permeability, several methods 
have been employed. Chemical modification of chemotherapeutic agents for instance, 
carmustine into its lipophilic variants (CCNU and methyl-CCNU) increase lipophilicity 
and has been reported to modestly improve survival in patients with glioma (Loo et al., 
1966) probably due to ready binding of lipophilic agents to plasma proteins reducing 
their concentration in the CNS (Lesniak 2005). Alternatively, the lipophilicity could be 
changed by encapsulating the drug in nanoparticulate systems, such as liposomes, 
micelles, and polymeric systems (Kreuter 2001) which could traverse the BBB. Recent 
developments in using new transport systems such as receptor-mediated transport with 
monoclonal antibodies and inhibiting drug efflux using PgP inhibitors have also drawn 
Chapter 2                                                                                                  Literature Review                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
13 
attention. Disruption of the BBB, on the other hand involves infusion of hyperosmolar 
agents such as mannitol (Groothuis 2000), bradykinin agonist RMP-7 (Elliott et al., 1996) 
which results in acute dehydration of the endothelial cells, cell shrinkage, widening of 
tight junctions with an increase in the selective uptake of the drug concerned. However, 
the nanoparticulate systems have limited targeting property to result in therapeutic drug 
levels locally and hence inefficacious. On the other hand, the disruption of the BBB 
brings about penetration of undesired molecules into the brain which could be detrimental 
to the patient.   
 
 The most direct strategy is to circumvent the BBB by means of administering drugs 
locally. Local drug administration could achieve therapeutic drug levels with 100% drug 
retention at the target site and reduced systemic toxicity. Moreover, malignant gliomas 
are incapable of metastasizing systemically, but are highly aggressive locally within CNS 
and are observed to locally recur within 2 cm of the original resection field (Geurin et al., 
2004). This feature of glioma seems most befitting to test new therapies locally rather 
than systemically (Rainov et al., 2006). Intratumoral injection is the simplest method and 
involves direct infusion of the drug via a catheter into the tumor tissue. Various drugs 
such as doxorubicin (Voulgaris et al., 2002), bleomycin (Patchell et al., 2002) and 
endogenous inhibitors (Giussani et al., 2003) have been intratumorally administered and 
reported therapeutic advantages. Another approach is microdialysis (de Lang et al., 1995) 
where in an implanted probe communicates by diffusion with the brain’s extracellular 
space. However, these local delivery methods are dose-limited by neurotoxicity and have 
drawbacks such as uncontrolled and variable spatial distribution and drug concentration 
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in the target site. In addition, the half-life of the drugs within the brain tissue is short and 
frequent administrations are necessary to maintain therapeutic drug levels sustainably.  
 
 The most promising local drug delivery technique so far has been the biodegradable 
controlled release polymeric drug delivery implants. The simplest approach to overcome 
the BBB has been to circumvent it by implanting local drug delivery devices at the target 
site. The devices could be either non-biodegradable or biodegradable matrices 
encapsulating the drug. 
 
2.2.4 Non-biodegradable and biodegradable polymeric implants 
 The first non-biodegradable drug delivery matrix was made from ethylene vinyl 
acetate (EVAc) polymer for controlled release of macromolecules (Langer and Folkman, 
1976). Typically, these devices depend on the diffusion of the molecules through their 
porous matrix. However, the major limitation of non-biodegradable matrices is the non-
utility of the devices as a foreign body in the host after the drug has been completely 
released.  
 
 On the other hand, biodegradable polymeric implants with the functionality of 
degrading over time resulting in both controlled drug release and self-depletion in the 
host are very attractive for clinical applications. Thus their development for controlled-
release of many anti-neoplastic drugs, proteins and genes has been researched upon and 
has been exciting. Biodegradable polymers offer several advantages over diffusion-
controlled matrices because the matrix degrades at a steady rate, the drug can be released 
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over an extended period of time with a relatively steady concentration. Additionally, 
different polymers degrade differently. To be specific, some polymers degrade through 
surface erosion where as others by bulk erosion (Wang et al., 2002) and thus the choice 
of polymers in terms of degradation phenomena also could be used to tailor the release 
profile. Also by varying the relative ratios of monomers in the copolymer, the rate of 
degradation can be controlled. Finally the need for surgical removal of the polymer is 
eliminated (Ranade 1990). 
      
2.3 Local Chemotherapy by Polymeric Implants 
2.3.1 Biodegradable Drug Delivery Implants  
 Local chemotherapy using biodegradable polymeric implants is an adjuvant therapy 
to the conventional tumor debulking surgery and radiotherapy. Typically these devices 
are implanted intracranially into the tumor resected cavity of the brain following 
debulking surgery as depicted in Figure 2.2. These implants constitute a biodegradable 
polymeric carrier encapsulating the chemotherapeutic drug and can be in the form of 
wafers, microspheres, compressed discs, etc. They are efficient as the rate and sustenance 
of drug release can be manipulated with reduced risk of systemic toxicity through 
controlled degradation of the polymer matrices and selection of suitable materials with 
favourable release mechanisms.  
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Figure 2.2 Intracranial implantation of biodegradable drug delivery devices for local 
chemotherapy of GBM (adapted from Brem and Langer, 1996). 
 
2.3.2 Gliadel®
 Local intracranial drug delivery as chemotherapy for recurrent GBM was pioneered 
in a few pre-clinical and clinical trials using biodegradable polymeric wafers delivering a 
chemotherapeutic drug, carmustine in 1990s (Brem et al., 1991; Brem et al., 1994; 
Valtonen et al., 1997). These wafers were made of prolifeprosan 20 polymer with 3.85% 
(w/w) of carmustine and manufactured as Gliadel
 Wafers:  The Pioneer 
® wafers by MCI Pharma Inc., 
Bloomington, MN. Currently Gliadel® is the only type of interstitial chemotherapy 
implant licensed for local chemotherapy of recurrent GBM (Gallia et al., 2005). Since 
then many efforts have been made to investigate its efficacy. Brem and co-workers (Brem 
et al., 1991) showed an improved survival advantage of Gliadel® wafers over placebo in 
patients with recurrent malignant glioma. The study showed that the median survival for 
patients receiving Gliadel® wafers was 31 weeks in comparison to 23 weeks for patients 
with placebo wafers (p=0.006). In another randomized clinical trial, polymer-delivered 
carmustine significantly improved survival rates; patients with GBM in the active 
Chapter 2                                                                                                  Literature Review                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
17 
treatment group had a median survival time of 58.1 weeks compared to only 39.9 weeks 
for placebo-treated groups (Valtonen et al., 1997). More recently, a phase III multicenter 
study involving Gliadel® wafer treatment (in addition to surgery and external beam 
radiotherapy) in 240 patients showed that the median survival in the intent-to-treat 
population was 13.9 months for the Gliadel® treated group and 11.6 months for the 
placebo-treated groups with a 29% reduction in death risk in the treatment group 
(Westphal et al., 2003). Subsequently, studies were focused at augmenting the clinical 
effects of Gliadel® chemotherapy. 44 adult patients with newly diagnosed glioma were 
treated with locally implanted Gliadel® wafers showed a median survival of 12 months 
(Olivi et al., 2003). Also, the study confirmed that 20% carmustine wafers are relatively 
well tolerated with minimal systemic exposure.  
 
 Despite Gliadel’s demonstration of statistical benefit in prolonging survival, in 
maintaining neurological functions and performance status in patients with malignant 
glioma, the performance has been rather modest probably due to limited response of 
glioma patients to carmustine (Brem and Gabikian, 2001), Gliadel® associated 
complications like cerebral edema (Weber and Geobel, 2005) along with dose-limiting 
effects, short half life (<15 min) (Wang et al., 2002) and rapid transcapillary exchange 
due to high lipophilicity (Fleming and Saltzman, 2002). These limitations have since then 
led to many efforts in the development and exploration of other drug-polymer 
combinational implants.  
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2.3.3 Polymer-Drug Combinations 
 5-Fluorouracil (5-FU), a proven drug against various metastatic gastrointestinal 
cancers and other malignancies was successfully encapsulated into PLGA microspheres 
showing good release characteristics (Boisdron-Celle et al., 1995). When tested against 
established rat intracranial C6 glioma model, treatment with 5-FU loaded microspheres 
significantly decreased mortality while treatment with placebo and systemic 5-FU 
injection had no effect (Menei et al., 1996).  
 
 A chemotherapeutic and anti-angiogenic drug, suramin was incorporated in EVAc 
polymer and formed into triangular shaped implants. Intralesional polymer mediated 
delivery of suramin into 9L glioma model in Fischer 344 rats showed no significant 
survival with a mean survival of 14.2 ± 1 days for suramin treated group to 13.8 ± 2 days 
for the control group (p = 0.82) (Bellinzona et al., 2004).  
 
 Doxorubicin (DOX) incorporated into polyanhydride (PCPP-SA) polymer as 
compressed disc and interleukin-2 polymer microspheres (IL-2 MS) produced via the 
complex coacervation of gelatin and chondroitin sulfate was tested against intracranial 9L 
gliosarcoma cells in Fischer 344 rats (Hsu et al., 2005). Compared to control animals 
treated with empty microspheres and blank polymer, animals receiving IL-2 MS 
combined with DOX polymer (p<0.0000002) showed statistically significant 
improvement in survival. Doxorubicin loaded PCPP-SA polymeric cylindrical wafers 
were evaluated against intracranial 9L gliosarcoma in Fischer 344 rats. Results confirmed 
that animals receiving DOX had significantly extended survival compared to control 
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animals treated with no polymers or blank polymer (21 days vs. 34 days (p<0.01) for the 
3% DOX group and 45 days (p<0.0001) for the 5% DOX group) (Lesniak et al., 2005).  
 
 Carboplatin incorporated into biodegradable polymeric microspheres was reported to 
be released in vivo in nearly zero order kinetics and showed tolerable reaction in 
intracranially implanted animals (Chen et al., 1997). In another study, biodegradable 
anhydride polymeric devices were loaded with carboplatin and implanted into rat brains.  
Locally delivered carboplatin prolonged survival of rats infected intracranially with F98 
glioma cells and maximal treatment effect was seen with 5% loading, with 3-fold survival 
increase compared to intraperitoneal treatment (Olivi et al., 1996).   
 
 Recently, aclarubicin (ACL) loaded cationic-albumin pegylated nanoparticles 
(CBSA-NP-ACL) were tested for therapeutic potential against intracranial C6 glioma in 
rats (Lu et al., 2007). They showed that when the tumor rat model was subjected to 4 
cycles of 2 mg/kg of ACL in different formulations, a significant increase of median 
survival time was found in the CBSA-NP–ACL group compared with that of saline 
control animals, animals treated with NP–ACL and ACL solution.  
 
 4-hydroxyperooxycyclophosphamide (4-HC), the active metabolite of cytoxan was 
encapsulated into FAD-SA polymer matrix and used against intracranial F98 glioma in 
rat models (Judy et al., 1995) which was reported to extend the median survival from 
fourteen days for the controls to seventy-seven days for the FAD-SA-4-HC treated rats. 
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 Methotrexate (MTX) delivered from methylmethacrylate polymer pellet into rat 
brains harboring intracranial tumors demonstrated an improvement in survival (69%) 
over the controls (Rama et al., 1987). In another study, to slower MTX elimination rate, it 
was chemically conjugated with dextran and showed improved diffusion into the 
extracellular matrix (Dang et al., 1994).    
 
 These efforts are testimonial to the enormous potential of biodegradable polymeric 
local implants delivering various chemotherapeutic drugs for glioma chemotherapy. 
However, none of these devices have realized translational or clinical trials in human 
GBM patients even though they are biologically effective against glioma. The major 
reason for the therapeutic inefficacy could be due to limited penetration of the drug into 
the tumor tissue (Davis et al., 2009) owing to the drug’s transport properties in the tumor. 
Unfortunately, not much research has been directed towards understanding the role of 
transport properties of drugs and drug release rate (from implants) in brain tumor barring 
a few.     
 
2.4 Chemotherapeutic Drug Transport to Brain Tumors 
 The understanding of the roles of drug transport properties and drug release (from 
local implants) in deciding drug penetration in brain tumors and the subsequent treatment 
efficacy is paramount and is thus discussed in this section. The drug distribution in the 
brain/tumor (post release from polymeric implants) has been studied only by a handful of 
researchers either experimentally or using computer simulations/models or both. Studies 
on drug distribution in the brain tissue post release from polymeric wafers by employing 
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a one-dimensional model was initiated (Saltzman and Radomsky, 1991) and showed that 
rapid elimination of drugs via brain capillaries significantly reduced drug distribution in 
the brain. In another study, pharmacokinetic analysis of interstitial delivery of various 
drugs from polymeric implant in monkey brain was investigated by comparing the 
experimental data and a mathematical model (Fung et al., 1998). The model assumed 
negligible convection in the brain and diffusion and elimination were important. They 
reported exponential drop in the drug concentration from the polymer/tissue interface. 
Effective penetration of carmustine in the brain because of steep concentration gradient is 
thus determined by the transport properties of the drug itself.  
 
 The role of convection could be accentuated due to edema after debulking surgery, 
but could only bring about larger short-term spread of the drug. The enhanced penetration 
of the drug centimeters away from the implant in some cases over the course of a week 
could be presumed to be due to the convection effects of cerebral blood flow or CSF flow 
(Fleming and Saltzman, 2002). The contribution of convection was accounted in an 
improved three-dimensional model of human brain tumor (Wang et al., 1999). They used 
Darcy’s law for flow through porous media and used to represent the interstitial flow 
through the porous brain tissue and showed that the interstitial convection has 
insignificant effect on carmustine penetration in the tumor.  In another study, realistic 
rabbit brain geometry was presented, but with the limitation of a two-dimensional 
geometry of anatomical features (Kalyanasundaram et al., 1997). A recent review 
reported the inadequacy in mechanistically realistic models which account for drug 
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transport in the implants as well in the brain/tumor tissue (Siepmann et al., 2006). Such 
models would efficiently predict the drug concentration-time profiles at the target site.  
 
 An interesting and elucidating research by Arifin et al. (2009) studied and compared 
the distribution/penetration of four chemotherapeutic drugs (paclitaxel, 5-fluorouracil (5-
FU), methotrexate (MTX) and carmustine) in human brain tumor using computational 
fluid dynamics simulation in a three-dimensional tissue geometry extracted from 
magnetic resonance imaging (MRI) of a glioma patient. Assuming ideal zero-order 
release kinetics, this study demonstrated that paclitaxel penetration into the brain tumor is 
at least two orders of magnitude greater than the other drugs owing to its slow capillary 
elimination and enhanced diffusion due to convective bulk flow resulting from post-
surgical edema (only during the early days of surgery). Additionally, the drug availability 
in the tumor resection cavity (that depends on the drug release rate of the local delivery 
implants) seems to be critical in deciding the penetration into the brain/tumor tissue.  
 
 Based on the above results, it can be inferred that the critical factors that decide the 
efficacy of intracranially implanted drug delivery devices are properties of the 
encapsulated drug, type of polymer and geometry of the implant. Properties of the 
encapsulated drug such as its molecular weight, diffusivity in the brain tissue and drug 
elimination constant are keys to determining the penetration distance of the drug in the 
brain tissue, whereas drug cytotoxicity is crucial to treatment efficacy. Selection of the 
polymer as the implant material is critical because of the desired properties such as 
biocompatibility and controllable degradation. The geometry of the implant and surface 
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area to volume ratio play key roles in determining polymer degradation and drug release 
kinetics. Hence, the need of the hour is to identify drugs with favorable transport and 
anti-tumor properties and develop polymeric drug delivery implants that possess features 
such as easy intracranial application, near-constant drug release for extended time periods 
facilitating high drug penetration into the tumour bed, slow sustained drug release 
resulting in low systemic and local toxicity, and bio-compatibility.  
 
2.4.2 Paclitaxel 
 Paclitaxel is a well known mitotic inhibitor used in cancer chemotherapy originally 
isolated from the bark of the pacific yew tree, Taxus brevifolia (Li et al., 1996). It is a 
highly hydrophobic drug with a solubility of 0.3 µg/ml in water (Goldspiel, 1997) and the 
chemical structure is illustrated in Figure 2.3. Its mechanism of action comprises of 
interaction with microtubule degradation resulting in increased mitotic arrest, decrease in 
cellular motility, disruption in intercellular signal transmission and binding to Bcl-2 
inducing apoptosis (Fang et al., 1998; Rodi et al., 1999). Despite its known potent 
cytotoxic activity against malignant gliomas in vitro (Cahan et al., 1994; Tishler et al., 
1992), paclitaxel administered systemically has failed to prolong survival of glioma 
patients (Prados et al., 1996; Chamberlain et al., 1999; Chang et al., 2001) mainly due to 
its hydrophobic nature and fast clearance from the plasma (Hempel et al., 2003) and poor 
absorption across BBB due to P-gP efflux effects (Kemper et al., 2003). Also, its 
commercial form, Taxol® formulated with a 50:50 mixture of non-ionic surfactant 
Cremophor EL and dehydrated ethanol is often associated with anaphylactic 
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hypersensitivity reactions and neurotoxicity when used systemically (Gelderblom et al., 
2001).  
 
Figure 2.3 Chemical structure of paclitaxel. 
 
Paclitaxel has been reported to possess higher cytotoxicity (low LD90
 Owing to its reported cytotoxicity and radio-sensitizing effects against glioma, but 
inefficacious treatment results from systemic administration, paclitaxel was seen as an 
interesting drug candidate for local chemotherapy. Additionally, paclitaxel is eliminated 
much slower than carmustine, 4-HC and most other drugs and has been shown to 
penetrate better in the brain/tumor tissue (Fung et al., 1998) when released from 
polymeric implants. Another study demonstrated that paclitaxel penetration into the brain 
 against glioma) 
in comparison to other drugs such as carmustine and 4-HC (Fung et al., 1998). This 
suggests that to obtain the same therapeutic effect, lower dose of paclitaxel should 
suffice.  
 
2.4.2 Paclitaxel-delivering Biodegradable Polymeric Implants 
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tumor is at least two orders of magnitude greater than the other drugs owing to its slow 
capillary elimination (Davis et al., 2009) following release from polymeric implants. As a 
direct reflection of these advantages, myriads of paclitaxel-delivering polymeric implants 
have been developed and evaluated and a review of these is presented next.  
 
 Following the phase I-II study using nitrosourea-delivering PCPP-SA discs, paclitaxel 
was incorporated into biodegradable PCPP-SA (20:80) matrix and evaluated to treat 
experimental glioma (Walter et al., 1994). The polyanhydride matrix was reported to 
release paclitaxel over a period of 40 days in vitro and penetrated up to 8 mm (from the 
implant site) in the rat brain after 30 days. However, another study also used PCPP-SA 
(20:80) to encapsulate and deliver paclitaxel, but reported contrasting in vitro release 
results showing very slow release (9% in 180 days) in PBS (Fung et al., 1998). In a 
separate study, paclitaxel and carmustine loaded into a polymer mixture of PCPP-SA and 
PLGA in the form of discs were evaluated against subcutaneous U-87 MG glioblastoma 
in nude mice and the results confirmed complete tumor remission in some animals and 
the potential of local paclitaxel delivery for improved chemotherapeutic effects 
(Vogelhuber et al., 2002).  
 
 In another study, paclitaxel-delivering Paclimer® implants based on polyphosphoester 
p(DAPG-EOP) microspheres mixed with polyethylene glycol (PEG-1000) were 
implanted intracranially into male Fischer 344 rats bearing intracranial rat 9L 
gliosarcoma tumor. The implants released active drug up to 30 days with good 
penetration into the rat brain (up to 5 mm) and doubled the median survival of treated 
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animals vs. control animals (Li et al., 2003). A liquid crystalline cubic phase 
encapsulating carboplatin and paclitaxel was developed and tested against intracranial 
F98 rat tumor which reported reduction in tumor. Brain tissue concentration of paclitaxel 
showed little or no drug in the vicinity of 3 mm beyond 7 days (von Eckardstein et al., 
2005) due to very low release rate.  
 
2.4.3 Poly (D,L-lactic-co-glycolic) Acid (PLGA)   
 Biodegradable polymeric carriers are as much important as the drugs themselves 
since the rate of drug release and its availability at the implant surface depends on the 
degradation of the polymeric matrix. Ideally, a zero-order drug release is desired that can 
maintain a constant drug concentration at the implant surface to aid diffusion of the drug 
into the tissue. Hence a precise control over the polymer degradation is very critical.  
 
 PLGA is a polymer approved by the FDA for clinical use as drug delivery or tissue 
engineering implants and confirms its biocompatibility (Shi et al., 2002). As depicted in 
Figure 2.4, it is a co-polymer of monomers polylactic acid and polyglycolic acid, PLGA 
possess an interesting relationship between its co-polymer ratio and degradation 
properties.  
 
Figure 2.4 Chemical structure of PLGA co-polymer. 
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PLGA degrades by hydrolysis of ester linkages in the presence of water and thus the 
hydrophilicity of the monomers controls the rate of degradation. Generally, the 
degradation process involves the by-products of various metabolic pathways in the body 
and hence causes minimal systemic toxicity. This makes PLGA an ideal carrier for 
encapsulating and releasing hydrophobic drugs. However, PLGA and related polymers 
have been shown to degrade non-uniformly (Granfils et al., 1996) making it difficult to 
prevent the sporadic dumping of high drug doses due to bulk erosion process. 
Micro/nano-structuring PLGA based drug delivery implants are an engineering solution 
to maintain the uniformity in the degradation of PLGA. Fabricating the drug-loaded 
polymers as microspheres, nanoparticles, micro/nano-fibers, micro-porous foams, etc 
would increase the surface area available for water penetration and polymer degradation 
by many folds. A few such PLGA based implants are reviewed here.  
 
 More recently, injectable PLGA 50:50 microparticles and glycerol tripalmitate based 
implants loaded with paclitaxel showed significantly increased drug release within 7 days 
due to elevated hydrolysis rate of PLGA and paclitaxel solubility in the presence of N,N-
diethylnicotinamide (DENA) (Elkharraz et al., 2006). Very recently a study examined the 
chemotherapeutic efficacy of PLGA based paclitaxel releasing implants (microspheres, 
spray dried microparticles and discs) against subcutaneous C6 glioma tumors in BALB/c 
nude mice (Naraharisetti et al., 2008). Results confirmed inhibited tumor growth over 
placebo control after 21 days for the different formulations.  
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 We have lately reported on the development of PLGA based microporous foams 
delivering paclitaxel in two studies. In the first study, by using a two-step production 
process of spray drying from DCM followed by supercritical gas foaming from CO2, 
dissolution of paclitaxel in a porous polymer matrix was achieved (Lee et al., 2009). 
Micro-porous foams also have short diffusion paths within the polymer and this allows 
for more rapid drug release. The release profiles for the micro-porous foams fabricated as 
3mm disks exhibit a relatively constant release rate up to 8 weeks in vitro. The micro-
porous foams with small pores (around 50 µm) and uniform pore structure were observed 
to be mechanically stable and could be used as an implant in surgical experiments. 
Therapeutic levels of paclitaxel were achievable in brain tissue even after 28 days up to 
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Figure 2.5 In vivo bio-distribution of paclitaxel in mouse brain released from F100 foam and 
F200 foam after 28 days of implantation. Each data point represents five samples (n = 5 animals) 
and error bars represent standard deviation (adapted from Lee et al., 2009). 
 
 In a follow up study, two types of PLGA co-polymers were utilized to fabricate two 
types of micro-porous foams with different drug loadings (Ong et al., 2008). The more 
hydrophobic PLGA 85:15 was used to fabricate F1 foam containing 5% (w/w) paclitaxel, 
whereas, F2 foam encapsulating 10% (w/w) paclitaxel was fabricated from PLGA 50:50 
as the drug carrier. These combinations were used to provide paclitaxel-delivering 
implants with different release rates and doses and evaluate their penetration in the rat 
brain.    
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Figure 2.6 In vivo bio-distribution of paclitaxel in the rat brain from the site of implantation of 
(A) 5% paclitaxel loaded PLGA 85:15 (F1) rods; (B) 10% paclitaxel loaded PLGA 50:50 (F2) 
rods. Each data point represents five samples (n = 5 animals). Error bars represent standard 
deviation (adapted from Ong et al., 2009).  
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 The results for the F1 and F2 foams shown in Figure 2.6, respectively, suggest that 
paclitaxel concentrations in the tissue could be sustained even up to 28 days after 
implantation. These results indicate that the rate of drug elimination is lower than the 
release of paclitaxel from the foam and could be justified by the fact that paclitaxel 
degradation half-life in the brain is reported to be 17,000 min (Fung et al., 1998). Also, 
after 28 days, paclitaxel levels beyond 3 mm from the site of implantation were observed 
to drop off by 500 times. Nonetheless, the paclitaxel concentrations observed were in the 
desired range of 1 ng/mg tissue (~1 µM) similar to the mean peak serum concentration 
for cancer chemotherapy reported (Sonnichsen and Relling, 1994; MicroMedex®
 Angiogenesis is the growth of new vasculature (blood vessels) to sustain the growth 
of gliomas and help them invade into normal brain tissue. It refers to an invasive behavior 
involving endothelial cell proliferation, adherence to extra-cellular matrix (ECM) and 
migration (Bello et al., 2001) and angiogenesis is potentially the rate limiting step of the 
tumor growth. In case of malignant gliomas, a distinct dependence on angiogenesis on 
tumor growth is often observed. The process involves mainly integrins and 
metalloproteinases among other growth factors, ECM proteins, adhesion receptors, and 
 
healthcare series) and consistent with the depth reached by Li et al., (2003) (5–7 mm) due 
to the tissue-binding nature of paclitaxel. These results suggest that sustained release of 
paclitaxel up to a month is achievable and thus the foams could be potentially utilized as 
implants for glioma chemotherapy in the future.  
 
2.5 Anti-angiogenic Therapy against Glioma 
2.5.1 Angiogenesis in Malignant Glioma 
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proteolytic enzymes (Blood and Zetter, 1990). The activities of these molecules are 
tightly regulated to lead to endothelial cell proliferation, cellular migration/invasion and 
even differentiation. If this delicate balance is disrupted, uncontrolled neo-vascularization 
can contribute to a number of pathological processes including tumor growth and 
metastasis. 
 
 Matrix metalloproteinases (MMPs) are a family of zinc-dependent matrix-degrading 
enzymes, which are able to degrade extracellular matrix (ECM) proteins (Mignatti and 
Rifkin, 1993). MMPs play a very critical role in regulating angiogenesis since inhibitors 
of the enzymes could block neo-vascularization by reducing MMP-directed proteolytic 
activities. In gliomas, MMP-2 is found most abundantly co-localized with integrin ανβ3 
(a receptor) on the surface of glioma and blood vessels (Brooks et al., 1996) due to the 
interaction of C-terminal hemopexin-like domain (CTD) of MMP-2 with integrin αvβ3. It 
has been reported that angiogenesis is also dependent on endothelial cell adhesion, 
mediated by αvβ3 (Brooks et al., 1994a). MMP-2 also known as human gelatinase-A 
(72kDa), thus localized can break down the interstitial components by directly cleaving 
collagen in a similar fashion to collagenase, a key step in angiogenesis (Minh et al., 
2001).  
 
2.5.2 Anti-angiogenesis in Malignant Glioma: Role of PEX Protein 
 Anti-angiogenesis is the inhibition of neo-vascularization or growth of new blood 
vessels using inhibitors affecting different pathways of angiogenesis and ultimately 
resulting in inhibiting glioma growth. Anti-angiogenic therapy involves the use of 
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negative regulators of cell proliferation, migration and angiogenesis, also known as anti-
angiogenic agents. A few known inhibitors such as angiostatin, endostatin, 
thrombospondin-1, PEX, and platelet factor-4 have been evaluated over the years (Rege 
et al., 2005). However, tumor hypoxia and blocking angiogenesis with inhibitors of 
VEGF-2 receptor has been shown to aid invasion (Kunkel et al., 2001). Hence the 
simultaneous blocking of angiogenesis and invasion could be beneficial to suppress 
glioma growth.  
 
 In this research, we focus on the interaction between MMP-2 and integrin αvβ3 which 
is one of the critical processes controlling angiogenesis and invasion. This interaction is 
regulated by PEX, a naturally occurring, non-catalytic fragment derived from MMP-2, 
containing the hemopexin-like domain (CTD). By possessing a similar domain as MMP-
2, PEX is able to interact and bind readily onto MMP-2 in a dose-dependent manner 
(Brooks et al., 1998). Thus through competitive binding against MMP-2 for integrin 
αvβ3, the cellular concentration of the bound MMP-2 is reduced, consequently, blocking 
cell-mediated collagen degradation by MMP-2 and disrupting angiogenesis (Gohlke et 
al., 1996). Moreover, PEX is known to inhibit glioma angiogenesis, cell proliferation and 
migration (Bello et al., 2001; Brooks et al., 1998) and thus is a powerful molecule to 
achieve simultaneous blocking of angiogenesis and invasion.  
 
2.5.3 Systemic Anti-angiogenic Therapy against Malignant Glioma 
 Many anti-angiogenic agents such as angiostatin, endostatin, PEX, thrombospondin-1 
and platelet factor-4 are being evaluated in clinical trials and many in experimental 
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studies. However, the therapeutic efficacy of these inhibitors depends on their daily large 
dose (grams of purified protein) administration, apart from a sustained administration to 
prevent local recurrence. There are two critical disadvantages of this systemic approach; 
(1) huge cost involved in the purification of large quantities of protein, daily 
administration resulting in low patient compliance; 2) insufficient local concentration at 
the target site due to rapid clearance and diffusion limitations of large proteins in the 
tissue. For instance, endostatin (20 kDa) dose of 2.5 mg/kg need to be administered on a 
daily basis (O’Reilly et al., 1997) and 2 mg/kg of PEX was used in a pre-clinical study 
(Pluderi M et al., 2003), which accentuates the huge costs involved in the purification of 
these anti-angiogenic proteins. Proteins are found to permeate across the brain capillary 
very slowly and systemically administered proteins do not cross the BBB due to low 
plasma half-life, large molecular weight and low diffusion coefficient (Haller and 
Saltzman, 1998). Thus alternate delivery methods such as local delivery using polymeric 
implants, continuous infusion and transplanted protein secreting cells are essentially seen 
to achieve therapeutically relevant concentrations locally.  
 
2.5.3 Local Anti-angiogenic Therapy against Malignant Glioma 
 To achieve therapeutic concentrations locally, the anti-angiogenic proteins can be 
administered directly to the target site (tumor region or residual tumor) by bypassing the 
BBB. There exist various methods of local administration such as continuous infusion 
using osmotic pumps, intracranial implantation of protein-delivering polymeric carriers, 
and intracranial injection of stem cells delivering the anti-angiogenic proteins. It has been 
reported that by using osmotic mini pumps to continuously infuse recombinant PEX and 
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PF-4/CTF proteins intracranially, a better therapeutic efficacy was achieved with a 
reduced amount of protein (Guissani et al., 2003). However, the continuous infusion on a 
daily basis could be financially non feasible in most cases and could cause contamination 
at the wound site. Polymer based protein delivery has been very popular for glioma 
treatment recently. PLGA based polymeric microspheres delivering PEX and PF-4/CTF 
(Benny et al., 2005) and PF-4/CTF delivering microspheres (Benny et al., 2008) have 
demonstrated the practicality of providing local delivery in a sustainable manner leading 
to a significant inhibition of glioma growth. But, such delivery needs purified proteins to 
be encapsulated which involves huge costs, efficient encapsulation methods not affecting 
the biological activity of the proteins. Also, the protein tends to lose its biological activity 
after a prolonged stay in the implant. Another local delivery method was evaluated which 
involved the intracranial injection of human neural stem cells producing PEX protein. 
The stem cells are capable of tracking glioma cells and deliver PEX to inhibit glioma 
growth and angiogenesis (Kim et al., 2005). Despite its unique tumor tracking ability, this 
delivery method has three limitations. Firstly, limited PEX expression was observed from 
the stem cells and any effort to increase the PEX gene in them would trigger apoptosis in 
the stem cells themselves leading to an inhibition in their tumor tracking ability. 
Secondly, the selection of stem cells is critical since it could give rise to immune 
rejection from the host and initiate differentiation.  
 
 Despite the obvious advantages of the above local protein delivery methods over 
systemic administration, an alternate delivery method is desirable that could provide a 
sustainable protein supply in its physiologically active state without the need to purify it.  
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2.6 Cell Micro-encapsulation Technology 
 Cell micro-encapsulation is very popular in industrial biotechnology used for the 
large scale production of recombinant proteins. However, it has not realized widespread 
use in drug delivery applications clinically, despite promising pre-clinical results. Cell 
micro-encapsulation essentially means immobilizing cells (capable of secreting 
therapeutic protein) in polymeric matrices to achieve controlled and continuous delivery 
of therapeutic proteins. Typically these systems are micron sized microcapsules 
encapsulating the cells within a semi-permeable membrane controlling the ingress and 
egress of bio-molecules across it. Additionally, such mini bioreactors are expected to 
protect the encapsulated cells from the host immune response and be mechanically stable 
during the duration of their application. In the biomedical area, cell micro-encapsulation 
technology was first introduced by Lim and Sun (1980) who designed the alginate-poly-
L-lysine (PLL) system for encapsulating islets of langerhans islets to deliver insulin.  
 
2.6.1 Cell Micro-encapsulation for Local Anti-angiogenic Therapy against Glioma 
 Until now the application of cell micro-encapsulation technology to treat glioma has 
only focused on endostatin (an anti-angiogenic protein) only. In fact these studies have 
concentrated more on the material aspect of the bioreactors. Specifically, efforts have 
been made to develop bioreactors with biocompatible materials possessing controlled 
permeability and high mechanical stability apart from the type of encapsulated cells. 
Endostatin secreting 293-EBNA cells were encapsulated in calcium cross-linked alginate 
microcapsules for treatment of glioma (Read et al., 2001). They reported that endostatin 
production was achieved up to four months after implantation resulting in significant 
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survival in treated animals compared to untreated animals. In another study, BHK-21 
cells expressing endostatin were encapsulated in alginate microcapsules with a poly-l-
lysine (PLL) membrane coating (Joki et al., 2001) and reported the sustained release of 
bioactive endostatin. In a separate study, APA microcapsules encapsulating 293-endo 
cells were evaluated for its integrity as a function of homogeneity of gel core, presence of 
PLL membrane and cell proliferation (Rokstad AM et al., 2002). Endostatin production 
plateaued after 23 days of encapsulation. Following this study, the authors evaluated the 
growth and endostatin expression of 293-endo cells encapsulated in six different alginate 
microcapsules and reported that enzymatically tailored alginate was stronger (Rokstad et 
al., 2003). Recently, APA microcapsules encapsulating CHO cells producing endostatin 
were evaluated in terms of cell growth, protein production and capsule integrity (Zhang et 
al., 2007). They demonstrated that smaller capsules (240 µm in diameter) were more 
stable and also resulted in higher endostatin production.  
 
 All the above microcapsules despite demonstrating continuous delivery of endostatin 
and improved treatment efficacy, has the major limitation of PLL induced cytotoxicity 
(Rokstad et al., 2003) and fibrotic immune-reactions (Strand et al., 2001). Additionally, 
there is no evidence in these studies with regards to the exclusion of immune 
macromolecules such as immunoglobulins (IgG). This is a crucial element because the 
IgGs would attack the encapsulated cells and kill them in the event of them diffusing into 
the microcapsules. Moreover, the presence of proliferating cells is a major concern 
because the cell growth severely affects the stability of the microcapsules resulting in the 
disruption and leakage.  Hence favorable materials for encapsulation that could provide 
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controlled permeability and biocompatibility should be identified apart from selecting 
suitable cells for encapsulation.  
 
2.6.2 Selection of Cell Lines for Micro-encapsulation 
 Selection of cell lines should be evaluated from two perspectives; 1) efficiency of 
protein expression; 2) proliferative ability of the encapsulated cells. Historically, 
recombinant E.coli was the preferred choice to express proteins because of simplicity and 
high yield (Suzuki et al., 2006). However such proteins expressed in the cytoplasm of 
bacteria tend to be misfolded as insoluble inclusion bodies, and thus inactive to produce 
any therapeutic effect. Hence mammalian cells are preferred currently to produce 
recombinant proteins. All the previously discussed cell lines, 293-endo, BHK-21 and 
CHO are of mammalian origin and proven efficiency in bioactive protein expression.  
 
 Secondly, the proliferative ability of the encapsulated cells is a major concern 
because it tends to disrupt the microcapsules as the cells grow resulting in cell leakage 
(Rokstad et al., 2002; Rokstad et al., 2003; Zhang et al., 2007) and serious immune-
reactions. To address this, cell lines which could stop growing but express proteins are 
being considered. Myoblasts are cells that have the ability to terminally differentiate into 
fused myotubes upon the withdrawal of serum from the medium. In this terminally 
differentiated state they are capable of surviving and expressing the protein. A few 
studies have utilized encapsulated C2C12 mouse myoblasts to express different proteins 
(Li et al., 2006; Rokstad et al., 2006) and demonstrated the long term mechanical stability 
of the microcapsules and sustained protein production. Similarly, quail myoblasts (QM7) 
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have been reported to express PEX protein very efficiently at high concentrations (Song 
et al., 2007). Moreover, with removal of serum, QM7 cells withdraw from cell growth 
cycle and fuse into myotubes. This terminally differentiated state exerts less pressure 
onto the encapsulating matrix and helps maintain the structural stability and also 
continues producing bioactive PEX protein.  
 
2.6.3 Selection of Materials for Cell Micro-encapsulation 
 Protein delivery for cancer therapy using cell micro-encapsulated bioreactors has a 
very critical dependence on the materials used as the cell encapsulation matrices. Typical 
characteristics desired of the materials are: 1) biocompatibility of the microcapsules 
toward the host; 2) high selectivity in membrane permeability; 3) adequate mechanical 
stability; 4) compatible extra cellular matrix for cell survival. Unfortunately, a single 
material cannot satisfy all these characteristics and hence composite cell-encapsulation 
systems are being developed and a few suitable materials are discussed below.  
 
2.6.3.1 Alginate  
 Alginate, a naturally derived polysaccharide is a linear co-polymer of epimers α-L-
guluronic acid (G) and β-D-mannuronic acid (M) residues arranged in homo-polymeric 
(MM/GG) or hetero-polymeric blocks (MG). Alginates undergo ionotropic gelation with 
divalent metals such as Ca2+ and Ba2+ ions under mild conditions resulting in cross-
linking of different parts of the same G polymeric chain or different G chains to form a 
three dimensional gel network as depicted in Figure 2.7.  
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Figure 2.7 Preferential binding of Ca2+ 
 
ions with G blocks of alginate to form ionic cross-links. 
 
 
 Due to thermodynamic compatibility with water, alginate swells in aqueous media 
causing relaxation and expansion of the gel structure (Peppas et al., 2000). A few 
applications of alginate include scaffolds for cell growth (Abbah et al., 2006), entrapment 
of biological enzymes (George et al., 2007) and carriers of drug loaded microparticles 
(Bodmeier et al., 1989) and as drug delivery systems. However alginate hydrogel has 
been used extensively in cell encapsulation and transplantation as a synthetic ECM (Read 
et al., 2001) due to low toxicity to the encapsulated cells and good bio-compatibility with 
the host.  
 
 Despite its ability to form hydrogel, the reversibility of the ionic cross-linking render 
the alginate matrix weaker and the swelling ability of alginate aggravate the problem. 
Hence to achieve alginate hydrogel with high integrity, low swelling ability and high 
perm-selectivity, efforts to coat alginate microcapsules with a poly-anion such as PLL 
were made. These alginate-PLL-alginate (APA) microcapsules were very popular in the 
cell micro-encapsulation studies until recently before PLL induced cytotoxicity (Rokstad 
et al., 2003) and fibrotic immune-reactions (Strand et al., 2001) were reported. 
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2.6.3.2 Chitosan 
 Chitosan, an abundantly available polysaccharide is a co-polymer of D-glucosamine 
and N-acetylglucosamine (derived from chitin). Chitosan is capable of forming ionic 
bonds with negatively charged poly-cationic alginate in a process termed coacervation 
(Gåserød et al., 1998) and form a semi-permeable membrane (Gåserød and Skjåk-Bræk, 
1999). Figure 2.8 illustrates the alginate-chitosan (AC) complex formation.  
 
 
Figure 2.8 Co-acervation reaction between chitosan and alginate resulting in an AC complex 
membrane (adapted from Chen et al., 2006). 
 
 AC complex is preferable over PLL due to its higher mechanical strength conferred 
by stronger binding of chitosan to alginate and good biocompatibility. Since then the 
applications of AC complex based microcapsules in cell micro-encapsulation have been 
widespread (Chandy et al., 1999; Baruch and Machluf, 2006; Chen et al., 2007) apart 
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2.6.3.3 Genipin 
 Genipin is an iridoid glucoside derived from the Gardenia fruits (Djerassi et al., 
1960). It is a natural cross-linker of polyelectrolytes with amine groups and capable of 
binding chitosan through covalent cross-linking (Sung et al., 1999) to form semi-
interpenetrating polymeric network (semi-IPN). Recently, it was shown that the cross-
linking of genipin and chitosan produces a fluoregenic membrane (Chen et al., 2005). 
They reported two possible reaction mechanisms as depicted in Figure 2.9. The reaction 
intermediates were shown to be fluorescent at 390 nm.  
 
Figure 2.9 Predicted reaction mechanism between genipin and chitosan (adapted from Chen et 
al., 2005). 
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 Compared to synthetic cross-linkers such as glutaraldehyde, genipin possesses about 
10,000 times lower cytotoxicity level (Sung et al., 1999). Additionally, the membrane 
thickness and permeability can be controlled precisely by varying parameters such as 
cross-linking time, temperature and concentration (Chen et al., 2006). The most striking 
feature of genipin-chitosan is its fluoregenic attributes that can be used to characterize the 
membrane.     
 
2.7 Micro/nano-structuring of Polymers 
 Bulk eroding polymers such as PLGA possess the disadvantage of non-uniform, 
uncontrolled degradation resulting in sporadic dumping of high drug doses leading to 
suboptimal tissue exposure profile and unexpected toxicity (Wang et al., 2002).  Hence 
such polymers need to be structured as devices possessing high porosity, surface area and 
monodispersity to facilitate controlled polymer degradation along with drug diffusion. 
Such devices can take the form of micro/nano-particles, micro/nano-fibers or micro-
porous foams, etc. The techniques of fabricating such devices are very critical as they 
dictate the monodispersity, and porosity.  
 
2.7.1 Electrohydrodynamic Atomization (EHDA) 
 EHDA is a technique of fabricating drug loaded microspheres/particles by atomizing 
a volatile solvent containing drug/polymer through a fine nozzle under the influence of 
high ring and nozzle voltages. The desired mode of operation to achieve mono-disperse 
microspheres is a single cone spray mode from Taylor cone that can be obtained at 
particular values of nozzle and ring voltages (Ding et al., 2005). Particle size and 
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distribution can be controlled by varying solution flow rate, ring and nozzle voltages 
where as particle collection efficiency and solvent evaporation can be controlled using a 
suitably designed chamber and pneumatic conveying from nitrogen flow into the 
chamber (Xie et al., 2006a). Additionally, EHDA has been reported to yield microspheres 
with high encapsulation efficiency of hydrophobic drugs such as paclitaxel and sustained 
release for more than 60 days (Xie et al., 2006b).  
 
2.7.2 Electrospinning  
 Electrospinning is a modification of EHDA, where in the charged liquid jet stretches 
towards the grounded collector forming micro/nano-fibers following the evaporation of 
the solvent (Zong et al., 2002).  This simple yet versatile technique can yield polymeric 
fibers with diameters in the range of micron to nanometer. This technique offers 
flexibility in controlling the fiber diameter by controlling polymer solution injection rate, 
polymer concentration, electric field strength, etc (Xie et al., 2006c). Electrospinning is 
also reported to yield extremely high drug encapsulation efficiencies (>90%) in the fibers 
and to maintain a molecular dispersion of paclitaxel in the matrix.  
 
2.7.3 Electrospray in Dripping Mode 
 In the cases of liquid solutions with high viscosity, conductivity and surface tension 
such as water based protein solutions, gel systems and cell suspensions, very high nozzle-
ground potential difference is necessary to establish a stable electrospray, but with the 
dangers of corona discharge (Tang and Gomez, 1994). In such situations, micro-dripping 
mode in the EHDA process at low nozzle voltages facilitates the fabrication of mono-
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dispersed droplets with the presence of a ring voltage (Xie and Wang, 2007). They also 
reported that at high flow rates, uniform microbeads encapsulating cells could be 
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 This section is a brief summary of the research approach adopted to address the 
problem statements.  
 
3.1 Problem Statements 
Broadly, two problem statements were identified and efforts were made to address them. 
They are: 
a) Improving chemotherapeutic drug penetration in the brain/tumor tissue following 
release from polymeric implants and evaluating its effects in treating malignant 
glioma in mice models.  
b) Improving mechanical stability and perm-selectivity of membrane based 
microcapsules for applications in anti-angiogenic protein therapy against malignant 
glioma.  
 
3.2 Research Approach 
 Problem statement (a) was approached first by identifying and analysing the factors 
affecting the drug penetration. From literature review discussed in the previous section, it 
was clear that transport properties of the drug and drug release kinetics of the implant are 
critical in determining the drug penetration. Paclitaxel was chosen as the drug due to its 
favourable transport properties and proven cytotoxicity and radiosensitization towards 
glioma. PLGA was opted as the drug carrier in the implant because it is FDA approved, 
has the advantage of tuneable degradation and able to encapsulate hydrophobic drugs 
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such as paclitaxel.  Next, since PLGA degrades non-uniformly through bulk erosion, to 
control the erosion process at a uniform rate and simultaneously maintain a constant, 
sufficiently high drug release, we micro/nano-structured the PLGA. Two types of 
implants were fabricated to achieve this. Firstly, paclitaxel-loaded PLGA was 
micro/nano-structured into fibers. Electrospinning process was used for the fabrication 
since it has been reported to yield highly monodisperse fibers with high drug 
encapsulation efficiency. Two co-polymers of PLGA were used to study the effect of co-
polymer and fiber size on drug release rates. Secondly, paclitaxel-loaded PLGA 
microspheres were entrapped in alginate hydrogel matrix to decrease the initial drug burst 
and to provide a sustainable drug release. The microspheres were produced using the 
EHDA process and micro-dripping was used to produce droplets of alginate with 
microspheres, the reasons being proven efficiency of EHDA in producing highly 
monodisperse microspheres and aiding micro-dripping of water based solutions. The 
effect to gelation time, gelling bath concentration and microsphere loading on the bead 
disintegration and drug release were studied. Both the formulations were later evaluated 
for their treatment efficacies at both in vitro cellular level and in vivo subcutaneous tumor 
level.  
 
 Later, the two formulations (fibers and hydrogel beads) were screened based on their 
in vitro release profiles. Formulations with near zero-order release kinetics and different 
release rates were chosen to evaluate this effect on the penetration data. An earlier 
simulation (computational model) was used to compare the experimental paclitaxel 
penetration data in mouse brain and examine the processes that control the penetration of 
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paclitaxel in the brain. The improved penetration due to high drug availability in some 
implants was deduced to be due to high drug availability at the implant surface and slow 
elimination of paclitaxel. Later the effects of improved penetration were tested in an 
intracranial glioma model in mice using bio-imaging and histology.  
 
 Problem statement (b) was approached firstly from the materials perspective. 
Alginate is a very well documented material for microcapsule core for cell micro-
encapsulation as it mimics the ECM and hence was selected. To improve integrity and 
perm-selectivity of the microcapsules, alginate was complexed with chitosan, a 
biocompatible material. To further improve mechanical stability, chitosan was cross-
linked with genipin, a natural cross-linker with very low cytotoxicity. The GCA 
microcapsule was evaluated in terms of the effects of microcapsule size and membrane 
characteristics (extent of cross-linking and thickness) on the mechanical stability and 
perm-selectivity for various bio-molecules.  
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CHAPTER 4 
Biodegradable Micro/Nano-Fiber Implants Delivering Paclitaxel for 
Post-Surgical Chemotherapy against Malignant Glioma† 
4.1 Introduction 
 Malignant gliomas such as glioblastoma multiforme (GBM) being characterized by 
aggressive proliferation of undifferentiated cells, pervasive invasion into distant healthy 
brain tissue and a high penchant to recur is among the most recalcitrant tumors to be 
treated. In spite of access to state-of-the-art imaging, neurosurgery, radiotherapy and 
chemotherapy, patients have a median survival time of around 3 months and most of 
them die within 6 months to 2 years post diagnosis (Ohgaki and Kleihues, 2005; Ohgaki 
et al., 2004). This is probably suggestive of the fact that local recurrence of the tumor is 
the primary etiology of death which is confirmed from observed local glioma recurrence 
within 2 cm of the original tumor resection field (Geurin et al., 2004). Thus by inhibiting 
local recurrence, improvement in the patient’s survival seems achievable.  
 
 Chemotherapy through local intracranial drug delivery using biodegradable polymeric 
wafers (Gliadel®) delivering BCNU showed promise (Brem et al., 1991; Brem et al., 
1995; Domb et al., 1999; Westphal et al., 2003) but development of drug resistance has 
brought down its success over the years.  
 
----------------------------------------------------------------------------- 
†This chapter highlights the work published in Ranganath SH, Wang CH. Biodegradable 
microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant 
glioma. Biomaterials, 29, 2996-3003. 2008. 
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This limited success has since then led to the development of other drug-polymer 
combinational implants (Menei et al., 1996; Bellinzona et al., 2004; Hsu et al., 2005; 
Chen et al., 1997; Lesniak et al., 2005; Manome et al., 2006; Lu et al., 2007) with 
promising pre-clinical results.  
 
 Paclitaxel is a well known mitotic inhibitor and radiosensitizing agent (Niero et al., 
1999) used in cancer chemotherapy. Its mechanism of action comprises of interaction 
with microtubule degradation resulting in increased mitotic arrest, decrease in cellular 
motility, disruption in intercellular signal transmission and binding to Bcl-2 inducing 
apoptosis (von Eckardstein et al., 2005; Fang et al., 1998; Rodi et al., 1998). Despite its 
known potent cytotoxicity against malignant gliomas in vitro (Cahan et al., 1994; Tishler 
et al., 1992), paclitaxel administered systemically has failed to prolong survival of glioma 
patients (Prados et al., 1996; Chamberlain and Kormanik, 1999; Chang et al., 2001) 
mainly due to its hydrophobic nature and fast clearance from the plasma (Hempel et al., 
2003) and poor absorption across the blood brain barrier (BBB) due to P-gP efflux effects 
(Kemper et al., 2003). Also, its commercial form, Taxol® formulated with a 50:50 
mixture of non-ionic surfactant Cremophor EL and dehydrated ethanol is often associated 
with anaphylactic hypersensitivity reactions and neurotoxicity when used systemically 
(Gelderblom et al., 2001). Thus, locally delivered paclitaxel offers advantages over other 
drugs and development of efficient paclitaxel delivery implants would augment the 
efficacy of chemotherapy against glioma. 
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 Most of the polymeric implants delivering paclitaxel developed are either 
micro/nano-particles, compressed micro/nano-particle discs or wafers. However, due to 
very high interstitial pressure in the brain/tumor, intratumoral injection of drug loaded 
microparticles will always run the risk of being expelled out of the target site thus 
negating the advantages of local delivery (Naraharisetti et al., 2007). The other 
disadvantage of using microparticles is the high initial burst due to the presence of the 
drug on the surface (Naraharisetti et al., 2007; Elkharraz et al., 2006) which might lead to 
undesired neurotoxicity. On the other hand, drug loaded compressed discs and wafers 
have low surface area to volume ratio available for polymer degradation and drug 
diffusion and hence would result in low drug release rates and undesired secondary burst 
(Wang et al., 2003). 
 
 PLGA is one of the most widely studied biodegradable polymer and its 
biocompatibility has been well documented. One of the greatest advantages of using 
PLGA is that by varying the lactic to glycolic acid monomer ratio, the polymer 
degradation and thus the drug delivery can be controlled (Wang et al., 2002). Xie and 
colleagues have shown that paclitaxel loaded PLGA fiber films can be successfully 
fabricated using electrospinning to deliver paclitaxel sustainably for more than 60 days 
(Xie and Wang, 2006c).  
 
 Thus it was anticipated that PLGA based microfiber implants could provide the much 
needed implantability, favourable release profile due to increased surface to volume ratio 
and controlled polymer degradation. Hence in this study our objectives were to fabricate 
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and evaluate PLGA microfiber implants (fabricated by electrospinning) in the form of 
discs and sheets delivering paclitaxel for post-surgical chemotherapy against glioma. 
Four dosage forms with different geometry and degradation rate were fabricated and 
assessed for in vitro drug release properties. Subsequently, apoptosis study was 
performed to compare sustainable drug release effects from the implants in comparison to 
systemic Taxol®
 The co-polymers used in fiber fabrication, PLGA 50:50 and PLGA 85:15 (Av. Mol 
Wt, 40000-75000 Da) were purchased from Sigma Aldrich. Paclitaxel used in the present 
study was a generous gift and Taxol
 administration using in vitro cell culture. Efficacy of the formulations 
was evaluated in vivo through subcutaneous C6 tumor inhibition study in BALB/c nude 
mice model. Subsequently, electrospinning was used to fabricate PLGA nanofibers and to 
better understand the contributions of co-polymer and fiber diameter towards the drug 
release, six fiber disc dosage forms with varying co-polymer and fiber diameter were 
fabricated and characterized in terms of in vitro release profiles. Overall, we show that 
biodegradable fiber implants releasing paclitaxel can be promising post-surgical local 
delivery devices against glioma.  
   
4.2 Materials and Methods 
4.2.1 Materials 
® was purchased from Bristol-Meyers Squibb 
(Princeton, NJ). Dichloromethane (DCM), dimethylformamide (DMF), acetonitrile 
(ACN) and tetrahydrofuran (THF) purchased from TEDIA (Fairfield, OH, USA) were of 
HPLC grade. Phosphate buffer saline (PBS) was bought from Sigma Aldrich, containing 
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0.1 M sodium phosphate, 0.15 M sodium chloride, pH 7.4. All other materials and 
reagents used were of analytical grade. 
 
4.2.2 Paclitaxel-PLGA Microfibers Fabrication by Electrospinning 
 PLGA was dissolved in a mixture of DCM and DMF at 30% (w/v) concentration. 
9.1% (w/w) paclitaxel was then dissolved in the solution and the drug-polymer solution 
was pumped at a predetermined rate using a syringe pump, forming a bead of solution at 
the tip of syringe. A high voltage difference (12-20 kV) was applied between the nozzle 
(27 G needle with diameter of 0.34 mm), a negative potential and a grounded collection 
target. As the jet breaks up into fibers from the taylor cone, DCM is evaporated giving 
rise to relatively dry fibers which are subsequently spun on the aluminium foil wrapped 
rotating shaft until multilayered fiber mat is obtained. 
 
 Paclitaxel-PLGA fiber discs were obtained by punching the fiber mats into 3 x 1 mm 
discs. The mats were cut into 5 x 5 mm sheets to obtain paclitaxel-PLGA fiber sheets. 
PLGA 85:15 was used to fabricate microfiber disc (MFD) and sheet (MFS), whereas 
PLGA 50:50 was used for submicrofiber disc (SFD) and sheet (SFS). The dosage forms 
were freeze dried for approximately one week to remove residual DCM. The discs were 
sterilized using Co-60 gamma irradiation at a dose of 15 kGy before using for in vitro and 
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4.2.3 In vitro Characterization  
4.2.3.1 Fiber Diameter, Distribution and Morphology 
 The size, distribution and surface morphology of the microfibers were examined 
using Scanning Electron Microscope (SEM) (Jeol JSM 5600LV, Tokyo, Japan). The 
fibers were cut in half and mounted onto copper studs using double-sided adhesive tape, 
exposing both the surface and cross section. The samples were then sputtered with 
platinum for 60 seconds using a JFC-1300 Platinum Coater (JEOL, Tokyo, Japan) prior 
to the analysis. Analysis of fiber diameter was done using SmileView software (version 
2.0, JEOL) at n>50.   
 
4.2.3.2 Thermal Analysis of the Drug in the Fiber Matrices 
 Thermal analysis was performed using Differential Scanning Calorimeter (DSC) 
(Mettler Toledo, 822e, Greifensee, Switzerland). Fibers weighing between 3-4 mg were 
hermetically sealed in a standard 40 µl aluminium crucible and an empty crucible was 
used as a reference. The thermal analysis was conducted over a temperature range of 
25oC to 300oC with a heating rate of 10oC/min. The equipment was purged with N2 at a 
rate of 30 ml/min and liquid nitrogen was used to reinstate the instrument to the starting 
temperature. Calibration of the instrument’s temperature and enthalpy were done using 
pure indium. Characteristic peaks were obtained by analyzing pure paclitaxel and the 
fiber discs/sheets. The results were assessed using the accompanying STARe software. 
Normalization was performed on the obtained result with respect to respective samples 
masses to facilitate comparison. 
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4.2.3.3 Degradation Analysis of the fiber Matrices 
 Degradation of the polymer in the fiber matrix was studied through PLGA molecular 
weight determination using Gel Permeation Chromatography (GPC) equipped with a 
refractive index detector (Waters, Model 1515, Mildford, Massachusetts). The samples 
were dissolved in THF at specified concentrations and eluted at a flow rate of 1 ml/min. 
Polystyrene standards (molecular weight from 1.31 x 103 to 1.97 x 105 Da) (Polysciences, 
Warrington, Pennsylvania) were used to obtain a primary calibration curve. 
 
4.2.3.4 Drug Encapsulation Efficiency and In vitro Paclitaxel Release Study 
 Paclitaxel encapsulation efficiency of the fiber discs/sheets is defined as the ratio of 
actual drug loading in each fiber disc or sheet to the theoretical drug loading in each fiber 
disc or sheet.         
   
 To quantify encapsulation efficiency, fiber discs/sheets weighing approximately 3 mg 
each were dissolved in 2 ml of DCM. The solutions were then left overnight in the fume-
hood for evaporation of DCM. The residues were then re-dissolved in 10 ml of mobile 
phase consisting of acetonitrile/water (50:50 v/v) and the resulting solutions were mixed 
using a sonicator until complete dissolution. The solutions were then filtered into 2 ml 
vials using 0.22 μm Millipore syringe filter (Massachusetts, USA) and subsequently 
analyzed using High Performance Liquid Chromatography (HPLC) as mentioned in the 
paragraph below.  
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 In vitro paclitaxel release study was conducted by immersing fiber discs/sheets 
weighing approximately 3 mg each into 5 ml PBS buffer (pH 7.4) containing 0.05% (w/v) 
Tween 80 to enhance paclitaxel solubility in 15 ml centrifuge tubes and incubated at 37o
 The cell line used was rat C6 glioma (ATCC
C 
and 120 rpm in a shaking water bath to simulate physiological conditions of the body. At 
each specified time interval, 5 ml of the buffer was withdrawn from three tubes 
(triplicates) and 5 ml of fresh PBS buffer was added back to maintain a constant sink 
condition before keeping back in the shaker. The withdrawn solution was added with 2 
ml of DCM to extract paclitaxel from the aqueous phase by allowing mass transfer for 
one day. A mixture of acetonitrile/water (50:50, v/v) was added to the extracted paclitaxel 
after DCM had evaporated. The resulting solution was analyzed using HPLC using a C-
18 column and the mobile phase was delivered at a rate of 1 ml/min. 100 µl of sample 
was injected by an auto-sampler and the column effluent was detected at 227 nm using an 
ultra violet (UV) detector. The detection data were corrected according to the extraction 
efficiency. Standard paclitaxel concentration samples were used to produce calibration 
plot.   
 
4.2.3.5 Cell Culture and Maintenance 
® Number: CCL-107™) established by 
Benda et al. 1968, and reported to be derived from N-methyl-nitrosourea-transformed rat 
astrocytes. The cells were grown in DMEM (Dulbecco’s Modified Eagle Medium, 
Sigma) supplemented with 10% bovine fetal serum (Gibco, Invitrogen) and 1% 
penicillin/streptomycin (Gibco, Invitrogen) in a humidified incubator under the 
conditions of 37oC, 5% CO2 and 90% relative humidity. After reaching confluence, the 
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cells were prepared by washing in PBS and detached from the T-flask with trypsin-
EDTA (Gibco, Invitrogen). The cells were re-suspended at a speed of 1,500 rpm for 6 
minutes to obtain a concentration of 3 x 105 cells/2.5 μl before inoculation into a 75 cm3 
tissue culture flask containing 15 ml of fresh media.   
 
4.2.3.6 In vitro Cellular Apoptosis 
 Investigations of cellular apoptotic response to MFD, SFD, MFS and SFS were 
carried out in comparison with 5 control groups namely blank and four Taxol® groups. 
Each group consisted of triplicates. Cell density and apoptosis studies were done after 
days 4, 8 and 12. All groups were inoculated with 1 x 106 C6 glioma cells each in 175 ml 
tissue culture flasks with 50 ml of DMEM culture medium on day 0. The cells were 
allowed 2 days to attach and grow in the flask before the respective discs were added to 
the flasks. Equivalent amount of commercial Taxol® corresponding to paclitaxel release 
from MFD, SFD, MFS and SFS after 12 days (from in vitro release profiles) were 
administered to flasks containing the four Taxol® control groups on day 2. Taxol® laden 
mediums were removed after 24 hours and the cells were washed twice by PBS before 
replenishing with fresh medium. These controls were used to simulate acute paclitaxel 
exposure and subsequent clearance during systemic administration. Cellular recovery was 
anticipated after drug clearance in the Taxol®
 3 x 10
 group.  Cell counting was performed using 
a haemocytometer after days 2, 4, 8 and 12 to obtain the cell density.  
 
6 cells were collected for caspase-3 activity level measurement (indicative of 
apoptosis extent) using a caspase-3/CPP32 fluorometric assay kit from Biovision. 
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Caspase-3 activity level was determined by re-suspending the cells in 50 μl chilled lysis 
buffer and incubating on ice for 10 minutes before adding 50 μl of 2x reaction buffer 
(with 1% 10 mM DTT) to each sample. 5 μl of 1 mM DEVD-AFC substrate were then 
added before the samples were transferred to a 96 well plate. The plate was then 
incubated at 37o
 BALB/c nude male mice of about 5 weeks were purchased from Animal Resource 
Centre, Murdoch, Western Australia under import license from AVA. They were housed 
in cages of fives and left to acclimatize for a week in Satellite Animal Holding Unit 
C for 2 hours in a humidified incubator before reading the samples in a 
fluorometer equipped with a 405 nm excitation and 485 nm emission filters. Upon 
cleavage of the substrate by CPP32 or related caspases, free AFC will emit a yellow-
green fluorescence (max = 505 nm). Absorbance for the experimental groups was then 
compared with the controls for caspase-3 activity (extent of apoptosis) and paclitaxel 
release sustainability comparison studies. 
 
4.2.4 In vivo Characterization 
4.2.4.1 Animal Care and Maintenance 
 All animal experiments were performed with approval from the National University 
of Singapore’s Institutional Animal Care and Use Committee (IACUC) and experimental 
practices were conducted in accordance with the National Advisory Committee for 
Laboratory Animal Research (NACLAR) guidelines (guidelines on the care and use of 
animals for scientific purposes) in facilities licensed by the Agri-food and Veterinary 
Authority of Singapore (AVA).  
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(sAHU) of National University of Singapore prior to the experiment. Free access to food 
and water was given. The tranquilization, induction and maintaining agents administered 
during surgical procedures contained 75 mg of Ketamine /kg body weight and 75 mg of 
Medetomidine/ kg body weight. 
 
4.2.4.2 In vivo Subcutaneous Tumor Inhibition Study 
 Animals were randomized into different groups with five animals in each group: two 
control groups namely placebo disc control (no drug) and Taxol®; four experimental 
groups namely MFD, SFD, MFS and SFS with each fiber implant weighing about 3 to 4 
mg with an average paclitaxel amount of 0.357mg per implant. On day 0, all the animals 
were inoculated with 1 x 106 C6 glioma cells subcutaneously by injecting with a 27G 
needle to the left flank (Vogelhuber et al., 2002). The tumor was allowed to grow for 12 
days after which treatment with the fiber discs/sheets or Taxol® injection was 
commenced. For animals under placebo and experimental groups, using aseptic surgery a 
small incision was made on the skin and tumor was reached after which another incision 
was made into the tumor. The fiber discs/sheets were then implanted well into the tumor 
and then wound was closed using subcutaneous suturing. Animals in the Taxol® control 
group were administered with 0.06 ml of commercial Taxol® injection (concentration of 
6 mg paclitaxel/ml) directly into the tumor mass. This dose was equivalent to the total 
amount of paclitaxel encapsulated in each fiber disc which was 0.357 mg. Equal amount 
of paclitaxel was administered into animals from Taxol® group and experimental groups 
for sensible comparison of the treatments. Every four days, length of the major axis 
(longest diameter) and minor axis (perpendicular to the major axis) of the tumor were 
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calculated to measure the ellipsoidal tumor volume using the formula (Volume = [Π/6] x 
A x B2
 Two PLGA based fiber formulations loaded with 9.1% paclitaxel (w/w) were 
fabricated using electrospinning as described earlier. The first formulation was fabricated 
using PLGA 85:15 co-polymer, where as the second formulation made use of PLGA 
50:50 co-polymer, where 85:15 and 50:50 represents the molar ratio of lactic acid to 
glycolic acid. The reason for choosing two different PLGA co-polymers was that PLGA 
50:50 having higher hydrophilic glycolic acid (G) content is known to degrade at a faster 
), where A and B represent lengths of the major axis and minor axis of the tumor 
respectively (Naraharisetti et al., 2007). Weight monitoring of the animals was carried 
out twice a week in order to detect any experimental abnormalities. 
 
4.2.5 Study on Effects of PLGA Co-polymer and Fiber Size on In vitro Drug Release 
 To compare the effect of co-polymer and fiber diameter on drug release profile, 
PLGA 85:15 co-polymer was used to fabricate microfiber (E1), submicrofiber (E2) and 
nano-fiber (E3) and PLGA 50:50 was used to fabricate microfiber (F1), submicrofiber 
(F2) and nano-fiber (F3) using electrospinning set up explained in section 4.2.2. The 
operating parameters for these formulations are tabulated in Table 4.3. Fiber diameter, 
morphology and size distribution were characterized using SEM as explained in the 
section 4.2.3.1. The in vitro paclitaxel release studies on these six formulations were 
performed as explained in section 4.2.3.4.  
  
4.3 Results and Discussion 
4.3.1 Paclitaxel-PLGA Microfibers Fabrication  
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rate than PLGA 85:15 owing to faster hydrolysis. This difference in bulk degradation 
rates was utilized to develop faster and slower releasing formulations. Additionally, by 
varying the fiber diameter for the two formulations the difference in surface area to 
volume ratio was availed to aid faster or slower release. Table 4.1 provides the operating 
electrospinning parameters used for the fabrication of the two formulations. 
 




4.3.2 In vitro Characterization  
4.3.2.1 Fiber Diameter, Distribution, Morphology and Drug Encapsulation Efficiency 
 From Table 4.1 it is evident that higher flow rate and DMF content yielded a 
microfiber of mean diameter around 3.5 ± 0.32 µm compared to lower flow rate and 
higher DMF content which yielded a submicrofiber of mean diameter around 930 ± 35 
nm. Lower polymer flow rate resulted in much finer fibers from the jet. Higher DMF 
content was used for submicrofiber in order to increase the conductivity of the polymer 
solution providing more fluidity. 
 
 SEM images in Figure 4.1 suggest that electrospun non-woven fibers were formed 
with good monodispersity in fiber diameters which was also confirmed in Table 4.1. 
Figure 4.1 also confirmed that the surface of the fibers were smooth. High encapsulation 
Chapter 4                                                                      Paclitaxel-PLGA Micro/nano-fibers                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
62 
efficiency of paclitaxel was observed both for MF and SF at around 98% and 94% 
respectively. The drug loadings for MF and SF are shown in Table 4.1. Such a non-
woven fiber was hypothesised to provide higher surface area to volume ratio for drug 
release when compared to conventional drug delivery discs/wafers made of either 
compressed drug-polymer mixture or compressed drug-polymer microparticles.   
 
Figure 4.1 SEM images of electrospun fibers. (A) Paclitaxel-PLGA microfiber (MF) (bar 10 
µm); (B) Paclitaxel-PLGA submicrofiber (SF) (bar 2 µm). 
 
4.3.2.2 Physical Status of Paclitaxel in the Fiber Matrix 
 This study aimed at characterizing the physical status of paclitaxel in the fiber matrix 
after electrospinning. DSC thermographs depicted in Figure 4.2 provide information on 
the physical state of paclitaxel in MF and SF. Polymer-drug crystallinity of PLGA fibers 
has been a key concern related to rate-controlled delivery and drug delivery efficiency. It 
has been established that molecular dispersions give better release profiles as compared 
with particulate dispersions of the same drug (Freiberg and Zhu, 2004). Pure paclitaxel 
has been reported to show a sharp endothermic melting peak at 223.0oC which was 
representative of crystalline paclitaxel (Mu and Feng, 2001) and a later sharp exothermic 
peak indicative of degradation at 250oC (Ligging et al., 1997). From Figure 4.2, no peaks 
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were obvious at the temperature range of 150 to 300oC suggesting that paclitaxel in MF 
and SF was not crystalline but was in a molecular dispersion or solid solution state which 
agreed well with other electrospinning results (Xie and Wang, 2006c). The molecular 
dispersion state of paclitaxel is ideal for drug diffusion from the polymer matrix.  Glass 
transition temperature (Tg) of both PLGA 50:50 and PLGA 85:15 ranges from around 40 
to 50o
 
Figure 4.2 DSC thermograms of electrospun paclitaxel-PLGA microfiber (MF) and 
submicrofiber (SF). 
 
C. The endothermic event (peak) seen refers to the relaxation peak that follows 
glass transition. The slight shift in the glass transition range of the polymer was possibly 
due to the additional endothermic overlap representing the energy required to overcome 
the microstructure of the polymer during the electrospinning process (Dubernet, 1995).  
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 Later, from the two formulations (MF and SF), four dosage forms (MFD, SFD, MFS 
and SFS) were prepared as described earlier. A comparative study was performed on the 
polymer degradation, in vitro drug release, apoptotic activity and in vivo subcutaneous 
tumor inhibition from discs and sheets. 
 
4.3.2.3 Degradation Analysis of Fiber Discs/sheets 
 GPC was performed on the four dosage forms to investigate the extent of polymer 
degradation in PBS buffer after day 60 in comparison to day 0 in an effort to correlate 
with the subsequent drug release study. SEM images of MFD, SFD, MFS and SFS were 
examined for morphological changes in the fibrous structure after 60 days of incubation 
in PBS buffer. Figures 4.3A1 and 4.3A3 indicate that MFD and MFS after 60 days 
maintained their fibrous structure to a great extent apart from signs of bulk degradation 
shown by small holes in the figure due to penetration of buffer. However the images from 
SFD and SFS after 60 days in Figures 4.3A2 and 4.3A4 reveal that the fibrous structure 
was deformed to irregular structures showing higher extent of bulk degradation. These 
images revealed by SEM suggest that the SFD and SFS degrade faster than MFD and 
MFS owing to higher hydrophilicity and surface area to volume ratio (smaller fiber 
diameter for SFD).  
 
 Molecular weights of PLGA 85:15 and PLGA 50:50 used in this study have been 
reported to be 40,000 to 75,000 Da (Xie and Wang, 2006c). Change in the molecular 
weight was used as the criterion to determine the degradation extent and gel permeation 
chromatograms in Figure 4.3B reveal that for MFD and MFS, there were slow and fast 
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degradation domains corresponding to molecular weights of 33909 Da, 646 Da and 
25397 Da, 647 Da respectively.  
 
 The presence of the slow domain could be attributed to inner core and the fast domain 
to the exposed surface of the disc. Also, due to the presence of low glycolic acid content 
in MFD/MFS, the extent of degradation after 60 days is not significant. Because of higher 
compactness in MFD, its degradation was slightly slower compared to the sheets. For 
SFD, slow degradation domain was also observed but it represented a much lower 
molecular weight of around 4500 Da. The presence of fast releasing domain with 
significant decrease in molecular weight to 646 Da was attributable to faster hydrolysis 
due to high glycolic acid content. Submicrofiber sheets on the other hand degraded 
slightly faster than SFD (1013 Da) with less prominent slow degradation domain 
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Figure 4.3 Degradation analysis of paclitaxel-PLGA fiber discs/sheets. (A) SEM images of 
different dosage forms after 60 days; (A1) Microfiber Disc (MFD) (bar 5 µm); (A2) 
Submicrofiber Disc (SFD) (bar 10 µm); (A3) Microfiber Sheet (MFS) (bar 5 µm); (A4) 
Submicrofiber Sheet (SFS) (bar 10 µm). (B) Gel permeation chromatograms (GPC) of MFD, 
SFD, MFS and SFS after 60 days. 
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4.3.2.4 In vitro Release of Paclitaxel from Fiber Discs/sheets 
 This study was aimed at quantifying the % cumulative release of paclitaxel from the 
four dosage forms under simulated physiological conditions over an extended period of 
time. The in vitro release profiles shown in Figure 4.4 suggest that paclitaxel release was 
sustained for more than 80 days for all the dosage forms. While the fiber discs showed 
nearly zero order release kinetics with slight initial burst (6% for MFD and SFD after 9 
days), the fiber sheets (MFS and SFS) exhibited a relatively high initial burst (16% for 
SFS and 10% for MFS after 9 days) followed by a zero-order release. For MFD, after day 
7 the release rate was almost linear and after day 80, 26% of total paclitaxel was released. 
For SFD, till day 31 a slow release rate was observed followed by a slight increase in 
release rate up to day 80. After day 80, around 35% of total paclitaxel was released from 
SFD. SFD and MFD also exhibit two slightly different release rates. We can notice that 
for SFD, the release profile from day 0 till day 35 is strikingly similar to the release 
profile from day 30 to day 70. Whereas for MFD, after day 64 a slight burst is seen which 
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Figure 4.4 In vitro paclitaxel release from different dosage forms. () SFS; () SFD; () MFS; 
() MFD. Each data point represents the average of triplicate samples and error bars represent 
standard deviation. 
 
 The results from the release profile confirm the fact that SF has a higher release rate 
than MF for the most obvious reason of faster bulk degradation rate due to higher 
glycolic acid content in PLGA 50:50 compared to PLGA 85:15. This correlates well with 
the GPC results shown in section 4.3.2.3. MFD and SFD in our study demonstrate low 
initial burst probably due to the disc geometry and multilayered structure of fibers, where 
as MFS and SFS due to less compact structure exhibit a relatively higher initial burst. 
Furthermore, SFD and MFD were made by multilayered fiber sheets, thus not all the 
sheets were equally exposed to release buffer. This multilayered structure made them 
exhibit two slightly different release rates. The reason for this was as the old layer 
degraded and exposed the new layer; a slight burst was seen followed by a constant 
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release which went on till most of the polymer had degraded. Since PLGA 85:15 
degrades much slower than PLGA 50:50 the slight second burst was seen much later than 
for MFD. Even though the discs exhibited two different release rates, they were not much 
different in magnitude in comparison to the biphasic release seen in the fiber sheets. 
 
 Other paclitaxel loaded polymeric discs/wafers like PLGA spray dried microparticle 
discs (Wang et al., 2003), MPEG 2000-DSPE liquid crystalline cubic phases (von 
Eckardstein et al., 2005), polilactofate microsphere discs (Li et al., 2003) exhibit 
significantly lower release rates probably because of lower surface area to volume ratio 
available for polymer degradation and drug diffusion. On the other hand, other dosage 
forms like PLGA micro/nano-fiber films (Xie and Wang, 2006), PLGA microparticles by 
EHDA and spray drying (Naraharisetti et al., 2007), polilactofate microspheres (Li et al., 
2003), PCPP-SA microsphere discs (Walter et al., 1994) and docetaxel loaded PCPP-SA 
microsphere discs (Sampath et al., 2006) exhibit very high initial burst in comparison to 
fiber discs and sheets. The large burst in some cases was due to fast degrading polymer 
like PCPP-SA (Sampath et al., 2006) or due to surface bound drug release (Naraharisetti 
et al., 2007; Li et al., 2003). The large burst has been reported to cause sporadic toxicity 
among experimental animals (Walter et al., 1994). In comparison, the fiber discs and 
sheets have the advantages of low initial burst, near constant drug release rate and longer 
drug release sustainability which might be crucial for treating recurrent glioma. This 
provides the flexibility in selecting dosage forms with different drug release rates 
according to patient specific glioma chemotherapy (based on residual tumor post-
surgery).   
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4.3.2.5 In vitro Cellular Apoptosis 
 This study was designed to demonstrate the long term paclitaxel release sustainability 
at a cellular level. Paclitaxel induced apoptosis was quantified for C6 glioma cells treated 
with MFD, SFD, MFS and SFS and compared with blank and Taxol®
 
 
 controls for 
sustained apoptotic activity. Figure 4.5 shows quantitative results of extent of apoptosis 
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Figure 4.5 Extent of apoptosis in C6 glioma cells in vitro treated with different groups after 4, 8 
and 12 days. (A) Blank, (Taxol)1, MFD, (Taxol)2, MFS; (B) Blank, (Taxol)3, SFD, (Taxol)4, 
SFS. (Taxol)1, (Taxol)2, (Taxol)3, (Taxol)4 represent equivalent amounts of commercial Taxol®
 Figures 4.5A and 4.5B show low level of apoptosis in C6 glioma cells treated with 
blank discs/sheets, where as large apoptotic activity was observed on day 4 for Taxol
 
corresponding to paclitaxel release from MFD, SFD, MFS and SFS after 12 days (from in vitro 




groups. For the fiber treated groups, apoptotic activity slightly higher than that of blank 
discs and considerably lower than that of Taxol® controls was observed. Once Taxol® 
was washed off and fresh media was replaced on day 3, the cells started recovering which 
is reflected in increased cell density (data not shown) and decreased apoptotic activity 
after days 8 and 12 as seen in Figures 4.5A and 4.5B. In contrast, for the fiber treated 
groups the cell density continued to decrease (data not shown) and apoptotic activity 
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continued to increase after days 8 and 12. Also, SFS treated group showed the highest 
apoptotic activity after 12 days, whereas MFD showed the least among the fiber treated 
groups.  
 
 Cellular recovery observed in Taxol®
 This study was aimed at evaluating the efficacy of MFD, SFD, MFS and SFS in 
comparison with placebo fiber discs and commercial Taxol
 treated groups was indicative of the limitations 
of systemic drug administration because it only provided short and acute exposure due to 
low terminal half life of paclitaxel. But for the fiber treated groups, due to sustained 
release of paclitaxel at therapeutic concentrations, we could observe continued decrease 
in cell number even after 12 days (data not shown). Sustained increase in apoptotic 
activity for the four fiber treated groups was indicative of continued paclitaxel induced 
apoptosis. Furthermore probably due to higher release rate from submicrofiber 
formulations, higher apoptotic activity was observed compared to microfiber treated 
group. This result also confirms GPC and in vitro release results. 
 
4.3.3 In vivo Characterization 
4.3.3.1 In vivo Subcutaneous Tumor Inhibition 
® in inhibiting subcutaneous 
C6 glioma tumor in BALB/c nude mice after surgical implantation. It was observed from 
Figure 4.6 that for animals with placebo discs the tumor grew unabatedly (more than 
2000 mm3) till day 24 after which the animals had to be sacrificed owing to animal ethics 
consideration and IACUC regulations on maximum allowable tumor size (~ 1.7 cm in 
diameter). Tumor volume inhibition (TVI) was calculated using the formula (TVI = [VC-
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VE]/VC), where VC and VE represent the tumor volumes of animals from control and 
experimental groups respectively. Table 4.2 depicts TVI (%) for MFD, SFD, MFS and 
SFS against placebo and Taxol®
 
Figure 4.6 In vivo subcutaneous tumor inhibition profiles for different treatment groups. () 
Placebo control; () Taxol
 control groups after 24 and 32 days.  
®
 MFD and SFD treated groups had ~75% and ~78% smaller tumors on day 24 
compared to placebo control and ~38% and ~44% smaller tumors on day 24 in 
comparison to Taxol
 control; () MFD; () SFD; (x) MFS; () SFS. Each data point 
represents five samples (n = 5 animals). Animals were sacrificed after they reached a specified 
tumor volume (~1.7 cm in diameter) irrespective of day of treatment. Error bars represent the 
standard deviation. 
 
® control respectively, where as MFS and SFS treated groups had 
~69% and ~71% smaller tumors on day 24 against placebo control and ~21% and ~26% 
smaller tumors on day 24 in comparison to Taxol® control respectively. After day 32, 
Chapter 4                                                                      Paclitaxel-PLGA Micro/nano-fibers                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
74 
MFD, SFD, MFS and SFS treated animals had ~55%, ~59%, ~40% and ~61% smaller 
tumors respectively when compared to Taxol® treated animals.  
 
Table 4.2 In vivo subcutaneous tumor volume inhibition (%) for MFD, SFD, MFS and SFS 
against placebo and Taxol® 
Dosage 
Forms 
control. (TVI: Tumor volume inhibition) 
 
TVI (%) against Placebo 
control (day 24) 
TVI (%) against Taxol® TVI (%) against Taxol 
control (day 24) 
® 
control (day 32) 
MFD 75 ± 2 38 ± 6 55 ± 6 
SFD 78 ± 6 44 ± 11 59 ± 4 
MFS 69 ± 9 21 ± 2 40 ± 13 
SFS 71 ± 12 26 ± 2 61 ± 5 
 
 In comparison to spray dried microsphere disc having a very low paclitaxel release 
rate, and EHDA microspheres with a very high initial burst and release rate (Naraharisetti 
et al., 2007), in the present study  the animals having fiber implants had approximately 
45% to 60% and 40% to 55% smaller tumors respectively. This shows that a constant 
paclitaxel release rate within the therapeutic limit could enhance the therapeutic efficacy. 
The tumor volume inhibition results positively show that the fibrous dosage forms are 
able to provide sustainable paclitaxel release for at least more than a month in vivo which 
was reflected in the considerable tumor volume inhibition effects when compared to the 
control groups. Even though Taxol® group could inhibit the tumor significantly initially, 
it could not extend the effect for long because of its low terminal half life of less than a 
day in vivo. Once the drug cleared off, the tumor growth rate approximated that of 
placebo group and reached more than 2000 mm3 after 32 days. But for the fiber treated 
animals tumor volume was relatively smaller (less than 1000 mm3) until day 32 expect 
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for MFS (~1300 mm3
 
). Comparing the tumor inhibition from discs and sheets, there was 
no significant difference. This was probably due to compacted fiber sheets owing to 
limited implantation space.  However, SFS having a higher degradation and drug release 
rate resulted in a relatively higher tumor inhibition.  
 
 Thus the choice of the dosage forms depends on the tumor resection cavity in 
patients. Sheets could be used in case of a larger cavity and discs could be implanted into 
smaller cavities. Nevertheless, these results suggest that paclitaxel-PLGA based fiber 
discs/sheets fabricated from electrospinning might be potential local paclitaxel delivery 
implants for patient specific chemotherapy against malignant gliomas. 
 
4.3.4 Effects of PLGA Co-polymer and Fiber Size on In vitro Drug Release 
 The previously evaluated formulations SFD and MFD were renamed as F2 and E1 
respectively. Additionally, four other formulations were fabricated (F1, F3, E2 and E3) at 
the electrospinning operating parameters shown in Table 4.3.  
 
Table 4.3 Electrospinning operating parameters, fiber diameter and paclitaxel encapsulation 
efficiency of six fiber formulations.  
 
Microfibers were fabricated at higher flow rates, polymer concentration and voltage 
difference compared to sub-microfiber and nanofiber. In nanofiber fabrication, to avoid 
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formation of beads at low polymer concentrations, 20 mM of organic salt (TATPB) was 
used. The salt increased the conductivity of the solution, thus resulting in continuous 
nanofibers. Figure 4.7 shows that the fibers are monodisperse with smooth morphology 
and have good encapsulation efficiency of 90 to 98 %.  
 
 
Figure 4.7 SEM and FESEM images of PLGA-paclitaxel electrospun fibers. (A) PLGA 85:15 
microfiber disc (E1); (B) PLGA 85:15 submicrofiber disc (E2); (C) PLGA 85:15 nanofiber disc 
(E3); (D) PLGA 50:50 microfiber disc (F1); (E) PLGA 50:50 submicrofiber disc (F2); (F) PLGA 
50:50 nanofiber disc (F3). 
 
 This study aimed at investigating the effect of PLGA co-polymer and fiber diameter 
on in vitro paclitaxel release from each of the six dosage forms. Clearly, from Figure 4.8, 
we notice that the effect of co-polymer on release kinetics at the same fiber diameter is 
not significant as the profiles are similar. But it is quite obvious that the fiber diameter 
has a very significant effect on the release rate especially when nanofibers are compared 
with submicro and microfibers. This highlights the fact that increasing the surface area to 
volume ratio using nanofiber would augment polymer degradation and drug release. 
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When fabricated as nanofibers, even PLGA 85:15 achieves drug release rates comparable 
to PLGA 50:50 probably due to improved drug diffusion and polymer degradation due to 
larger surface area. At all the three scales, PLGA 50:50 exhibits slightly higher release 
rate compared to PLGA 85:15 owing to its greater hydrophilicity. 
 
 More importantly, unlike other available dosage forms for delivering paclitaxel 
(Naraharisetti et al., 2007; Li et al., 2003; Xie and Wang, 2006) these exhibit relatively 
smaller initial burst and near constant release profile. Owing to slightly higher release 
rate, for further in vivo studies we screened F3 and F2 as the dosage forms to be applied. 
F3 has fast release profile while F2 has slow release profile and hence would provide the 
neurosurgeons to choose between for patient specific glioma chemotherapy. 
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Figure 4.8 In vitro paclitaxel release from different dosage forms. (A) Paclitaxel-loaded PLGA 
85:15 fiber discs; (B) Paclitaxel-loaded PLGA 50:50 fiber discs. Each data point represents the 
average of triplicate samples and error bars represent standard deviation. 
 
4.4 Conclusions  
 The study showed that electrospinning was successfully used to fabricate 
monodisperse fibers with high drug encapsulation efficiency. Thermal analysis results 
confirm that paclitaxel was in a molecular dispersion state after the fabrication process 
which is ideal for diffusion from the polymer matrix. The four dosage forms were shown 
to provide sustained paclitaxel release for more than 80 days with low initial burst which 
exhibits clear advantage over conventional systemic delivery of Taxol®. Submicrofiber 
discs/sheets exhibited faster release compared to microfiber discs/sheets. In vitro cellular 
apoptosis study suggested that the fiber discs/sheets were better than acute Taxol® 
administration against C6 glioma cells in terms of drug sustainability and cytotoxic 
Chapter 4                                                                      Paclitaxel-PLGA Micro/nano-fibers                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
79 
effect. In vivo tumor inhibition study against subcutaneous C6 glioma in BALB/c nude 
mice showed that the fiber discs/sheets treated animals had much smaller tumors on day 
24 and day 32 post tumor inoculation when compared to placebo control and Taxol®
 
 
control groups confirming sustained release of paclitaxel and improved tumor inhibition. 
 
 Additionally, fibers discs were selected for further studies since they could be ideal 
for intracranial chemotherapy because of low initial burst, sustained drug release and 
compactness. Six fiber disc dosage forms (E1, E2, E3, F1, F2, and F3) were fabricated by 
varying co-polymer and fiber diameter. It was shown that the co-polymer had very little 
effect on drug release rate compared to fiber diameter. Nanofiber discs demonstrated a 
significantly higher release rate in comparison to submicro and microfibers of the same 
co-polymer. But all the six dosage forms exhibited inhibited initial burst and near 
constant drug release rate. Hence PLGA micro/nano-fiber discs/sheets could be utilized 
as drug delivery implants to deliver paclitaxel for post-surgical chemotherapy against 
malignant brain tumors. Due to higher release rates, F3 and F2 were screened for further 
in vivo characterizations involving intracranial experiments such as drug biodistribution 
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CHAPTER 5 
Hydrogel Matrix Entrapping PLGA-Paclitaxel Microspheres: Drug 
Delivery with Near Zero-Order Release and Implantability Advantages 
for Malignant Brain Tumour Chemotherapy† 
5.1 Introduction 
 The critical challenge faced by modern clinical pharmacology in treating brain 
neoplasms, such as malignant glioma, is to deliver the therapeutic agents to the target site 
at the necessary therapeutic concentration level(s) while reducing systemic levels of the 
drug to minimise systemic toxicities. The limited ability of most chemotherapeutic agents 
to penetrate the blood-brain barrier (BBB) (Petri et al., 2007; Pradilla et al., 2006; 
Limentani et al., 2005; von Eckardstein et al., 2005) has been addressed by the 
development of polymeric devices for local delivery of chemotherapeutic agents (Brem, 
1990; Tamargo et al., 1993; Brem et al., 1991); these devices bypass the BBB while 
reducing the risk of systemic toxicity effects.  
 
 Ever since Gliadel® was used in clinical trials and showed promise (Brem et al., 
1995), a myriad of drug-polymer combinatorial delivery devices has been developed and 
evaluated with promising preclinical results (Menei et al., 1996; Bellinzona et al., 2004; 
Hsu et al., 2005; Chen et al., 1997; Lesniak et al., 2005; Lu et al., 2007; Walter et al., 
1994).  
-------------------------------------------------------------------------- 
†This chapter highlights the work published in Ranganath SH, Kee I, Krantz WB, et al. Hydrogel 
matrix entrapping PLGA-paclitaxel microspheres: Drug delivery with near zero-order release and 
implantability advantages for malignant brain tumour chemotherapy. Pharmaceutical Research, 
26(9), 2101-2114. 2009. 
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However, the need to develop polymeric drug delivery implants that possess features 
such as easy intracranial application, near-constant drug release for extended time periods 
facilitating high drug penetration into the tumour bed, slow sustained drug release 
resulting in low systemic and local toxicity, and bio-compatibility still remains to be 
addressed. The critical factors that decide the efficacy of such implants are properties of 
the encapsulated drug, type of polymer and geometry of the implant. Properties of the 
encapsulated drug, such as its molecular weight, diffusivity in the brain tissue and drug 
elimination constant, are keys to determining the penetration distance of the drug in the 
brain tissue, whereas drug cytotoxicity is crucial to treatment efficacy. Selection of the 
polymer as the implant material is critical because of the desired properties, such as 
biocompatibility and controllable degradation. The geometry of the implant and surface-
area-volume ratio will play key roles in determining polymer degradation and drug 
release kinetics. 
 
 Paclitaxel is a very widely used chemotherapeutic agent for treating various cancers, 
but has proven to be ineffective against malignant gliomas when administered 
systemically (Prados et al., 1996; Chamberlain et al., 1999; Chang et al., 2001) at the 
maximum tolerated doses due to the resulting very low levels in the brain (Glantz et al., 
1995). In contrast, paclitaxel delivered locally by polymeric devices (von Eckardstein et 
al., 2005; Li et al., 2003) is known to reach therapeutic concentrations at least 3 mm from 
the implant site in the brain. However, implants with more favourable release kinetics, 
sustainability and penetration in the brain need to be developed. Paclitaxel has a higher 
molecular weight, lower diffusivity in the brain, higher elimination constant and higher 
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cytotoxicity against glioma compared to other drugs such as carmustine (Gliadel®) and 4-
HC (Fung et al., 1998). Thus, poly(D,L-lactic-co-glycolic)acid (PLGA), an FDA 
approved biodegradable polymer that undergoes hydrolytic degradation (that can be 
controlled by varying the co-polymer ratio), could be ideal to encapsulate highly 
hydrophobic paclitaxel in comparison to matrices such as PCPP-SA (Walter et al., 1994) 
and polilactofate (Li et al., 2003). Several forms of paclitaxel-delivering implants have 
been developed, such as compressed discs (Fung et al., 1998; Vogelhuber et al., 2002; 
Wang et al., 2003), cubic phases (von Eckardstein et al., 2005), micro/nano-fiber discs or 
sheets (Ranganath et al., 2008), microparticles (Walter et al., 1994; Xie et al., 2006; 
Elkharraz et al., 2006) and nanoparticles (Xie and Wang, 2005). Paclitaxel encapsulated 
in discs, wafers and sheets provides efficient intracranial application; however, due to the 
low surface area available for polymer degradation and drug diffusion, the release rate is 
generally low, which could subsequently lead to low therapeutic efficacy. On the other 
hand, paclitaxel-loaded biodegradable micro/nanoparticles provide a higher release rate 
due to a larger surface area (Walter et al., 1994; Xie et al., 2006; Elkharraz et al., 2006; 
Xie and Wang, 2005), but they have been shown to exhibit a large initial burst that could 
result in significant neurotoxicity effects. Nevertheless, microsphere-based local drug 
delivery to treat glioma is promising due to the fact that the gliomas tend to recur within 
2 cm of the resected tumour site post surgery (Geurin et al., 2004) and microspheres 
could reach remote tumour regions in the cavity by cerebrospinal fluid flow and edema. 
However, a challenge remains to contain the microspheres (suspension) in the cavity 
during the injection and treatment period and also to minimize or even prevent the initial 
drug burst. Consequently, we hypothesized that to provide containment, a solid matrix 
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could be utilized to entrap the microspheres. In addition, the matrix could act as a barrier 
to drug diffusion from the microspheres and thus could inhibit the initial burst. One such 
matrix could be alginate, a natural polysaccharide derived from seaweed and algae that 
has realized numerous applications in the microencapsulation of cells (Joki et al., 2001) 
and bio-molecules, tissue engineering (Fantazzini et al., 2007) and drug delivery 
(Rokstad et al., 2003; Chen et al., 2007) due to its biocompatibility and hydrogel-forming 
abilities. Alginates undergo instantaneous gelation under mild reaction conditions in the 
presence of divalent cations such as Ca2+ and form cross-linked three-dimensional 
hydrogel matrices.  
 
 Thus, in this study, the main objectives were to design, develop and evaluate a novel 
composite implant that couples the sustained release properties of PLGA-paclitaxel 
microspheres with the intracranial implantability advantages of the alginate matrix for 
post-surgical chemotherapy to treat malignant glioma. PLGA-paclitaxel microspheres 
were fabricated using Electrohydrodynamic Atomization (EHDA), since this process has 
been shown to be very efficient in controlling the microsphere size, morphology and 
monodispersity (Xie et al., 2006). An electrospray in dripping mode was utilized to 
entrap the microspheres in alginate hydrogel beads owing to its ease of operation and 
demonstrated monodispersity (Xie and Wang, 2007). Furthermore, the effects of various 
parameters, such as gelation time, gelation bath concentration and microsphere loading 
on in vitro drug release, were studied, followed by cell culture studies (evaluation of 
cytotoxicity and paclitaxel induced apoptosis in C6 glioma cell in vitro) and an in vivo 
anti-tumour efficacy study in a subcutaneous tumour model. 
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5.2 Materials and Methods 
5.2.1 Materials 
 All materials and reagents used were of analytical grade unless otherwise indicated. 
The co-polymer used in microsphere fabrication, PLGA 50:50 (Av. Mol Wt, 40,000–
75,000 Da), was purchased from Sigma Aldrich. Paclitaxel was supplied courtesy of 
Bristol-Meyers Squibb (New Brunswick, NJ). The low viscosity sodium salt of alginic 
acid (sodium alginate) from macrocyctis pyrifera (Mol Wt, 12,000–80,000 Da) and 
polyoxethylene-sorbitan monoleate (Tween 80) were purchased from Sigma Aldrich; 
calcium chloride dehydrate from Nacalai Tesque (Kyoto, Japan); Taxol®
 Fabrication of PLGA-paclitaxel microspheres was done using EHDA as reported 
earlier (Xie et al., 2006). Briefly, PLGA (50:50) was dissolved in DCM in 8% (w/v) 
proportion (i.e., 1 ml DCM to 0.08 g polymer) along with 16.7% (w/w) paclitaxel. A 
potential difference was applied between the nozzle (10–12 kV) and ring (9 kV) using 
high voltage generators (Glassman High Voltage Inc., NJ, USA) in order to obtain highly 
 from Bristol-
Meyers Squibb (Princeton, NJ); HPLC-grade dichloromethane (DCM) and acetonitrile 
(ACN) from TEDIA (Fairfield, OH, USA); phosphate buffer saline (PBS) containing 0.1 
M sodium phosphate, 0.15 M sodium chloride (pH 7.4) from Sigma Aldrich;. Dulbecco’s 
modified eagle medium (DMEM); penicillin-streptomycin and trypsin-EDTA from 
Sigma Aldrich; and fetal bovine serum (FBS) from Gibco (Life Technologies, AG, 
Switzerland). A Takara Bio Inc. (Japan) Premix WST-1 cell proliferation assay system 
and a Biovision (CA, USA) Caspase-3/CPP32 fluorometric assay kit were used.  
 
5.2.2 Fabrication of PLGA-Paclitaxel Microspheres by EHDA Process 
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monodisperse particles with an average diameter of approximately 12 μm and to ensure 
that a single spray cone was maintained during the fabrication process. The nitrogen flow 
rate was set at 40 l/min to act as a sink for solvent evaporation from the dispersed 
droplets. The polymer-drug solution was pumped at a rate of 5 ml/h through the nozzle 
forming a liquid cone with a thin emerging jet. Jet break-up then occurred causing the 
formation of mono-dispersed droplets. The subsequent evaporation of DCM caused the 
accumulation of solid microspheres onto a petri-dish placed at the sample collection point 
at the side opening of the chamber. The fabricated microspheres were frozen in liquid 
nitrogen (roughly at a temperature of −196°C that is much  lower than the melting point of 
DCM (−96°C)) and later freeze-dried for 5 days to remove any residual DCM. 
 
5.2.3 Fabrication of Alginate Beads Entrapping PLGA-Paclitaxel Microspheres by 
Electrospray 
 The electrospray process as shown in Figure 5.1 was employed to entrap the 
PLGA-paclitaxel microspheres in the alginate beads. The apparatus consisted of a high-
voltage generator, syringe pump with a metal tip (tapered conical section made of copper 
sheet) and a grounded stage. The metal tip was connected to the syringe and used instead 
of a needle to avoid clogging by the microspheres. A dish filled with CaCl2 solution was 
placed on the grounded stage. PLGA-paclitaxel microspheres were suspended in 
deionized water (with 0.1% w/v of Tween 80 surfactant) to form a uniform dispersion. 
Sodium alginate was added to the dispersion at 1% (w/v) and then completely dissolved 
to create a viscous suspension. The suspension was then pumped at 1 ml/min using the 
syringe pump with the metal tip connected to the high-voltage generator at 6 kV. Due to 
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the high potential difference at the metal tip, the suspension broke into monodisperse 
droplets that were dripped into the CaCl2 solution. The alginate in the droplets instantly 
underwent gelation in the CaCl2 solution, thereby resulting in calcium-cross-linked 
hydrogel beads that entrapped the microspheres within their matrix. Additionally, 
paclitaxel-loaded alginate beads were fabricated to compare the in vitro release profiles. 
An equivalent amount of paclitaxel (free-form) was dispersed into a 1% (w/w) sodium 
alginate solution and dripped into a CaCl2
 
Figure 5.1 Schematic for the fabrication of alginate beads entrapping PLGA-paclitaxel 
microspheres by electrospray dripping followed by CaCl
 solution using the electrospray technique as 
described earlier. 
2
 The following preparative variables were evaluated in an effort to understand their 
effect on the drug release profiles: Gelation time (1, 5, 15 min), CaCl
 gelation. 
 
2 concentration (0.5, 
1, 2% w/v) and microsphere loading (50, 80, 90% w/w). Following gelation, the beads 
were washed with deionized water (to remove any non-cross-linked Ca2+ ions) and 
freeze-dried for at least 7 days to remove water. The beads were sterilized by exposure to 
UV light for 12 h before using them for the cell culture and animal studies. Table 5.1 
summarizes the different formulations that were prepared and studied.  
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Table 5.1 Preparative variables for hydrogel bead fabrication and respective formulations 
Preparative Variables 
Formulations 
H50 M50 L50 H80 M80 L80 H90 M90 L90 
Microsphere Loading (% w/w) 50 50 50 80 80 80 90 90 90 
Gelation Time (min) 15 5 1 15 5 1 15 5 1 
CaCl2 2  Concentration (% w/v) 1 0.5 2 1 0.5 2 1 0.5 
H: High extent of cross-linking 
M: Medium extent of cross-linking 
L: Low extent of cross-linking 
 
 
5.2.4 Physicochemical Characterization of Hydrogel Beads 
5.2.4.1 Morphology, Size Distribution and Uniformity of Microsphere Entrapment 
 The surface morphology of the microspheres and uniformity of microsphere 
entrapment in the hydrogel beads were examined using Scanning Electron Microscopy 
(SEM) (JEOL JSM 5600LV, Tokyo, Japan). The free microspheres were evenly spread 
onto a copper stub using double-sided adhesive tape to expose the surface. Similarly, the 
hydrogel beads were cut in half and mounted on a copper stub to expose their cross-
section. The samples were then sputtered with platinum for 60 s using a JFC-1300 
Platinum Coater (JEOL, Tokyo, Japan) prior to the analysis. Scanning of the samples was 
performed using a high-energy electron beam with an accelerating voltage of 15 kV. 
Analyses of the hydrogel bead size were done using SmileView software (version 2.05, 
JEOL) at n>50. A Coulter LS230 particle size analyzer (Beckman Coulter, CA, USA) 
was used to analyze the size distribution of the microspheres. The samples were prepared 
by resuspending the microspheres in distilled water with 0.1% (w/v) Tween-80. The 
volume size distribution was analyzed by a computerized analysis for spheres.  
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5.2.4.2 Encapsulation and Loading Efficiencies 
 The amount of paclitaxel present in each hydrogel bead depends on two factors: the 
drug encapsulation efficiency (EE) and the microsphere loading efficiency (LE), defined 
as follows: 
 
 The EE for the paclitaxel-loaded PLGA microspheres was determined as previously 
reported (Xie et al., 2006). To quantify the loading efficiency of the hydrogel beads, each 
bead was accurately weighed in triplicate and completely dissolved in 5 ml of 0.1 M 
sodium citrate. Then the suspension was centrifuged at 12,000 rpm for 40 min after 
which the supernatant was separated from the collected microspheres. Two millilitre of 
DCM was then added to the supernatant solution, vortexed and left to stand for 2 days to 
allow mass transfer. The aqueous supernatant was discarded and the DCM was allowed 
to evaporate. The centrifuged microspheres were dissolved in 1 ml of DCM that was then 
allowed to evaporate completely. Subsequently all the samples were re-dissolved in 5 ml 
of an acetonitrile-water solution (50:50 v/v) followed by filtering the solution through a 
0.22 μm syringe filter (Millipore, MA, USA) into 2 ml sample vials. The amount of 
paclitaxel in each sample was then analyzed using high-performance liquid 
chromatography (HPLC). Paclitaxel was detected at a wavelength of 227 nm with an 
ultraviolet variable wavelength detector after the sample solution was pumped through a 
Encapsulation Efficiency (%) = 
Actual drug loading in microspheres 
× 100     (5.1) 
Theoretical drug loading in microspheres 
Loading Efficiency (%) = 
Measured amount of microspheres in a bead (µg) 
× 100        (5.2) 
Total amount of microspheres (µg) / number of 
beads fabricated 
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C-18 column using acetonitrile-water (50:50 v/v) as the mobile phase. A calibration graph 
was obtained by plotting the reported peak areas from the HPLC analysis and 
corresponding known concentrations of paclitaxel. The concentration of paclitaxel in the 
samples was then obtained using the calibration plot. The amount of microspheres in each 
bead was estimated from the encapsulation efficiency and amount of paclitaxel 
determined from HPLC. The loading efficiency was then calculated using Eq. (5.2). 
 
5.2.4.3 Thermal Analysis of Hydrogel Beads 
 Thermal analysis was performed using Differential Scanning Calorimetry (DSC) 
(Mettler Toledo, 822e, Greifensee, Switzerland) to evaluate the physical state of the drug 
after encapsulation and entrapment. Beads weighing between 3 and 4 mg were 
hermetically sealed in a standard 40 μl aluminium crucible; an empty crucible was used 
as the reference. Thermal analysis was conducted over a temperature range of 25 to 
300°C using a heating rate of 10°C/min. The equipment was purged with N2 at a rate of 
30 ml/min and liquid nitrogen was used to re-establish the starting temperature. 
Calibration of the instrument’s temperature and enthalpy were done using pure indium. 
Characteristic peaks were obtained by analyzing alginate hydrogel beads with PLGA 
microspheres without paclitaxel (control) and with paclitaxel. The results were assessed 
using the accompanying STARe software. Normalization was performed on the obtained 
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5.2.5 In vitro Characterization of Hydrogel Beads 
5.2.5.1 Hydrogel Bead Disintegration Study 
 This study was conducted to evaluate the effects of gelation time, CaCl2 
concentration and microsphere loading on the disintegration time of the beads. All the 
formulations reported in Table 5.1 were fabricated under the specified conditions and 
were used in this study. Each bead was suspended in 5 ml of PBS at 37°C and agitated at 
120 rpm in a water bath to shorten the experiment duration. The time required for total 
disintegration of the bead was determined by direct observation. The density of cross-
linking in the alginate matrices was quantified by estimating the total Ca2+ ion content in 
the release media after total disintegration using inductively coupled plasma-optical 
emission spectroscopy (ICP-OES) with the Ca2+
(pH 7.4) containing 0.05% (w/v) Tween 80 (to enhance the paclitaxel solubility) in 12- or 
6-well plates and incubated at 37°C in a water bath to simulate physiological conditions 
of the body. Ten data points (days) were taken, each of which involved three beads. At 
each specified time interval, the buffer was withdrawn for analysis and the beads 
discarded. In order to maintain a constant sink condition, fresh PBS (1 to 3 ml depending 
on the incubation duration) was added to the remaining beads (for subsequent data 
points). Subsequently 2 ml of DCM was added to the withdrawn buffer solution to extract 
 absorbance at 317.33 nm (ICP Optima 
3,000 DV, Perkin Elmer, USA).  
 
5.2.5.2 In vitro Paclitaxel Release from Hydrogel Beads 
 An in vitro paclitaxel release study was conducted by immersing each bead (PLGA-
paclitaxel-loaded alginate bead or paclitaxel-loaded alginate bead) into a 1 ml PBS buffer 
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the paclitaxel from the aqueous phase by allowing mass transfer for 2 days. A mixture of 
acetonitrile-water (50:50, v/v) was added to the extracted paclitaxel after the DCM had 
evaporated. HPLC analysis was performed as explained previously for the loading 
efficiency study. 
 
5.2.6 In vitro Cell Culture Study 
5.2.6.1 Cell Culture and Maintenance 
 Rat C6 glioma (ATCC® Number: CCL-107™) was employed as the tumour cell line 
in this study. The cells were grown in DMEM (Sigma Aldrich) supplemented with 10% 
FBS and 1% penicillin/streptomycin in a humidified incubator under the conditions of 
37°C, 5% CO2 and 90% relative humidity. The cells were washed in PBS and detached 
from the T-flask using trypsin-EDTA after they had reached 90% confluence. The cells 
were centrifuged at a speed of 1,500 rpm for 6 min and resuspended to obtain a 
concentration of 3×105
 The cytotoxicity of selected formulations (H80 and M80 beads) was evaluated via a 
cell viability study using a premix WST-1 cell proliferation assay. 5×10
 cells/2.5 μl before inoculation into a 75 cc tissue culture flask 
containing 15 ml of fresh media. 
 
5.2.6.2 In vitro Cytotoxicity against C6 Glioma Cells 
3 C6 glioma cells 
were meticulously seeded into 48-well plates. Two hundred microliter of fresh medium 
was added per well before the plates were left to incubate for 24 h. Thereafter, the spent 
medium was removed and replenished with fresh medium. Hydrogel beads were added to 
the respective wells to give the specified paclitaxel concentrations (predicted using the in 
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vitro release profiles). Each 48-well plate was prepared to consist of at least one row of 
control (i.e., no drug administered to the wells) for the accurate monitoring of growth 
conditions that could vary from plate to plate. At the end of the 72-h exposure to the 
drug, the used medium and beads were removed. Each well was then filled with 400 μL 
of fresh medium coupled with 40 μL of the assay (volume ratio of 1:10). Addition of 
premix WST-1 was done in darkness due to the light sensitivity of the assay. To ensure 
accuracy, the plates were wrapped in aluminium foil after assay addition and left to 
incubate for an additional 4 h. Thereafter, the plates were observed by a microplate reader 
(Safire2, TECAN, Switzerland) at 430 nm with a reference wavelength of 620 nm. 
 
 Cell viability was calculated by normalizing the absorbance values of cells treated 
with hydrogel beads against the absorbance value of the control wells defined as follows: 
 
5.2.6.3 In vitro Cellular Apoptosis 
 Paclitaxel-induced apoptosis in the C6 glioma cells was quantified after the treatment 
with H80 and M80 beads and subsequently compared with three groups: blank control 
(no drug and implant), placebo control (implant with no drug) and Taxol® control. Each 
group consisted of triplicates. First, all the groups were inoculated with 1×106 C6 glioma 
cells each in 75 ml tissue culture flasks with 30 ml of DMEM. Before the treatment was 
initiated, the cells were allowed to attach and grow in the flask for 2 days (day 0). Studies 
of cell density and apoptosis were performed on days 2, 4 and 6. C6 cells in the Taxol® 
control group received commercial Taxol®
Cell Viability (%) = 
 on day 2 at doses equivalent to the paclitaxel 
Absorbance of test cells 
× 100                                        (5.3) 
Absorbance of control cells 
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released from H80 beads after 6 days (from in vitro release profiles), and, subsequently, 
the Taxol®-laden media were removed after 24 h and the cells were washed twice by PBS 
before replenishing with fresh medium. The Taxol® control was employed in this study to 
simulate the systemic chemotherapy (acute paclitaxel exposure and subsequent 
clearance). Cellular recovery was anticipated after drug clearance in the Taxol® group. 
For the H80 and M80 groups, the respective beads were introduced on day 2. Cell 
counting was performed using a haemocytometer after days 2, 4, and 6 to obtain the cell 
density.  
 
 On days 2, 4 and 6, 1×106 cells were collected for caspase-3 activity-level 
measurement (indicative of apoptosis extent) of the samples using a caspase-3/CPP32 
fluorometric assay kit. Apoptotic (caspase-3) activity level was quantified by re-
suspending the cells in 50 μl chilled lysis buffer and incubating them on ice for 10 min 
before adding 50 μl of 2x reaction buffer (with 1% 10 mM DTT) to each sample. 
Subsequently, 5 μl of 1 mM DEVD-AFC substrate was added before the samples were 
transferred to 96-well plates. The plates were then incubated at 37°C for 2 h in a 
humidified incubator before reading the samples in a microplate reader (fluorometer) 
from Tecan Genios, Switzerland, equipped with a 405 nm excitation filter and 485 nm 
emission filter. Upon cleavage of the substrate by CPP32 or related caspases, free AFC 
emits a yellow-green fluorescence (max = 505 nm). Absorbance for the experimental 
groups was then compared with the controls for caspase-3 activity (extent of apoptosis) 
and paclitaxel-induced apoptosis. 
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5.2.7 In vivo Evaluation 
5.2.7.1 Animal Care and Maintenance 
 All animal experiments were performed at the Sing-Health Experimental Medicine 
Center (SEMC), Singapore General Hospital (SGH) with approval from the SGH 
Institutional Animal Care and Use Committee (IACUC). Experimental practices were 
conducted in accordance with the National Advisory Committee for Laboratory Animal 
Research (NACLAR) guidelines (guidelines on the care and use of animals for scientific 
purposes) in facilities licensed by the Agri-food and Veterinary Authority of Singapore 
(AVA).  
 
 BALB/c nude male mice of about 5 weeks were purchased from the Animal Resource 
Centre, Murdoch, Western Australia under an import license from the AVA. They were 
housed in cages of fives and left to acclimatize for a week at the SEMC prior to an 
experiment. Free access to food and water was given. The anaesthesia administered 
before surgical procedures contained 50 mg/kg Ketamine and 5 mg/kg Valium. The 
painkiller contained 5 mg/kg Toradol and antibiotics contained 15–20 mg/kg Baytril.  
 
5.2.7.2 In Vivo Subcutaneous Tumour Volume Study 
 Animals were randomized into different groups with five animals in each group: three 
control groups namely control group (no beads and no drug), placebo control (beads 
without drug) and Taxol®; and two experimental groups, namely H80 and M80. Animals 
in the H80 and M80 groups were implanted with three beads each, weighing in total 
about 2 mg with an average paclitaxel amount of 162 μg per animal. On day 0, all the 
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animals were inoculated with 5×105 C6 glioma cells subcutaneously by injecting using a 
27G needle to the right flank. The tumour was allowed to grow for 7 days after which 
treatment was commenced. For animals under placebo and the M80 groups, the beads 
were implanted by aseptic surgery as follows: a small incision was made into the skin and 
the tumour was reached after which another incision was made into the tumour in order 
to implant the beads. The wound was closed using subcutaneous suturing. However, for 
the animals in the H80 group, the beads were implanted around the tumour. Animals in 
the Taxol® control group were administered with a dose equivalent to the total amount of 
paclitaxel administered using the beads (0.03 ml of commercial Taxol® injection 
(concentration of 6 mg paclitaxel/ml)) directly into the tumour mass. Equal amounts of 
paclitaxel were administered into animals from the Taxol® group and the experimental 
groups for an equitable comparison of the treatments. Every seven days, the lengths of 
the major (longest diameter) and minor axes (perpendicular to the major axis) of the 
tumour were measured to determine the ellipsoidal tumour volume using the formula 
(Volume = [Π/6] x A x B2), where A and B represent the lengths of the major and minor 
axes of the tumour, respectively. Weight monitoring of the animals was carried out once 
a week in order to detect any experimental abnormalities. For easy comparison, the 
percent reduction in tumour volume (RTV) was calculated for the H80 and M80 groups 
against the blank control and Taxol® groups using the formula % RTV = 100 x (VC-
VE)/VC, where VC and VE represent the tumour volume of animals from the control 
(blank or Taxol®) and experimental groups, respectively as shown in Table 5.3. 
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5.2.7.3 Statistical Analysis 
 An ANOVA single-factor test at a significance level of 0.05 was used to determine if 
the apoptotic levels between the M80 and H80 groups were significantly different from 
that of the blank and Taxol® groups. In the subcutaneous tumour study, statistically 
significant differences (p<0.05) in the tumour volume among groups were analyzed by 
one-way analysis of variance (ANOVA). 
 
5.3 Results 
5.3.1 Physicochemical Characterization of Hydrogel Beads 
5.3.1.1 Morphology, Size Distribution and Uniformity of Microsphere Entrapment 
 PLGA-paclitaxel microspheres fabricated using the EHDA process yielded highly 
monodisperse microspheres with a spherical shape and smooth surface morphology as 
shown in Figure 5.2A, and the size distribution analysis revealed that the microspheres 
had a mean diameter of 11.76 ± 2.79 μm with 86% of the total volume comprising 
microspheres between 9 to 18 μm.  
 
 The electrospray process followed by gelation at the specified operating parameters 
listed in Table 5.1 yielded monodisperse beads with the average bead diameters shown in 
Table 5.2. Importantly, the microspheres were uniformly distributed throughout the 
hydrogel matrix and maintained their original morphology, which is confirmed in the 
representative images in Figures 5.2B, C and D. All the formulations had a uniform 
distribution of microspheres inside the gel matrix.  
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Figure 5.2 Representative SEM images of (A) PLGA-paclitaxel microspheres fabricated 
by the EHDA process; (B) cross-sectional view of an alginate gel bead entrapping 
PLGA-paclitaxel microspheres; (C) high magnification image of (B) with the large arrow 
showing the microspheres and the small arrow pointing to the gel matrix; (D) higher 
magnification of the alginate matrix with the arrow showing the hydrogel. 
 
 
Table 5.2 Physicochemical Characterization of Hydrogel Beads Fabricated by Electrospray 
Formulations Average Bead Diameter (mm) Loading Efficiency (%) 
50% microsphere loaded beads 1.61 ± 0.04 98.02 ± 1.07 
80% microsphere loaded beads 1.65 ± 0.06 98.50 ± 2.02 
90% microsphere loaded beads 1.68 ± 0.05 97.10 ± 3.77 
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5.3.1.2 Encapsulation Efficiency and Loading Efficiency 
 Paclitaxel was well-encapsulated in the microspheres (82 ± 0.1%) after the EHDA 
process. Also, the electrospray process and instantaneous gelation facilitated achieving 
good microsphere loading efficiency (~98%) in the gel matrix.  
 
5.3.1.3 Thermal Analysis of Hydrogel Beads 
 Figure 5.3 shows the characteristic DSC thermographs obtained for representative 
samples. The endothermic peak centred close to 85°C represents the thermogram for pure 
calcium alginate described in the literature (Soares et al., 2004). Another endothermic 
peak was observed at around 45 to 50°C corresponding to the relaxation event following 
the glass transition of PLGA 50:50 that have been reported to have a glass transition 
temperature (Tg) range of about 40 to 60°C (Xie et al., 2006b). Interestingly, with an 
increase in alginate content in the beads, the endothermic peak of PLGA increased 
slightly as seen for the H90 thermogram in Figure 5.3. Pure crystalline paclitaxel has 
been reported to show a sharp endothermic melting peak at 223°C (Xie et al., 2006b), but 
none of the formulations exhibited an endothermic melting peak at 223°C. However, an 
exothermic peak at around 246°C was observed in the samples containing paclitaxel.  
Chapter 5                                Hydrogel matrix entrapping PLGA-paclitaxel microspheres                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
99 
 
Figure 5.3 Representative DSC thermographs of alginate beads entrapping PLGA-paclitaxel 
microspheres under the gelation conditions of 2% (w/v) CaCl2
 The nine formulations whose preparative variables are summarized in Table 5.1 
constituted the entire range for this study. The prefixes H, M and L refer to the extent of 
cross-linking in the beads, (high, medium and low) brought about by the corresponding 
conditions of gelation time and gelation bath concentration. The other variable studied 
was the microsphere loading that was fixed at 50, 80 and 90% (w/w). For example, H80 
would mean that the bead was fabricated using 2% (w/w) CaCl
 and a 15-min gelation time. The 
Control represents the alginate beads entrapping blank microspheres without paclitaxel. 
 
5.3.2 In Vitro Characterization of Hydrogel Beads 
5.3.2.1 Hydrogel Bead Disintegration Study 
2 solution, gelled for 15 
min and contained 80% (w/w) microspheres. Results from Figure 5.4A reveal that the 
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disintegration time of the beads decreased with an increase in microsphere loading. 
Furthermore, at the same microsphere loading, an increase in the extent of cross-linking 
resulted in slower disintegration of the beads.  
 
 To understand the effect of gelation time, gelling bath concentration and microsphere 
loading on the cross-link density of the beads, the total Ca2+ 
 
 
ion content was measured in 
the beads. Data from Figure 5.4B suggest that at any microsphere loading, increase in 
gelling bath concentration and gelation time would increase the cross-link density. 
However, with an increase in microsphere loading there is an optimum cross-link density 
observed. 
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Figure 5.4 (A) Effect of microsphere loading on the disintegration of the alginate beads in PBS 
solution at 37°C and 120 rpm at different gelation conditions. Each data point represents the 
average of triplicate samples and the error bars represent the standard deviation; (B) Effect of 
microsphere loading on the total Ca2+
 This study was performed to evaluate the effect of various preparative variables on 
the paclitaxel release from the alginate matrix entrapping microspheres in an in vitro 
environment. Figures 5.5A, B and C show the paclitaxel release profiles for the various 
formulations. Generally it can be seen that in comparison to the free PLGA-paclitaxel 
microspheres (Xie et al., 2006b), the initial burst from all the formulations was smaller 
 ion content of the alginate beads after complete 
disintegration in PBS solution at 37°C and 120 rpm at different gelation conditions. Each data 
point represents the average of triplicate samples and the error bars represent the standard 
deviation. 
 
5.3.2.2 In vitro Paclitaxel Release from Hydrogel Beads  
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and decreased as the microsphere loading increased. Importantly, near-zero-order release 
kinetics was exhibited by most of the formulations. In case of the 50 and 90% 
microsphere loaded beads, an increase in the extent of cross-linking usually resulted in 
lower release rates indicated by the percent cumulative release after 60 days. 
Interestingly, for the 80% microsphere-loaded beads, an increase in the extent of cross-
linking brought about an increase in the release rate as seen from Figure 5.5B. Moreover, 
the percent drug released after 60 days decreased as the microsphere loading was 
increased. For the paclitaxel-loaded alginate beads, we noticed that the alginate matrix 
disintegrated within 1 or 2 days depending on the extent of cross-linking and resulted in 
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Figure 5.5 In vitro release of paclitaxel from different formulations of the alginate beads. (A) 
50% (w/w) microsphere-loaded beads and paclitaxel-loaded beads; (B) 80% (w/w) microsphere-
loaded beads and paclitaxel-loaded beads; (C) 90% (w/w) microsphere-loaded beads and 
paclitaxel-loaded beads. Each data point represents the average of triplicate samples and the error 
bars represent the standard deviation. H90P, M90P, etc. refers to paclitaxel-loaded beads with 
equivalent amount of paclitaxel as compared to its microsphere loaded beads.  
 
5.3.3 In vitro Cell Culture Study 
5.3.3.1 In vitro Cytotoxicity against C6 Glioma Cells 
 Based on the release study, two formulations (H80 and M80) were screened to be 
used in the evaluation of in vitro cytotoxicity against C6 glioma cells. The cytotoxic 
potency was assessed based on the quantification of IC50 of the formulations in 
comparison to Taxol® (Xie et al., 2006b). IC50 refers to the concentration of the 
formulation required to inhibit 50% of cell growth in vitro. Figure 5.6 shows a gradual 
decrease in cell viability after 3 days of treatment with varying concentrations of the 
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beads (or paclitaxel concentrations). IC50
 
Figure 5.6 Cell viability of C6 glioma cells treated with different formulations of the alginate 
beads for 3 days in vitro. The dotted line represents 50% cell viability and the arrows point to the 
approximate IC
 values of M80 and H80 were approximately 
1,500 μg/ml and 4,800 μg/ml respectively (marked by the two arrows in Figure 5.6 and 
with good regression coefficients), which corresponds to about 25 μg/ml of paclitaxel 
based on the in vitro release profiles. 
 
50
 Figure 5.7 presents the extent of apoptosis or caspase-3 activity measured by 
fluorescence intensity in the C6 glioma cells being treated with various groups. Clearly, 
the blank and placebo groups showed negligible signs of apoptosis even after 6 days. On 
 value of the respective formulations. Each data point represents the average of 
triplicate samples and the error bars represent the standard deviation. 
 
5.3.3.2 In vitro Cellular Apoptosis 
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day 2, the Taxol® group exhibited significant apoptosis in comparison to the blank 
(p<0.05) and H80 groups (p<0.05), while the difference was not significant when 
compared to the M80 group. Interestingly, the level of apoptosis started to decrease 
gradually on days 4 and 6 for Taxol®. On all the treatment days for the H80 and M80 
groups, the extent of apoptosis was significantly higher than that of the blank (p<0.05). In 
contrast to Taxol® the H80 and M80 groups demonstrated a gradual increase in the 
apoptosis level. On day 6, both the H80 and M80 groups had a significantly higher 
apoptosis level compared to Taxol®
 
Figure 5.7 Extent of apoptosis (measured by absorbance or fluorescence intensity) in C6 glioma 
cells treated with different groups after 2, 4 and 6 days in vitro. The Taxol
.  
 
® group represents the 
equivalent amount of commercial Taxol® corresponding to paclitaxel release from M80 after 6 
days (from in vitro release profiles). Each data point represents the average of three samples and 
the error bars represent the standard deviation. The symbols * represents a significant difference 
(p<0.05) in comparison to the control by ANOVA and + represents a significant difference 
(p<0.05) between the two samples by ANOVA.  
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5.3.4 In vivo Subcutaneous Tumour Volume Study 
 As proof of concept, this study was intended to evaluate the efficacy of the H80 and 
M80 formulations in treating the subcutaneous C6 glioma tumour in mice in comparison 
to the blank control and Taxol® groups. Figure 5.8 shows the change in tumour volume 
after 7, 14 and 21 days of treatment for the various groups. The blank control and placebo 
control showed similar tumour growth for the entire period of study. In comparison to the 
blank control, animals in the Taxol® group had smaller tumours, but the difference was 
not significant (p>0.05). For both the H80 and M80 treated animals, the tumours were 
significantly smaller in comparison to those treated with the blank control (p<0.05) for 
the entire treatment period. However, in comparison to the Taxol® group, the tumours 
were not significantly smaller for the H80 treated mice (p>0.05), but the M80 treated 
animals had significantly smaller tumours (p<0.05) on days 7 and day 21. The H80 group 
exhibited about 52 and 32% smaller tumours in comparison to the blank control and 
Taxol® groups, whereas the M80 group showed about 85 and 78% smaller tumours 
compared to the blank control and Taxol® group, respectively.  
 
Table 5.3 Reduction in tumor volume for H80 and M80 groups in comparison to control and 
Taxol®
Formulations 
 groups after 21 days of treatment.  
 
RTV (%) against Control RTV (%) against Taxol® 
H80 beads 52 32 
M80 beads 85 78 
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Figure 5.8 In vivo subcutaneous C6 tumour volume profiles of mice treated with different groups 
for 21 days. (▲) Control; (x) Placebo control; (●) Taxol®
 Since EHDA is a proven simple and efficient fabrication technique, it was utilized to 
produce the microspheres in this study. The monodispersity of the microspheres was 
achieved by having a ring voltage to stabilize the electric field resulting in a single spray 
cone and a uniform particle size distribution (Xie et al., 2006a). Spherical shape and 
smooth morphology were obtained by controlling the flow rate, polymer concentration 
and nitrogen flow rate across the jet that aids in the evaporation of the organic solvent. 
The electrospray process to drip the suspension of microspheres into the gelation bath 
 control; (◆) H80 beads; () M80 
beads. Each data point represents five samples (n=5 animals). Animals were sacrificed after 21 
days. Error bars represent the standard deviation. 
 
5.4 Discussion 
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proved to be efficient in obtaining high monodispersity of the beads with high 
throughput. Furthermore, the uniformity of the microsphere distribution inside the gel 
matrix was facilitated by the presence of the surfactant Tween 80 in the sodium alginate 
solution, which helped the highly hydrophobic microspheres to stay uniformly suspended 
during the dripping. Also, the cross-linked alginate gel layer could be seen both on the 
surface and within the bead, which confirms that Ca2+ ions were able to diffuse into the 
bead and form the gel, thus entrapping the microspheres within them. The paclitaxel 
encapsulation efficiency in the microspheres was high, suggesting that the EHDA aided 
in uniformly dispersing the amorphous paclitaxel within them. The high microsphere 
loading efficiency proved that the electrospray process provided uniformly sized beads. 
Also, the instantaneous gelation of the bead with Ca2+
 The absence of an endothermic melting peak at 223°C in the thermal analysis (Figure 
5.3) revealed that paclitaxel was in a molecular-dispersion or amorphous state in the 
microspheres even after encapsulation and subsequent entrapment in the gel matrix. The 
slight increase in the endothermic (relaxation) peak following glass transition for PLGA 
with an increase in microsphere loading was probably due to additional endothermic 
overlap owing to the energy required to overcome the microstructure of the polymer 
(Dubernet, 1995). Broad peaks observed for alginate were in correspondence with the 
high poly-dispersity of alginate chains (Donth EJ, 1992). Polymer-drug crystallinity has 
been a key concern related to drug delivery efficiency. It has been established that 
molecular dispersions give better release profiles relative to particulate dispersions of the 
 ions prevented the escape of 
microspheres from the matrix, thereby resulting in a high loading efficiency. 
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same drug (Freiberg and Zhu, 2004). Hence, in view of the goal of the current 
formulations to provide constant drug release at a relatively higher rate, molecular 
dispersion of paclitaxel seems to be well-suited for the intended drug delivery 
applications.  
 
 Disintegration of the gel matrix due to dissociation of the Ca2+ cross-links resulting in 
the release of the microspheres was the controlling process in minimizing the initial burst 
release. Degradation of alginate has been reported to be very slow (Boontheekul et al., 
2005) and does not contribute to the release of the microspheres and the drug. The 
disintegration time of the bead is controlled by three major factors, namely gelation time, 
gelation bath concentration and microsphere loading. An increase in the first two factors 
increases the extent of cross-linking and thus the time needed to disintegrate the beads 
would be higher. But with an increase in microsphere loading, the diffusion of Ca2+
 For any given volume of the alginate-microsphere suspension dripped into the gelling 
bath, the cross-link density depends on volume of alginate available for cross-linking and 
the porosity of the bead. In case of 50% loaded beads, due to larger volume of alginate 
solution, the cross-link density could be relatively lower. With the 90% loaded beads, 
since the available alginate volume is lower, it could result in higher cross-linking 
 ions 
into the bead for cross-linking would be hindered due to a higher density of microspheres 
and lower porosity leading to a decrease in disintegration time. The disintegration study 
was performed with agitation (120 rpm) to shorten the duration of the experiment and 
thus does not adequately represent the actual scenario in a static environment.  
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density. Interestingly, the 80% loaded beads seem to possess the densest cross-linking 
probably due to the availability of an optimum volume of alginate and penetration of Ca2+
 From the in vitro release results, it can be seen that all the formulations were able to 
release the drug sustainably for more than 60 days with minimum initial burst. It is a well 
known fact that the initial burst is due to the surface bound drug that readily dislodges 
itself from the microsphere surface upon contact with the release medium. Polymer 
degradation could be safely ruled out because of the time scale of the initial burst. 
Diffusion of the drug from the core of the microsphere could also be slow since PLGA is 
hydrophobic and does not readily allow penetration of the aqueous release medium. To 
better understand the parameters affecting the initial burst, we compared our implants 
with free PLGA-paclitaxel microspheres reported by Xie et al., 2006b. Clearly, the data 
suggest that the free microspheres exhibit a high initial burst (around 30%) within 2 days 
followed by sustained release; the reason has been reported to be due to the surface-
 
ions. These results reveal that the microsphere loading could be more dominant in 
controlling the disintegration; thus, in Figure 5.4A, with an increase in microsphere 
loading, the disintegration time decreases. 
 
 The in vitro release of paclitaxel from the entrapped PLGA microspheres is controlled 
by three important factors. During the initial stages, the degree of cross-linking of the gel 
matrix and the density of microsphere packing in the matrix are important since they 
control the disintegration of the bead releasing the microspheres. Much later, the 
degradation of PLGA would dictate the release. 
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bound paclitaxel on the microspheres. In our case, due to the fact that not all the 
microspheres were exposed to the release medium and due to the presence of the alginate 
matrix barrier, the initial burst was avoided. Additionally, the data from Figures 5.5A, B 
and C suggest that as the microsphere loading increased (which increased the density of 
microsphere packing), the initial burst decreased. Thus, the decrease in the initial burst 
with an increase in microsphere loading could be due to the denser packing of 
microspheres and reduced porosity that hindered the penetration of buffer into the bead. 
This seems to contradict the disintegration study results, where the increase in 
microsphere loading showed a decrease in disintegration time. However, it should be 
noted that the disintegration studies were performed with agitation at 120 rpm that aided 
in the dispersion of the microspheres, while the release studies were done statically 
(without agitation to avoid disturbing the microspheres). 
 
 The in vitro release was also affected by the extent of cross-linking in the gel. For 50 
and 90% microsphere-loaded beads, the decrease in drug release rate with an increase in 
the extent of cross-linking as seen in Figures 5.5A and C was evidently due to two 
important factors. First, the increase in cross-linking would result in stronger beads, thus 
prolonging the disintegration time. Second, with higher gel content the beads would 
swell, thus increasing the drug diffusion pathway resulting in reduced release rates. 
However, the 80% microsphere-loaded beads behaved contrastingly, suggesting that 80% 
loading could be optimum (in terms of swelling and density of packing); hence, with an 
increase in the degree of cross-linking, the release rate increased. Additionally, in the 
case of paclitaxel-loaded alginate beads, data from Figures 5.5A, B and C reveal that due 
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to rapid disintegration of the alginate matrix, paclitaxel was released rapidly and proved 
that the paclitaxel itself did not provide controlled release. 
 
 Furthermore, zero-order kinetics is dictated by the geometry of the carrier and is more 
or less independent of the drug properties or composition. Hence the near-zero order 
release profile was exhibited by the formulations that maintained the geometry for a 
longer period before complete disintegration. For the 50% microsphere loaded beads, the 
release deviates slightly from zero-order kinetics as compared to the other two. Since the 
alginate hydrogel de-cross-links and dissolves in the release medium, the drug release 
then depends on PLGA degradation and drug diffusion into the release medium. But for 
80 and 90% microsphere-loaded beads, due to denser packing, the disintegration is 
slower, thereby leading to a relatively near-zero order release. Owing to the release 
properties of the H80 and M80 formulations in terms of minimum initial burst, near-zero-
order release kinetics and optimum microsphere loading, we chose to use them for the 
subsequent cell culture and animal studies.  
 
 Recently, a trans-lymphatic drug delivery system was reported that constituted a 
gelation sponge impregnated with PLGA-paclitaxel microspheres (Liu et al., 2007). 
However, these implants had very low microsphere loading (1% w/w), which means 
gelatine was used just to impregnate the drug-loaded microspheres and has no anti-cancer 
properties. Also, the spray drying process to fabricate the microspheres had very low 
yield (12.3%). But most importantly, the release profiles exhibited by PLGA-Taxol, 
Spon-PLGA (Taxol) and cross-linked Spon-PLGA (Taxol) were not significantly 
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different, thereby pointing to the fact that this previous publication did not demonstrate 
what parameters would affect the drug release from these implants. In comparison, the 
implants in the current study achieved very high microsphere loading (90% w/w) with 
high EHDA yield (40%) and possessed tuneable controlled drug release by varying 
different process parameters. Other paclitaxel-delivering microspheres such as PLGA 
microspheres (Xie et al., 2006b), polilactofate microspheres (Li et al., 2003) and PCPP-
SA microsphere discs (Walter et al., 1994) display a significant initial burst relative to the 
microspheres entrapped in the gel matrix developed in this study. The initial burst caused 
either by loosely bound drug or fast degrading polymer has been reported to result in 
sporadic toxicity in experimental animals (Walter et al., 1994). In comparison, the 
microspheres entrapped in gel have a minimum initial burst, near constant drug release 
rate and prolonged sustainability and thus strong clinical implications. Moreover, this 
composite drug delivery system synergizes the advantages of microsphere containment 
(implantability) and sustained drug release.  
 
 When paclitaxel was administered as Taxol® for three days to inhibit C6 glioma cells 
in vitro, the IC50 value was shown to be approximately 30 μg/ml (Xie et al., 2006b). 
Results from the cytotoxicity tests shown in Figure 5.6 reveal that about 1,500 μg/ml of 
H80 and 4,800 μg/ml of M80 would be necessary to bring about the same cytotoxic effect 
or reach an IC50 paclitaxel concentration. These results highlight the fact that the 
formulations pose similar cytotoxicity as systemically administered Taxol®. The 
advantage is that H80 and M80 need to be implanted only once to see the effect, whereas 
Taxol® needs repeated systemic administration at high concentration. From the apoptosis 
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results shown in Figure 5.7, for H80 and M80 the sustainability of paclitaxel-induced 
apoptosis in C6 glioma cells and low cellular recovery were evident due to near constant 
drug release. In contrast, Taxol®, which was cleared off after one day (simulating the 
drug clearance from the body), resulted in cellular recovery and reduced apoptosis after 6 
days. This demonstrates that the beads have the potential to sustain therapeutic levels of 
paclitaxel and would prevent cellular recovery ensuring apoptosis. 
 
 From the subcutaneous tumour volume study, it was evident that alginate or PLGA in 
the implant did not cause any cytotoxicity to the tumour. Taxol®
 A novel drug delivery implant comprising an alginate gel matrix entrapping 
paclitaxel-loaded PLGA microspheres was developed using the electrospray process in 
 injection was initially 
effective in reducing the tumour volume, but later due to drug clearance, a fast increase in 
the tumour size was seen, which underscores the limitations of systemic drug delivery. 
However, the two formulations (H80 and M80) showed significantly smaller tumours in 
comparison to the blank control due to sustained paclitaxel release during the entire 
treatment period. This accentuates the fact that these implants release therapeutic 
concentrations of paclitaxel even after 21 days. Since the tumours treated in this study 
were solid tumours and due to the space constraint, the beads implanted were limited, we 
could not observe a higher reduction in tumour volume. Nevertheless, these gel-matrix 
entrapped microspheres could be potential local chemotherapy implants to treat 
malignant glioma and could be engineered specific to patient requirements. 
 
5.5 Conclusions 
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dripping mode that yielded highly monodisperse spherical gel beads with a uniform 
microsphere distribution and high loading efficiency. Thermal analysis on the implants 
confirmed that paclitaxel was in an amorphous state after the fabrication process that 
facilitates its diffusion from the matrix. The hydrogel bead disintegration study revealed 
that with increase in gelation bath concentration and gelation time, the beads disintegrate 
slowly, whereas with an increase in microsphere loading the disintegration time 
decreased. In vitro release of paclitaxel revealed that the implants could deliver the drug 
sustainably for more than 60 days at a near-constant rate and minimum initial burst. The 
in vitro IC50 study against C6 glioma cells showed that the beads could induce a similar 
cytotoxicity effect as Taxol® that overcomes the need for repeated drug administering. In 
vitro cellular apoptosis of C6 glioma cells suggested that the formulations could provide 
sustainable paclitaxel-induced apoptosis in comparison to Taxol®. Furthermore, 
subcutaneously implanted gel beads in mice could reduce the tumour size in nude mice 
more effectively than Taxol®
 
 and the control, thereby demonstrating their potential in 
local chemotherapy for glioma treatment. However, further in vivo intracranial studies 
focusing on paclitaxel biodistribution in the brain, survivability analysis and evaluation of 
tumour volume regression through bio-imaging are warranted. 
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CHAPTER 6 
Micro/nano-structured Implants Delivering Paclitaxel: Enhanced 
Pharmacokinetics and Therapeutic Efficacy in Treating Intracranial 
Glioblastoma in Mice † 
6.1 Introduction 
The recalcitrance of glioblastoma multiforme (GBM) to a multitude of therapeutic 
modalities has often been contributed to the local tumor recurrence (Behin et al., 2003).  
Although repeated resection could improve survival rate, factors such as insufficient 
clinical trials and bias in patient selection prevents the evaluation of its benefits (Chang et 
al., 2006). On the other hand, the presence of tight capillary cellular junctions of the 
blood-brain barrier (BBB) (Donelli et al., 1992), rapid drug elimination (Loo et al., 1966) 
and neurotoxicity from high drug doses (Kochi and Ushio, 1999) render systemic 
chemotherapy inefficient. Hence, inhibiting GBM recurrence requires sustained and 
therapeutic local drug concentrations.  Local chemotherapy using polymeric drug 
delivery devices not only provides sustained delivery but also ensures protection to the 












This chapter highlights the work: Ranganath SH, Fu Y, Arifin DY, et al. Micro/nano-structured 
implants delivering paclitaxel: Enhanced pharmacokinetics and therapeutic efficacy in treating 
intracranial glioblastoma in mice. Submitted to The FASEB Journal. 2009.  
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GLIADEL® implant was approved by the USFDA for use in post-surgical local 
chemotherapy against recurrent malignant glioma (Brem et al., 1995).  Despite its 
potential, the treatment has demonstrated high variability in efficacy due to drug 
resistance in patients (Brem and Gabikian, 2001) and complications like cerebral edema 
(Weber and Goebel, 2005). But the critical factors that have been ignored are the 
transport properties of carmustine (BCNU). Fleming and Saltzman, 2002 have shown that 
the drug penetration was restricted to regions bordering the implant due to diffusion 
limitations. Furthermore, the lipophilicity and very low half life of BCNU sped up its 
elimination thus hindering the penetration into distant regions of the remnant tumor. 
Carmustine availability is also not highly sustainable since GLIADEL® 
A computational study by Davis et al. (Arifin et al., 2009) demonstrated that 
paclitaxel penetration into the brain tumor is at least two orders of magnitude greater than 
other drugs owing to its slow capillary elimination and enhanced diffusion due to 
convective bulk flow resulting from post-surgical oedema. Paclitaxel also has higher 
cytotoxic potency against malignant glioma in comparison to other drugs (Fung et al., 
is reported to 
release it in vivo over a brief period of 5 days (Fleming and Saltzman, 2002). While these 
limitations necessitated the urgent need to find better chemotherapeutic drugs with 
favourable transport properties, tuning the drug release properties using alternative 
polymers was also investigated (Walter et al., 1994; Menei et al., 1996; Chen et al., 1997; 
Bellinzona et al., 2004; Hsu et al., 2005; Lesniak et al., 2005; Lu et al., 2007), but with 
little evidence of enhanced drug penetration into the remnant tumor or improved 
treatment efficacy.  
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1998) and its penetration into the brain/tumor upon delivery from polymeric implants has 
been investigated (Fung et al., 1998; Li et al., 2003; Ong et al., 2009; von Eckardstein et 
al., 2005) but with unsatisfactory results. For instance, low paclitaxel penetration (1 to 2 
mm) was reported by Fung et al., 1998. Other paclitaxel delivering implants such as 
polilactofate microspheres (Li et al., 2003) and PLGA micro-porous foams (Ong et al., 
2009) have exhibited improved drug penetration, but not reported to have therapeutic 
concentration of 1 ng/mg tissue or ~1 µM (Sonnichsen and Relling, 1994) at distant 
regions of the tissue. Paclitaxel loaded crystalline cubic phases also has failed to provide 
sustainability and deeper penetration (von Eckardstein et al., 2005). The reason for 
insufficient penetration could be the unavailability of drug at sufficient concentration in 
the cavity. Other paclitaxel delivering implants such as compressed discs (Vogelhuber et 
al., 2002; Wang et al., 2003), microparticles (Xie et al., 2006b; Elkharraz et al., 2006) and 
nanoparticles (Xie et al., 2005) are lacking proper in vivo pharmacokinetic investigations.  
 
 These issues entailed us towards developing and investigating paclitaxel delivering 
implants with micro/nano-structures, high drug release sustainability and near zero-order 
kinetics. Firstly, paclitaxel loaded PLGA submicrofibers (F2) was developed (Ranganath 
et al., 2008). Secondly, we demonstrated a composite implant consisting of paclitaxel-
PLGA microspheres entrapped in alginate hydrogel matrix (H80 and M80) (Ranganath et 
al., 2009).  Hence, in this study, firstly, we have developed a new fiber formulation: 
paclitaxel-loaded PLGA nanofiber (F3) and characterized the in vitro drug release. 
Secondly, four formulations (F2, F3, H80, and M80) were investigated for in vivo release 
(in plasma) and in vivo biodistribution/penetration in mouse brain over time. Finally, two 
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formulations with the desired drug penetration were tested for therapeutic efficacy in an 
intracranial U87 MG-luc2 glioblastoma mice model through in vivo luciferase imaging & 
histochemical analysis. 
 
6.2 Materials and Methods 
6.2.1 Preparation of Paclitaxel-loaded PLGA Micro/nano-fibers  
Paclitaxel-PLGA submicrofiber (F2) with ~0.93 µm fiber diameter was fabricated 
using electrospinning technique as reported by Ranganath et al., 2008. Paclitaxel-PLGA 
nanofiber (F3) was fabricated as follows. Drug-polymer solution (8% (w/v) PLGA 50:50, 
10% (w/v) paclitaxel and 20 mM of tetrabutylammonium tetraphenylborate (TATPB) 
(Fluka Chemie, Switzerland) in dichloromethane (DCM) was pumped at 0.20 ml/h using 
a syringe pump through a 27 G needle. The high voltage difference (18-20 kV) applied 
between the nozzle, a negative potential and a grounded collection target created flow 
instability aiding the liquid jet to break up into fibers. The fibers were collected on a 
rotating shaft after DCM evaporated and then punched to obtain 3x1 mm discs. The 
formulations (F2 and F3) were then freeze dried for one week to remove any residual 
organic solvent. Placebo fiber discs were also fabricated under the same conditions 
without the drug. The discs were sterilized using Cobalt-60 gamma irradiation (15 kGy) 
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6.2.2 Fabrication of Alginate Beads Entrapping Paclitaxel-PLGA Microspheres 
The preparation of H80 and M80 formulations was done as described elsewhere 
(Ranganath et al., 2009). The beads were sterilized by exposure to UV light for 24 hours 
before using them in animal studies.  
 
6.2.3 Physicochemical Characterization of the Implants 
The fiber diameter, distribution and morphology of paclitaxel-PLGA nanofiber (F3) 
were examined as described elsewhere (Ranganath et al., 2008). Paclitaxel encapsulation 
efficiency of F3 was quantified and the study on the in vitro paclitaxel release from the 
F3 discs and its quantification was conducted as explained elsewhere (Ranganath et al., 
2008).   
 
6.2.4 Cell Culture and Maintenance 
 U87 MG-luc2, a luciferase expressing human glioblastoma, was purchased from 
Caliper Life Sciences, Hopkinton, MA. The cells were grown in Minimum Essential 
Medium (Invitrogen) with 10% fetal bovine serum (Gibco, Invitrogen) and 1% penicillin-
streptomycin (Gibco, Invitrogen) in humidified atmosphere containing 5% CO2
 All animal experiments were performed with approval from the SGH Institutional 
Animal Care and Use Committee (IACUC) and National University of Singapore (NUS) 
IACUC. Five weeks old BALB/c male mice were purchased from Animal Holding Unit, 
NUS and housed in cages of five. Ketamine (50 mg/kg) and Diazepam (5 mg/kg) were 
 at 37°C.  
 
6.2.5 Animal Care and Maintenance 
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administered during surgery via i.p. injection. Male BALB/c nude mice (about 5 weeks 
old) were purchased from Animal Resource Centre, Murdoch, Western Australia under 
import license from AVA and housed in individually ventilated cages of five. Sterilized 
food and water were accessible ad labium. All animals were left to acclimatize for a week 
prior to the experiments.   
 
6.2.6 In vivo Paclitaxel Release into Plasma and Bio-distribution in Mouse Brain 
 Male BALB/c mice were randomized into four groups: F2, F3, H80 and M80 with 15 
animals each. On day 0, the mice were anaesthetized and immobilized on a stereotactic 
head frame (Thermo Fisher Scientific). A midline incision was made on the scalp and a 
burr hole was placed 2 mm lateral to the sagittal sinus at the midpoint between the 
bregma and lambda. Respective formulations (~2 mg each) were then implanted into the 
burr hole and the wound closed by suture. Analgesic Burprenorphine was administered 
subcutaneously at 1.0 to 2.0 mg/kg for 3 days. Antibiotic Cephalexin was administered 
subcutaneously at 15 to 20 mg/kg over duration of SID for 7 days. At 14, 28 and 42 days 
post-implantation, the animals were sacrificed. The brain and plasma samples (intra-
cardiac blood) were collected and stored at -80 °C for further analysis.  
 
 Paclitaxel concentration in the brain and plasma samples were quantified using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) (Agilent Technologies, 
Germany) as detailed below. Each brain was sectioned into 11 sections by placing in an 
acrylic brain matrix (Harvard Apparatus, Holliston, MA, USA),  sliced into 1.0 mm thick 
coronal sections and each section was weighed. Docetaxel was added to the brain tissue 
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homogenate or plasma samples as internal standard (IS) and extracted using 1.5 ml of 
tert-butyl methyl ether. The samples were analyzed by LC-MSMS using a Thermo 
Hypersil BDS C-18 5 μm (100 x 2.1 mm) column with analytical Eclipse XDS C8 
narrow bore guard column and an API 2000 triple quadrupole mass spectrometer 
(Applied Biosystems, MDS Sciex, Ontario, Canada). An isocratic mobile phase 
consisting of methanol and 0.1% formic acid (50:50, v/v) was used at a flow rate of 0.25 
ml/min. Calibration standards were prepared by adding appropriate aliquots of the 
paclitaxel working solutions to the sham-operated brain tissue homogenate or plasma. 
Standard curves were determined using linear regression of the peak area ratios of 
paclitaxel to internal standard against actual standard concentrations. The inter- and intra-
day precision variability of the bio-analytical method was less than 15% while Inter- and 
intra-day accuracy for 40-400 ng/ml ranged between 96-104% and 85-115% for 2ng/ml. 
 
6.2.7 Therapeutic Efficacy Study in an Intracranial Glioblastoma Xenograft Model 
in Nude Mice 
 In each BALB/c nude mice, at the same brain co-ordinates, a burr hole was drilled 
and 300,000 U87-MG-luc2 cells in 10 μl of medium were injected to a depth of ~2.5 mm 
using a hypodermic needle and the wound was closed by suture. Animals were equally 
randomized into six groups (n = 10): Taxol® control, sham control, placebo H80, placebo 
F3, H80 and F3. Animals in Taxol® group received an intracranial injection of Taxol® 
(Bristol-Meyers Squibb, NJ, USA) weekly with total dose of 200 µg paclitaxel. No 
treatment was given to animals in the sham control group. Mice in the placebo groups 
had implants with no drug. Finally, animals in the F3 and H80 groups were implanted 
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with F3 and H80 devices respectively with a dose of ~200 µg paclitaxel/mouse by aseptic 
stereotactic surgery as explained in the previous section and performed 7 days post tumor 
inoculation. Daily monitoring of behavioral and neurological signs of tumor growth such 
as decreased motility or alertness, poor grooming, passivity, hemiparesis and gait 
disturbance was performed. Animals were sacrificed when these signs appeared. The 
brain samples were collected for bio-distribution study.  
 
6.2.8 In vivo Luciferase Imaging of Intracranial Glioblastoma in Nude Mice 
 To measure the intracranial tumor growth and to assess the therapeutic efficacy, the 
non-invasive bioluminescence imaging (BLI) was performed with IVIS® animal imaging 
system (Xenogen, Alameda, CA, USA) equipped with LivingImageTM software 
(Xenogen) and IGOR (Wavemetrics, Seattle, WA, USA). D-Luciferin potassium salt 
(Caliper Life Sciences), the substrate for firefly luciferase was dissolved in PBS at a 
concentration of 15 mg/ml and filtered through a 0.22 μm filter before use. Mice were 
injected with luciferin at a dose of 150 mg/kg body weight. During image acquisition, 2% 
isofluorane anesthesia in air was delivered via a nose cone system. An integration time of 
30 sec was used for luminescent image acquisition. The signal intensity was quantified as 
the flux of all detected photon counts (total flux) within a constant area of the region of 
interest (ROI) using the LivingImageTM software.  Peak signal time was obtained after 10 
minutes of luciferin administering. Bioluminescence was measured on days 6, 13, 20, 27, 
34, 41 post tumor inoculations.   
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6.2.9 Histology and Immunohistochemical Analysis 
 Mice in the six groups were sacrificed by pentobarbitone overdose. Brains were 
harvested in 4% buffered formaldehyde for 48 h, then sliced into 4 μm coronal sections 
using a microtome and H&E staining was performed. Immunostaining was carried out by 
incubating 5 μm dewaxed sections with 3% hydrogen peroxide for 10 minutes, rinsing 
with Tris Buffer Saline (TBS), and then incubating with mouse anti human Ki-67 (Dako, 
Glostrup, Denmark) 1:300 for 30 min. Ki-67 index was calculated as the percentage of 
total Ki-67 positive cells from four randomly selected high-power fields (400x) in 
intracranial tumor. 
 
6.2.10 Statistical Analysis 
 Comparison of the bio-luminescence data with control animals were performed using 
an unpaired 2-sided Student t test.  p<0.05 was considered statistically significant. For 
Ki-67 staining, comparison of H80 and F3 with their respective placebo groups was 
performed using 1-sided Student’s t test and p<0.001 and p<0.0001 was considered 
statistically significant respectively.  
 
6.3 Results  
6.3.1 Physicochemical Characterization of the Implants 
 FESEM micrographs from Figure 6.1A revealed that the F3 fibers were monodisperse 
and nano-scaled with mean diameter of 102 ± 20 nm, apart from possessing relatively 
smooth morphology. The F3 discs also exhibited a high paclitaxel encapsulation 
efficiency of 90.00 ± 1.09%. Similarly, we have reported high monodispersity and 
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paclitaxel encapsulation efficiency in the sub-micron fiber (F2) (Ranganath et al., 2008) 
and the H80 and M80 hydrogel beads (Ranganath et al., 2009). A representative image of 
the H80 bead is shown in Figure 6.1B.    
 
6.3.2 In vitro Paclitaxel Release from the Implants 
 The F3 discs exhibited slight initial burst and later the release profile was at near 
constant rate as depicted in Figure 6.1C with release sustainability for more than 60 days. 
Overall, the rate was approximated to be near zero-order with minimum initial burst. The 
release profiles of F2, H80 and M80 are reused in Figure 6.1C with permission from the 
publishers. Submicro-fiber discs (F2) have been reported to have slow release rate, lower 
initial burst and high sustainability (Ranganath et al., 2008).  Similarly, H80 and M80 
bead implants have demonstrated high drug release sustainability, low initial burst and 
near zero-order kinetics (Ranganath et al., 2009), but H80 has higher release rate. 
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Figure 6.1 Physical and in vitro release characterization of the formulations. (A) Representative 
FESEM image of paclitaxel-loaded F3 fiber disc; (B) Representative scanning electron 
microscopy image of the cross-sectional view of an alginate gel bead entrapping PLGA-paclitaxel 
microspheres (H80); (C) In vitro release of paclitaxel from 9.1 % paclitaxel-loaded F3 discs, 9.1 
% paclitaxel-loaded F2 discs (Ranganath et al., 2008), H80 and M80 beads (Ranganath et al., 









Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
128 
6.3.3 In vivo Paclitaxel Release in Mouse Plasma 
 This effort was to investigate whether the paclitaxel released from the implants would 
be eliminated systemically or not. After 14, 28 and 42 days of implantation in the brain, 
paclitaxel was undetectable in the mouse plasma samples or the concentrations were 
below the detectable limit (1 ng/ml) of LC-MS/MS. None of the implanted animals 
showed signs of weight loss or systemic toxicity during the entire period of study (data 
not shown).   
 
6.3.4 In vivo Paclitaxel Bio-distribution in Mouse Brain 
 An investigation of paclitaxel bio-distribution in the mouse brain resulting from the 
intracranial implantation of the formulations was performed. Paclitaxel levels were 
detectable at 14, 28 and 42 days post-implantation at distant regions in the brain as shown 
in Figures 6.2 (A-D). F2 discs have an exponential drop in concentration across the brain 
(at least 1000 times decrease). Barring day 28, the penetration on days 14 and 42 are just 
close to the therapeutic concentration at 3-5 mm. On the contrary, F3 discs demonstrate a 
uniform drug distribution with smaller gradient (roughly 50 times) and well above the 
desired therapeutic concentration up to at least 5 mm from the implant site. H80 and M80 
also exhibit exponential drop in concentration, however the initial drug penetration for 
M80 is below the therapeutic value at distant regions. In case of H80 however, farther 
from the implant the drug penetration is near the cutoff value.  Additionally, no 
behavioral or systemic irregularities were noticed in the animals implanted with these 
devices (data not shown).     
 
Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              





Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              





Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
131 
Figure 6.2 In vivo biodistribution of paclitaxel in mouse brain.  (A) 9.1% paclitaxel-loaded F2 
discs; (B) 9.1% paclitaxel-loaded F3 discs; (C) paclitaxel-PLGA microsphere entrapped alginate 
beads with high cross-linking extent (H80); (D) paclitaxel-PLGA microsphere entrapped alginate 
beads with medium cross-linking extent (M80). (n = 5 animals).  Error bars represent standard 
deviation. 
 
6.3.5 Investigation of the Transport Mechanism of Paclitaxel in Mouse Brain 
 The brain tissue can be modeled as a medium consisting of interstitial (extracellular), 
intracellular, and membrane phases (Arifin et al., 2009). In general, the delivery is 
dependent on the rate of transport (diffusion and convection), elimination (degradation 
and transcapillary exchange), and local binding. Upon release, the drug distribution is 
expected to be in quasi-steady state. Considering the penetration from the implant site to 
the posterior/anterior section, a one-dimensional transport equation will suffice. In small 
animals such as mouse, fluid convection appeared to be important during edema, 
specifically at the beginning first week of the treatment (Arifin et al., 2009). In this study, 
drug concentration profiles are available beyond this period, i.e. at days 14, 28, and 42. 
Hence convection can be assumed negligible. Therefore, the paclitaxel concentration 
profile would follow 
[ ]i i,0 dexpC C x LΓ = = −         (6.1) 
where i,0C  is the interstitial drug concentration at the implant site, x is the distance from 
the implant site (mm), and d =L D k  is the diffusion/reaction length scale, the only 
parameter to decide drug penetration to the brain tissue. For paclitaxel, dilution factor VF
is 3.5 x 10-5 s-1, D is 3.753 x 10-13 m2/s, k is 1.325 x 10-7 s-1 dL which results in  = 1.7 mm 
(Arifin et al., 2009). The penetration data for different delivery devices at various 
treatment days is compared with the model prediction and shown in Figure 6.3.  
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6.3.6 Therapeutic Efficacy Study in an Intracranial Human Glioblastoma Xenograft 
Model  
 In order to evaluate therapeutic efficacy of local chemotherapy using H80 and F3, the 
bioluminescence luciferase imaging was performed. Figure 6.4 show an increase in bio-
luminescence signal intensity (tumor progression) in animals with no treatment (sham) 
and placebo implants over the treatment period, where as a decrease (tumor inhibition) is 
observed in animals treated with Taxol®, F3 and H80. When BLI signal intensity for each 
time point is normalized against that of day 6 (before treatment) as in Figure 6.5, animals 
in sham and placebo groups had nearly 350 fold increase in the number of tumor cells 
showing unabated tumor growth. But, animals in Taxol®, F3 and H80 groups experienced 
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Figure 6.5 Intracranial U87 MG-luc2 tumor progression profile during treatment measured as 
normalized bioluminescence intensity for various groups. (n = 8-13 animals). Error bars show 
standard deviation. p<0.05 (H80, F3 and Taxol versus sham on days 13, 20, 27, 34, and 41); 
p<0.05 (H80 versus placebo H80 on days 34 and 41); p<0.05. (F3 versus placebo F3 on day 13, 
20, 27, 34, and 41). 
 
 Histological examination (H&E staining) of U87 MG xenograft after 34 days of 
treatment showed tumor cell invasion at the tumor–normal brain parenchyma interface in 
sham and placebo groups as seen in Figure 6.6A. However, H80 and F3 had fewer tumor 
cells. Marked tumor necrosis was observed in animals after F3 treatment. Images of Ki-
67 staining in Figure 6.6A showed higher degree of tumor proliferation in sham and 
placebo groups in comparison to Taxol®, F3 and H80 groups. Quantitative analysis of 
tumor cell proliferation (% Ki-67 positivity) revealed significant (2.5 and 3.6-fold) 
reduction after treatment with H80 (p<0.001 versus placebo H80) and F3 (p< 0. 0001 
Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
136 









































































































































































































































































Chapter 6                                               In vivo efficacy of micro/nano-structured implants                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
137 
 The presence of paclitaxel in glioblastoma-bearing mice brains was confirmed in 
Figure 6.6C, which shows that animals in the F3 and H80 groups had similar paclitaxel 
distribution profiles in comparison to non-tumor bearing mice after 42 days of treatment. 
The concentration levels in the H80 and F3 groups were comparable to those of Taxol®
 Our earlier study has shown that PLGA 50:50 could be used as microfibers to deliver 
paclitaxel with promising in vitro and in vivo anti-tumor (subcutaneous) efficacy 
(Ranganath et al., 2008). With the hypothesis that by further enhancing the drug release 
rate and drug availability, better drug penetration in the brain could be achieved, we have 
developed a new formulation i.e. paclitaxel-loaded PLGA 50:50 nanofiber (F3) using 
electrospinning. Continuous nanofibers (~100 nm in diameter) were obtained due to the 
presence of TATPB that increased the conductivity of the solution. Employing low 
 
group.   
 
6.4 Discussion 
 Unfortunately, paclitaxel’s hydrophobicity and poor absorption across the BBB due 
to P-gP efflux (Kemper et al., 2003) tagged with anaphylactic hypersensitivity reactions 
and neurotoxicity (Gelderblom et al., 2001) has accentuated the limitations of its systemic 
administration with no improvements in glioma patient survival (Prados et al., 1996; 
Chang et al., 2001). In the wake of these issues, we had developed micro/nano-structured 
paclitaxel delivery devices for post-surgical local chemotherapy (Ranganath et al., 2008; 
Ranganath et al., 2009). However, a better understanding and evaluation of drug 
penetration and anti-tumor efficacy in an intracranial model is done here.  
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polymer concentration, low flow rate and high voltage difference also contributed 
towards nano-structuring of the fibers due to the formation of a thinner jet. The high drug 
encapsulation efficiency of the F3 discs could be ideal for local chemotherapy.  
 
  The in vitro release of paclitaxel from the F3 nano-fiber discs was studied firstly to 
investigate the release kinetics, and secondly to correlate it with the in vivo bio-
distribution in the mouse brain. F3 nano-fiber discs are primarily made of PLGA 50:50 
that degrades faster than other PLGA co-polymers such as PLGA 85:15 due to higher 
hydrophilicity, facilitating better penetration of medium into the implant for hydrolysis 
and degradation. Additionally, the nano-structuring of the fibers in conjunction with the 
pore-like structure of the implant due to inter-woven fibers increased the surface area 
available for medium penetration and degradation, thus enhancing the release rate in 
comparison to F2 submicrofibers (Ranganath et al., 2008). The slight initial burst 
exhibited by F3 discs was supposedly due to surface bound paclitaxel that diffused 
readily upon contact with PBS. But, due to compactness of the disc, the initial burst was 
minimized and also resulted in the subsequent near constant drug release for more than 
60 days. Hence the F3 discs could be more suited for such applications as opposed to 
other implants such as compressed microsphere discs (Li et al., 2003), foams (Ong et al., 
2009) and crystalline cubic phases (von Eckardstein et al., 2005).   
 
 In this study, the previously tested formulations F2, H80 and M80 (Ranganath et al., 
2008; Ranganath et al., 2009) along with the new formulation F3 were screened for the 
subsequent in vivo evaluations such as bio-distribution in the brain and anti-tumor 
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efficacy in intracranial models. These four formulations possess different drug release 
rates. This has prompted us to investigate whether different release rates would result in 
different and improved drug penetration depths in the brain and would they be 
therapeutically efficacious or not.  
 
 In the bio-distribution study, we examined not only the spatial distribution (coronal) 
in the brain, but also dynamics of bio-distribution over a period of 42 days. The bio-
distribution data depicted in Figure 6.2 (A-D) confirms that the four formulations were 
able to maintain the drug at least up to 42 days, which is an improvement over 30 days by 
previously reported implants (Li et al., 2003; Ong et al., 2009; von Eckardstein et al., 
2005). When compared with each other, the four formulations have different bio-
distribution profiles. To be able to provide deeper drug penetration at high levels in the 
brain/tumor, the implants should have greater availability which in turn is related to the 
release rate, diffusion and drug elimination rate (Arifin et al., 2009). Since paclitaxel is 
the drug in all the four formulations, diffusion and elimination rates would be similar, 
thus the release rate could be the deciding factor. F3 discs with greater drug release rate 
provide very uniform and high concentrations in the brain even at distant regions. Due to 
high drug availability, the concentration gradient for diffusion would be higher thus 
enhancing diffusion distance. The exponential drop in concentration along the brain for 
F2, H80 and M80 could be attributed to lower diffusion rates resulting from low 
concentration gradient. The same reason could be contributing also to the general trend of 
penetration during early days of implantation (day 14) being lower to that of the later 
stages. From the bio-distribution results, F3 and H80 formulations were screened for the 
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subsequent intracranial anti-tumor efficacy study. While M80 failed to provide cutoff 
levels of paclitaxel at distant regions initially, F2 demonstrated irregular bio-distribution 
across the brain, making it difficult to predict the outcome. Since it is important to arrest 
residual glioma cells at G2
 The simulation has shown that paclitaxel has high diffusion/reaction length scale 
because it experiences minimal elimination in the brain tissue (Arifin et al., 2009). On the 
contrary, carmustine, which is currently being used in the Gliadel
-M phase early to prevent recurrence, the availability of the 
drug at the early stages of implantation is paramount.  Hence F3 discs providing 
therapeutically high and consistent levels of paclitaxel up to at least 42 days post 
implantation at distant brain regions were screened along with H80 which showed 




 wafers, is withdrawn 
quickly to the capillaries, resulting in very minimal penetration (Arifin et al., 2009). 
Furthermore, it was also found that, upon edema, paclitaxel transport in mouse brain is 
mainly dependent on diffusion. Consistent agreement on the penetration profiles at three 
different treatment days (Day 14, 28, and 42) bolsters the predictive ability of the model. 
These results suggest that high drug penetration will only depend on the drug 
concentration at the implant site ( ). In other words, for any i,0C , the penetration will 
always decrease exponentially by the same dL ; therefore, maintaining right concentration 
at the implant side is crucial. This will explain why different drug loadings and release 
rates will result in different treatment efficacies. In the current study, the initial drug 
loading is the same for the four different; thus, the resultant drug penetration profiles are 
mainly due to the variation in their release rates. This clearly suggests that drug 
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penetration is by diffusion during the treatment period, confirming assumption on 
negligible convective flow after edema for small animals.  
 
 From the tumor progression data in Figures 6.4 and 6.5, it is evident that PLGA itself 
doesn’t have any killing effect on the tumor cells (from placebo data) and the therapeutic 
efficacy of the implants is solely due to paclitaxel. Moreover, the periodical intratumoral 
Taxol® administration can be replaced by one-time implantation of F3 and H80 during 
the debulking surgery. The implants’ ability to inhibit the tumor more effectively at the 
initial stages of tumor growth as seen in Figure 6.5 could be attributed not only to high 
local drug concentration levels, but also to slow proliferation rate of the tumor. Hence, in 
typical post-surgical chemotherapy, the initial tumor growth inhibition will be critical to 
slow down the rate of glioma recurrence, there by inhibiting migration and invasion into 
healthy brain tissue. The histological changes also confirm typical paclitaxel induced 
apoptosis and tumor necrosis (Li et al., 2003) resulting due to prolonged exposure to 
active paclitaxel at therapeutic levels. The significant reduction in tumor proliferation 
index in animals treated with F3 or H80 implants further reinforces the paclitaxel induced 
mitotic arrest of the tumor cells at the G2M-phase. Typically GBM recurs within 2 cm of 
the resection site and hence the enhanced drug penetration shown by F3 and H80 
implants in the brain (no tumor) and tumor bearing brain shown in Figure 6.6C is critical. 
Despite these promising results, a resected intracranial glioblastoma model in larger 
animals should be used to study the improvement in survivability which is clinically 
relevant. Nevertheless, this study demonstrates the potential of the micro/nano-structured 
implants in enhancing paclitaxel penetration and sustainability and resultant significant 
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reduction in intracranial tumor progression. Finally, these implants could also be utilized 
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CHAPTER 7 
Control and Enhancement of Permselectivity of Membrane-based 
Microcapsules for Favorable Biomolecular Transport and 
Immunoisolation † 
7.1 Introduction 
 Cell microencapsulation is a membrane based technology that provides localized and 
controlled delivery of physiologically bio-active or “de novo” therapeutic proteins from 
encapsulated genetically engineered cells and immunoisolation. It has demonstrated 
exciting prospects in diverse biomedical applications (Lim et al., 1980; Emerich et al., 
1997; Prakash and Chang, 1996; Wollert and Drexler, 2006; Read et al., 2001; Joki et al., 
2001) since the pioneering work by Lim et al. of microencapsulating islets (Lim et al., 
1980) over the past three decades. However, extensive clinical success still eludes 
applications because of inefficient immunoisolation, low mechanical stability, bio-
incompatibility and mass transport limitations.      
 
 Alginate microcapsules with a poly-L-lysine (PLL) membrane coating or APA 
microcapsules were developed (Lim et al., 1980) and widely used for cell 
microencapsulation (Lanza et al., 1996; Peirone et al., 1998; Rokstad et al., 2002; Li et 
al., 2006; Zhang et al., 2007).  
 
------------------------------------------------------------------ 
†This chapter highlights the work: Ranganath SH, Tan AY, He F, et al. Control and enhancement 
of permselectivity of membrane-based microcapsules for favorable biomolecular transport and 
immunoisolation. Accepted for publication in AIChE Journal, 2010. 
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Unfortunately, PLL has been reported to trigger a fibrotic immune-reaction 
(Vandenbossche et al., 1993; Strand et al., 2001) and death of encapsulated cells 
(Rokstad et al., 2002). Also, insufficient mechanical stability (Fu et al., 2003; Orive et al., 
2004) and degradation (Van Raamsdonk et al., 2002) of the PLL membrane cause 
destabilization of the microcapsules resulting in limited graft survival and adverse 
immune responses. These serious drawbacks have motivated the exploration of chitosan 
as an alternative to PLL. Owing to its natural origin, abundance, low toxicity, and 
biocompatibility, chitosan has been used as the polycation to form an alginate-chitosan 
(AC) complex and investigated for drug delivery (Wheatley et al., 1991) and cell 
encapsulation applications (Bartkowiak and Hunkeler, 1999; Haque et al., 2005).  
 
 To further reinforce capsular strength, slow down chitosan biodegradation rate and 
bring about selective membrane permeability, cross-linking of chitosan with the bi-
functional reagent glutaraldehyde was introduced, but it has demonstrated cytotoxicity 
(Nishi et al., 1995) and is thus unsuitable for cell encapsulation. The covalent cross-
linking of chitosan with genipin, a naturally derived aglucone of geniposide (Djerassi et 
al., 1960) has the proven advantage of extremely low cytotoxicity relative to 
glutaraldehyde (Sung et al., 1999). The most striking feature of a genipin cross-linked 
chitosan membrane is its fluoregenic property that enables effective characterization of 
the membrane (Chen et al., 2006) and consequently the permeability. Recently, genipin 
cross-linked alginate-chitosan (GCA) microcapsules have been reported to possess 
improved membrane strength and reduced capsular swelling and thus have great potential 
for live cell therapy applications (Chen et al., 2007). However, studies of the membrane 
Chapter 7                                   Bio-molecular mass transport across GCA microcapsules                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
145 
permeability and diffusion characteristics of GCA microcapsules are lacking. Thus, the 
mass transfer properties of GCA microcapsules need to be investigated in order to 
systematically develop GCA microcapsules for clinical uses.   
 
 Several indexes have been used to characterize the mass transport through semi-
permeable membrane in microcapsules. One uncommon metric is the mass transfer 
coefficient h that is based on the theory that the controlling driving force is the difference 
in solute concentration between the bulk phase and the membrane interphase boundary 
(Rosinski et al., 2005). Most of the time, a certain degree of inaccuracy exists in 
estimating the surface area of the interphase boundary and the volume of the 
microcapsules, since it is difficult to ensure monodispersity of the microcapsules. A 
better fundamental approach to characterize permeability is the estimation of the 
diffusion coefficient of solutes through the membrane. Typically, this time-dependent 
diffusion is investigated in terms of marker ingress or egress kinetics based on Fick’s law 
with the assumptions of good mixing in the solution phase, negligible mass transfer 
resistance in the boundary layer around the microcapsule, identical capsule size and a 
release rate that is proportional to the concentration gradient of the solute, and in some 
cases the ideal gas approximation (Kwok et al., 1991; Kondo, 1990; Amsden and Turner, 
1999; Zhou and Wu, 2003). However, in reality, even in an equilibrium state, different 
fractions of the solute tend to distribute in the core, dispersing medium and the membrane 
(Takashi et al., 2003). Difficulty in getting microcapsule monodispersity renders an 
additional uncertainty to the use of models based on Fick’s law to predict the mass 
transfer in complex systems such as GCA microcapsules.  
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 A new mathematical model was developed by Takashi et al., 2003 to predict mass 
transport of molecules out of the microcapsules based on the assumption of a local 
equilibrium state, in which there exists uniformity in solute concentration in the core and 
the bulk, but a concentration gradient in the membrane that actuates the diffusion across 
the microcapsule. Finally the diffusion gradually drives the system towards a global 
equilibrium state. Accordingly, solute release from a microcapsule and solute diffusing 
into a microcapsule (Qi et al., 2006) can be expressed by Eq. (7.1) and Eq. (7.2), 
respectively:  
)1()( τteqSS eCtC





















          (7.2) 
where, )(tCS is the solute concentration in the extra-capsular medium (mg/ml) at time t,  
eq
SC is the equilibrium solute concentration in the extra-capsular medium (mg/ml), 
0
SC is 
the initial solute concentration in the extra-capsular medium (mg/ml), and τ represents 








µτ =              (7.3) 
where, r is the inner radius of the microcapsule, l the membrane thickness, mD  is the 
diffusion coefficient of the solute in the membrane, 'mµ and 
'
cµ are the concentration 
derivatives of the solute chemical potentials in the membrane and inner medium 
expressed as m
eq
mm dCCd )(µ and c
eq
cc dCCd )(µ , respectively, where mµ and cµ are the 
solute chemical potentials in the membrane and inner medium, respectively. For a given 
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solute the ratio '' cm µµ is a constant and hence τ is primarily related to the diffusion 
coefficient of the solute in the membrane for non-swellable microcapsules. However, it 
should be noted that for swellable microcapsules, τ can depend on r, l and mD .  
 
 We intend to explore the application of GCA microcapsules as implantable micro-
bioreactors delivering anti-angiogenic proteins for treating malignant brain tumors. 
However, an evaluation of membrane permselectivity to various biomolecules is 
critically essential. Hence, in this study, the mass transport properties of GCA 
microcapsules with varying size, membrane cross-linking density and thickness were 
investigated to determine the resulting membrane permeability characteristics. Scaling 
analysis was used to develop an equation interrelating the membrane thickness, chitosan-
alginate reaction rate constant and diffusion coefficient. Three bio-molecules covering a 
range of molecular weight, size and conformation were utilized to evaluate their ability to 
diffuse across the GCA microcapsules. The kinetic ingress/egress data of the bio-
molecules were fitted with the theoretical prediction from the mathematical models based 
on a chemical potential balance to estimate the characteristic time. Finally, the effects of 
microcapsule size, membrane density and thickness on the bio-molecular mass transport 
or the diffusion coefficient were investigated.  
 
7.2 Materials and Methods 
7.2.1 Materials 
Low viscosity sodium alginate (~250 cP, 2% and 25oC) was purchased from Sigma-
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Aldrich. Chitosan with an 80% degree of deacetylation and genipin (C11H14O5, MW of 
226.23) were purchased from Wako Bioproducts, Japan. Acetic acid (99.8%) was 
purchased from Honeywell, Seezle, Germany and phosphate buffered saline (PBS) was 
purchased from First Base. Calcium chloride was bought from Merck, Darmstadt, 
Germany. Vitamin B12
GCA microcapsules were fabricated in three steps. The first step involves formation 
of monodisperse sodium alginate droplets was achieved using an electrospray process 
followed by Ca
 powder, carbonic anhydrase (from bovine erythrocytes) and 
human immunoglobulin-G (IgG) were purchased from Sigma-Aldrich. All other reagents 
were of analytical grade.  
 
7.2.2 Fabrication of Genipin Cross-linked Chitosan-alginate (GCA) Microcapsules 
2+ ionotropic gelation of the droplets as depicted in Figure 7.1A. Briefly, 
the electrospray setup consists of a syringe pump equipped with a syringe filled with 
1.5% (w/v) sodium alginate solution and a needle (22G) connected to high voltage 
generators (Glassman High Voltage Inc., NJ, USA). The process was operated by varying 
parameters such as the nozzle voltage (VN), ring voltage (VR) and solution flow rate to 
fabricate microcapsules of different sizes as shown in Table 7.1.  Due to the application 
of a high potential difference to the nozzle, the solution experienced a flow instability and 
the jet broke into droplets that were then drawn towards a Petri dish containing a CaCl2 
solution (on a grounded platform). The droplets underwent instantaneous gelation with 
Ca2+ ions giving rise to calcium cross-linked alginate hydrogel beads. Following this, the 
beads were thoroughly washed with deionized water to remove any excess Ca2+ ions. The 
second step involves treating the calcium cross-linked alginate beads with 10 mg/ml of 
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chitosan solution (with 11 mg/ml of CaCl2 in 1% acetic acid, and pH 5.6-6.0). The 
coacervation reaction with chitosan was carried out for either 15 or 30 minutes at 37oC 
and 120 rpm that resulted in an alginate-chitosan (AC) co-acervated complex shell as 
depicted in Figure 7.1B. Thereafter, the microcapsules were washed twice using 
deionized water to remove traces of any unreacted chitosan. The third step involves 
reacting the alginate-chitosan microcapsules with 5 mg/ml of genipin solution for 6, 12 or 
18 hours at 37o
Size of the  
microcapsules (µm) 
C and 120 rpm in an incubator shaker (New Brunswick Scientific, USA) 
to form GCA microcapsules with a genipin cross-linked chitosan membrane shell as 
illustrated in Figure 7.1B. The microcapsules then were washed with deionized water to 
remove any unreacted genipin and then stored in deionzed water for subsequent use. 
Various types of GCA microcapsules were produced with two sizes (small and large), 
two different membrane thicknesses (determined by chitosan-alginate reaction time) and 
three levels of genipin-chitosan membrane crosslinking density (determined by the 
genipin crosslinking reaction time with chitosan) as summarized in Table 2, then washed 
with deionized water to remove any unreacted genipin and stored in DI water for further 
use.   
 




Nozzle voltage relative to 
ground, VN
Ring voltage relative to 
ground, V (kV) R (kV) 
200 – 300 0.5 11.5 0 
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reaction time (h) 
200 – 300 µm 500 – 600 µm 
15 
6 SS-6 LS-6 
12 SS-12 LS-12 
18 SS-18 LS-18 
30 
6 SL-6 LL-6 
12 SL-12 LL-12 
18 SL-18 LL-18 
 
 
Figure 7.1 Fabrication of genipin-chitosan-alginate microcapsules. (A) 3-D illustration of the 
electrospray process for producing calcium cross-linked alginate beads and (B) 3-D illustration of 
the cross-sectional view of the microcapsules after each reaction step. 
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7.2.3 Microcapsule and Membrane Characterization by Confocal Microscopy (CM) 
The thickness and genipin cross-linking extent of the fluoregenic genipin-chitosan 
membrane were characterized using a Nikon A1 confocal microscope (Nikon, Japan) 
equipped with a Nikon Eclipse TE2000-E inverted microscope and a multi-line argon 
laser. For image acquisition the microcapsules were placed on a Menzel-Glaser cover slip 
in the presence of deionized water. A single green fluorescence mode at an excitation of 
488 nm with an emission filter at 500-550 nm was used to scan the samples at galvano 
mode. An equatorial section of the microcapsules was chosen as the focal plane and all 
the images were acquired by keeping the microscope settings and laser power constant to 
ensure comparable images. NIS elements software was used to acquire and analyze the 
fluorescence intensity profiles corresponding to the line across the focal plane of the 
microcapsules. The size of the microcapsules was also quantified using NIS elements (N 
= 50).    
 
7.2.4 Bio-molecular Ingress into GCA Microcapsules 
Three bio-molecules, vitamin B12, immunoglobulin (IgG) and carbonic anhydrase 
(CA) were used separately in this study. A vitamin B12 solution (0.015%) was firstly 
prepared in a 0.9% NaCl solution. Roughly 1 ml of GCA microcapsules was immersed in 
1 ml of vitamin B12 solution and kept in a water bath at 37oC and mixed at 120 rpm to 
facilitate ingress. At predetermined time intervals, 2 µl of the extra-capsular medium was 
withdrawn and the absorbance at 360 nm was measured using a NanoDrop 1000 UV-VIS 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA).  By using a calibration 
curve of vitamin B12 concentration versus absorbance at 360 nm, the vitamin B12 
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concentration in the extra-capsular medium was estimated. The ingress mass transfer 
study was carried out until the system had reached equilibrium.  
 
IgG was dissolved in 1X PBS to obtain a concentration of 0.40 mg/ml. Roughly 1 ml 
of GCA microcapsules was immersed in 3 ml of IgG solution and kept in a water bath at 
37oC and mixed at 120 rpm to facilitate ingress. At predetermined time intervals, 2 µl of 
the extra-capsular medium was withdrawn and the protein concentration at 280 nm was 
measured using the Protein A280 module in a NanoDrop 1000 UV-VIS 
spectrophotometer. The ingress mass transfer study was carried out for about three days 
until the system had reached equilibrium. Similarly, carbonic anhydrase at a 
concentration of 0.65 mg/ml was prepared by dissolving in 1X PBS. Roughly 1 ml of 
GCA microcapsules was immersed in 1 ml of CA solution and kept in a water bath at 
37o
Firstly, carbonic anhydrase at a concentration of 1.70 mg/ml was allowed to ingress 
into the GCA microcapsules as explained in section 2.5. After the system had reached 
equilibrium, the extra-capsular medium was removed completely and replaced with 1 ml 
of 1X PBS, thus allowing egress of CA from inside the GCA microcapsules into the 
C and mixed at 120 rpm to facilitate ingress. At predetermined time intervals, 2 µl of 
the extra-capsular medium was withdrawn and the protein concentration at 280 nm was 
measured using the Protein A280 module (extinction coefficient of 19.0%) in a 
NanoDrop 1000 UV-VIS spectrophotometer. The ingress mass transfer study was carried 
out until the system had reached equilibrium.  
  
7.2.5 Bio-molecular Egress from GCA Microcapsules 
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extra-capsular medium. At predetermined time intervals, 2 µl of the extra-capsular 
medium was withdrawn and the protein concentration at 280 nm was measured using the 
Protein A280 module (extinction coefficient of 19.0%) in a NanoDrop 1000 UV-VIS 
spectrophotometer. The egress mass transfer study was carried out until the system had 
reached equilibrium. 
 
7.2.6 Scaling Analysis to Predict and Compare Membrane Thickness 
Recently, scaling analysis has been shown to effectively identify the dominant terms 
in an electrospray process26. Similarly, a scaling analysis was performed to understand 











(Krantz 2008). The chitosan-alginate coacervation reaction was assumed to be 
first-order and the effects of curvature were ignored based on the assumption that the 
penetration is relatively small in comparison to the radius of the microcapsules. Hence, 
considering the one-dimensional, unsteady-state diffusion and reaction of chitosan within 
a stationary matrix of crosslinked alginate, the appropriate form of the species-
conservation equation is given by the following:  
              (7.4) 
where Ac  is the concentration of chitosan in moles per unit volume, y  is the spatial 
coordinate measured from the interface of the microcapsule with the surrounding aqueous 
solution of chitosan, t  is the temporal coordinate, 1k  is the reaction rate constant, and 
ASD  is the diffusion coefficient of chitosan in the crosslinked alginate matrix, which is 
assumed to be constant. The initial and boundary conditions are given by the following: 
0     at     0Ac t= ≤                          (7.5) 
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    at     0     0A A cc c y t t= = < ≤
                      (7.6)  
0     at          0A d cc y t tδ= = < ≤                      (7.7)  
where Ac
  is the equilibrium molar concentration of chitosan at the interface of the 
microcapsule and ct  is the contact time. Eq. (7.7) states that the chitosan concentration 
drops to zero within some finite distance from the alginate matrix-solution interface dδ . 
This thickness is determined by the ability of chitosan to diffuse into the crosslinked 
alginate matrix. Introduce the following dimensionless variables containing unspecified 
scale and factors: 
;      ;      AA
As s s
c y tc y t
c y t
∗ ∗ ∗≡ ≡ ≡                                     (7.8) 
Substitute these dimensionless variables into the describing equations and divide through 
by the dimensional coefficient of one term in each equation. Since this is inherently an 














                                    (7.9) 
0   at     0Ac t
∗ ∗= ≤                                    (7.10) 




∗ ∗ ∗= = < ≤

                                 (7.11) 




δ∗ ∗ ∗= = < ≤                                  (7.12) 
 
Set appropriate dimensionless groups equal to one to determine the scale factors: 






                        (7.13)  
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δ δ= ⇒ =                       (7.14)  
 Three time scales are determined by the two dimensionless groups in Eq. (7.9) 
and the dimensionless group appearing in both Eqs. (7.11) and (7.12):  




= ⇒ =                                 (7.15a)  
2








= ⇒ ≡ =                       (7.15b) 
1
1
11             reaction time scale s s rk t t t k
= ⇒ ≡ =                        (7.15c) 
The appropriate time scale is the contact time ct , that is, the time allowed for the chitosan 
to contact the alginate matrix; hence, s ct t= . Since reaction cannot occur without chitosan 
diffusion, the unsteady-state term must balance the diffusion term, which then gives the 
penetration depth for the diffusion of chitosan: 
2





δ≅ ⇒ =                       (7.16) 
Where the proportionality constant K, which has a magnitude of order one, has been 
introduced to account for the approximate nature of scaling analysis. The dimensionless 













                         (7.17) 
0   at     0Ac t
∗ ∗= =                         (7.18) 
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1     at     0Ac y
∗ ∗= =                        (7.19) 
  
0     at     1Ac y
∗ ∗= =                        (7.20)
 The region wherein reaction occurs is thinner than the region wherein diffusion of 
chitosan has penetrated. Moreover, the reaction can begin only when diffusion causes 
chitosan to penetrate into the alginate. The reaction will go to completion only within the 
region wherein the contact time is greater than the sum of the diffusion time plus the 
reaction time. This provides a criterion for determining the thickness of the region 
wherein the chitosan reaction with the crosslinked alginate matrix has gone to 
completion. Hence, we have the following:  
2
1 1
1 1          rc r AS c
AS




= + ⇒ = − 
 
                      (7.21)      
Eq. (7.21) allows determining the reaction rate constant 1k  by comparing the thickness of 
the shell wherein the reaction of chitosan with the crosslinked alginate matrix has gone to 

























   −
                     (7.22) 
Once 1k  has been determined, Eq. (7.21) permits determining both the diffusion 
coefficient AsD  and the proportionality constant K. 
 
7.2.7 Computational Method   
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Initial ( 0SC ), equilibrium (
eq
SC ) and time dependent ( )(tCS ) concentrations of various 
bio-molecules were measured according to the procedures described in sections earlier. 
This experimental data were nonlinearly fit to Eq. (7.1) (for bio-molecular egress) and 
Eq. (7.2) (for bio-molecular ingress) using the method of multidimensional unconstrained 
nonlinear minimization in MATLAB software to obtain the value of the characteristic 
time τ  in the models.  
 
7.3 Results and discussion 
7.3.1 Fabrication and Physical Characterization of GCA Microcapsules 
 The biomolecular mass transport across the GCA microcapsules is primarily affected 
by the microcapsule size, membrane thickness and membrane crosslinking density. Each 
of these parameters was controlled in three serial steps as described below to investigate 
their effects on the biomolecular mass transport. First, the microcapsule size was 
controlled by the electrospray process as illustrated in Fig. 7.1A. The electrospray 
technique is a proven, simple and efficient method to produce spherical monodisperse 
droplets. For a range of nozzle voltages VN, there exists a linear relationship between 
voltage and droplet size [Xie and Wang, 2007]. Hence, we varied VN to obtain different 
sized droplets. Micro-dripping at a high VN (11.5 kV) and medium flow rate was utilized 
to obtain small droplets (273.89 ± 23.79 µm in diameter) as it is known to provide a 
narrow size distribution by reducing the formation of satellite particles. To produce large 
size droplets (571.68 ± 30.24 µm in diameter), an additional ring voltage VR was used to 
stabilize the electrospray, increase the droplet size and provide monodispersity. The 
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electrospray operating conditions required to obtain the small and large microcapsules are 
summarized in Table 7.1. 
  
Table 7.3 Average genipin-chitosan membrane thickness of microcapsules. 
 
Microcapsule Samples Membrane thickness (µm) 
SS-6 32.87 ± 4.40 
SS-12 33.11 ± 3.30 
SS-18 33.09 ± 3.41 
SL-6 60.56 ± 4.05 
SL-12 60.12 ± 3.56  
SL-18 58.46 ± 2.11 
LS-6 33.87 ± 3.29 
LS-12 31.11 ± 3.10 
LS-18 32.91 ± 2.78 
LL-6 57.65 ± 4.41 
LL-12 58.28 ± 6.73 
LL-18 62.05 ± 4.39 
 
Second, the membrane thickness was controlled by varying the chitosan-alginate 
coacervation reaction time (15 or 30 minutes). The calcium crosslinked alginate 
microcapsules when treated with chitosan resulted in a coacervation complex due to 
strong electrostatic interactions between the carboxyl groups in the alginate and the 
primary amine groups in chitosan [Chen et al., 2007] and pictorially represented in Fig. 
7.1B. This AC complex has been reported to be stronger than the conventional alginate-
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PLL binding. Since genipin does not react with alginate, the genipin-chitosan membrane 
thickness was fixed depending on the chitosan-alginate coacervation reaction time. Third, 
the genipin-chitosan membrane density was controlled by varying the genipin 
crosslinking reaction time with chitosan (6, 12 or 18 hours). The membrane formation is 
insensitive to changes in genipin concentration but highly sensitive to temperature [Chen 
et al., 2007]. Since the GCA microcapsules were to be used for encapsulation involving 
live cells, we chose 37oC to maintain a favorable condition for crosslinking and to sustain 
cell viability during the process. The membrane formation step involving reaction of 
genipin with the chitosan shell was carried out resulting in the formation of a genipin 
crosslinked chitosan membrane shell with a noticeable color change from colorless to 
bluish purple (data not shown), the intensity of which depended on the reaction time. 
Genipin is known to react with chitosan’s amino groups resulting in highly conjugated 
heterocyclic genipin derivatives that are bluish in color. In addition, reaction of the ester 
group in genipin with the amino group in chitosan could result in the formation of 
secondary amide linkages or crosslinking [Chen et al., 2005]. 
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Figure 7.2 Representative confocal images of GCA microcapsules showing alginate core and 
genipin-chitosan membrane shell. (A): SS-6 microcapsules; (B): SS-12 microcapsules; (C): SS-18 
microcapsules; (D): SL-6 microcapsules; (E): SL-12 microcapsules; (F): SL-18 microcapsules. 
Bar represents 100 µm. 
 
7.3.2 Genipin-chitosan Membrane Characterization of GCA Microcapsules 
 To further confirm the formation of a genipin crosslinked chitosan membrane shell as 
described earlier, the GCA microcapsules were viewed under a confocal microscope. All 
the microcapsule samples in Fig. 7.2 revealed an alginate core represented by the dark 
interior and the fluorescent genipin crosslinked chitosan membrane shell (green color). It 
is interesting to note that the microcapsules reacted with chitosan for 15 minutes 
possessed a similar membrane thickness irrespective of the changes in either genipin 
crosslinking reaction time or microcapsule size. Table 7.3 reveals the same for 
microcapsules reacting with chitosan for 30 minutes. From this, it is clear that within the 
domain of the chosen genipin crosslinking reaction times and microcapsule sizes, the 
membrane thickness is controlled only by the alginate-chitosan coacervation reaction 
time.  Specifically, the genipin crosslinking time of 6 hours is sufficient for genipin to 
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fully penetrate the AC complex shell (for both 15 and 30 minutes of alginate-chitosan 
coacervation reaction time) in both small and large size microcapsules. Any further 
increase in the genipin crosslinking reaction time would only increase the crosslinking 
density of the membrane and not the thickness. This could be because genipin only 
interacts with chitosan already bound to the alginate. Thus, the membrane thickness is 
mainly controlled by the thickness of the AC complex that is limited by alginate-chitosan 
coacervation reaction time.  
 
 Recently, genipin’s fluoregenic property has been exploited to characterize 
microcapsules. Owing to the high specificity of the genipin, the fluorescent signals are 
due to genipin-chitosan conjugates rather than the alginate-chitosan complex or alginate 
core [Chen et al., 2005]. Similar results were observed in our study as seen in Fig. 7.2 
that shows a dramatic difference in the signal intensity between the alginate core and the 
membrane, the crosslinking density in the membrane was quantified by measuring the 
fluorescence intensity along randomly drawn lines across the microcapsule as shown in 
Figs. 7.3A and 7.3B. The profiles also reveal very high signal intensity at the outer 
surface of the membrane, gradually decreasing towards the alginate core. The profiles 
also confirm the results from the confocal images in Fig. 7.2 regarding the membrane 
thickness and its change with alginate-chitosan coacervation reaction time. From Figs. 
7.3A and 7.3B, it can be seen that with the increase in genipin crosslinking reaction time, 
the non-homogeneity in the membrane density increases as indicated by the increasing 
slope in the profiles. This could be caused by the diffusion of genipin from the shell into 
the core of the microcapsule. The restricted diffusion of chitosan during the formation of 
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the AC complex shell could also have resulted in a non-homogeneous membrane and is 
consistent with other reports [Chen et al., 2005]. However, with longer crosslinking time, 
genipin penetrates deeper and forms more crosslinks, thus resulting in a more 
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Figure 7.3 Fluorescence intensity profiles of GCA microcapsules along the cross-section of the 
microcapsule. (A) Small microcapsules; (B) Large microcapsules. 
 
 
 7.3.3 Prediction of Membrane Shell Thickness 
 It is critical to control the thickness of the genipin-chitosan membrane shell due to the 
fact that it not only imparts capsular integrity but also controls biomolecular transport. 
Using Eq. (7.22), we first calculated the alginate-chitosan coacervation reaction constant 
(k1) by utilizing the known experimental results for the membrane thickness at two 
different alginate-chitosan coacervation reaction times as follows: tc1 = 15 min and the 






























= 30 min and the corresponding 
Chapter 7                                   Bio-molecular mass transport across GCA microcapsules                                                                                                   
Sudhir Hulikal Ranganath                                                                              
                                                                                                                                                                                                                                                       
164 
membrane thickness δ2 = 60 µm. Thus, the alginate-chitosan coacervation reaction 
constant (k1) was calculated to be 0.118 min-1. Subsequently, the diffusion coefficient 
DAS of chitosan in the alginate matrix and the proportionality constant K were calculated 
from Eq. (7.21) using the aforementioned conditions and known k1 and t to obtain the 
following results:   DAS = 1.67 x 10-6 cm2/min and K = 1.0. Now, using Eq. (7.21) with 
the known k1 and  DAS
 Fig. 4 shows representative profiles of the experimental results of the ingress of 
vitamin B
, the membrane thickness at any given alginate-chitosan 
coacervation reaction time can be predicted. Moreover, Eq. (7.21) shows that the 
membrane thickness depends only on the reaction time and is independent of the 
microcapsule size. However, this predictive model can be used with confidence only 
within the range of microcapsule sizes and genipin crosslinking times employed in this 
study.  The model assumes that the distance of chitosan penetration in the alginate matrix 
is small in comparison to the radius of the microcapsule, which is confirmed by the 
measured membrane thicknesses. 
 
7.3.4 Bio-molecular Ingress into GCA Microcapsules 
12
τ
 into the large LS microcapsules that had diameters in the range of 500-600 
µm and a chitosan-alginate coacervation reaction time of 15 min. The error bars in Fig. 
7.4 were determined from the standard deviation of replicate experiments and are 
representative of the error in all the experiments reported here. The data for the three 
dimensionless biomolecule concentrations shown in Fig. 7.4 along with data for nine 
other microcapsules were fit to Eq. (7.2) to obtain the characteristic ingress time ( ) 
values summarized in Table 7.4. The experimental data fit the model very well with 
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correlation coefficient (R2) values close to 1.  Ingress of vitamin B12 reaches equilibrium 
rapidly but at a different rate based on the type of microcapsule. Table 7.4 for vitamin 
B12 τ reveals that  increases as the genipin crosslinking time of the microcapsules 
increases.  Also, the diffusion is faster in microcapsules with a thinner membrane 
irrespective of the microcapsule size. It is also interesting to notice that at a given genipin 
crosslinking time and membrane thickness, the increase in microcapsule size seems to 
slow down the biomolecular transport (indicated by the increase inτ ).  
 
 
Figure 7.4 Representative plots of ingress of vitamin B12 into large GCA microcapsules. The 
points are experimental data and the solid curves are the theoretical predictions from Eq. 7.2 for 
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 Fig. 7.5 shows the IgG diffusion into the large LS-6 and LL-6 microcapsules that had 
diameters in the range of 500-600 μm and chitosan-alginate coacervation reaction times 
of 15 and 30 min, respectively. In contrast to the data of the large microcapsules shown in 
Fig. 7.5, all of the small and most large microcapsules (LS-12, LS-18, LL-6 and LL-18) 
completely excluded IgG ingress.  However, the large microcapsules (LS-6 and LL-6) 
allowed very slow IgG ingress and revealed that with an increase in the membrane 
thickness, IgG diffuses more slowly as shown in Fig. 7.5 and Table 7.5. The magnitude 
of τ  for IgG ingress is at least three orders of magnitude larger than that for vitamin B12
 
Figure 7.5 Representative plots of ingress of IgG into LS-6 and LL-6 microcapsules. The points 





















) being 0.99 and 0.97, respectively. 
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Characteristic time τ (min)  
Vitamin 
B Immunoglobulin 12 
Carbonic 
anhydrase 
SS-6 0.09 - 1.73 
SS-12 0.11 - 2.19 
SS-18 0.13 - 2.41 
SL-6 0.26 - 2.17 
SL-12 0.42 - 2.35 
SL-18 0.76 - 2.78 
LS-6 0.23 668 1.49 
LS-12 0.39 - 1.72 
LS-18 0.41 - 2.26 
LL-6 0.25 970 1.65 
LL-12 0.49 - 1.92 
LL-18 0.53 - 2.34 
 
“-“represents negligible diffusion (complete exclusion) of IgG into the microcapsules and thus no curve 
fitting was performed. 
 
 Representative profiles of the ingress of carbonic anhydrase through the large LS 
microcapsules that had diameters in the range of 500-600 µm and a chitosan-alginate 
coacervation reaction time of 15 min at different genipin crosslinking times are shown in 
Fig. 7.6. These profiles reveal that carbonic anhydrase diffuses faster than IgG and 
reaches equilibrium in approximately 10-15 minutes. As expected, CA shows slower 
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diffusion in microcapsules with higher genipin crosslinking time as shown by the τ  
values in Table 7.4. Also, the increase in membrane thickness slows down the CA ingress 
noticeably irrespective of microcapsule size. However, an important observation is that 
with an increase in the microcapsule size, diffusion of CA exhibits a completely opposite 
trend in comparison to vitamin B12
τ
. Specifically, at any genipin crosslinking time and 
membrane thickness,  decreases as the microcapsule size increases in case of CA 
ingress. This simply means that the ingress of CA is faster through the large 
microcapsules in comparison to the small microcapsules. The magnitude of τ  for CA is 
at least one order of magnitude larger than that of vitamin B12
 
.   
 
Figure 7.6 Representative plots of ingress of carbonic anhydrase into large GCA microcapsules. 
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for LS-6, LS-12, LS-18, microcapsules with correlation coefficient (R2
 In microcapsule-based protein delivery for biomedical applications, it is important to 
ensure efficient inward diffusion of nutrients (oxygen, vitamins, etc.), exclusion of 
immune-macromolecules (antibodies), removal of waste products (ammonia, etc.) and 
most importantly, outward diffusion of the therapeutic protein into the target site. 
Keeping this in mind, in this study we chose vitamin B





, IgG and CA as model 
biomolecules representing a nutrient, an antibody and a therapeutic protein, respectively. 
By varying the membrane properties (thickness and crosslinking density) and size of the 
microcapsules, the diffusive behavior of the biomolecules was evaluated. First, an 
increase in genipin crosslinking reaction time resulted in denser crosslinking and reduced 
the permeability, thus slowing down diffusion as indicated by an increasing  for all the 
three biomolecules. As discussed earlier, the increase in genipin crosslinking time only 
increased the crosslinking density and not the membrane thickness (which was already 
fixed by the alginate-chitosan coacervation reaction time). However, due to the large size 
of IgG (~150 kDa), most of the microcapsules (except LS-6 and LL-6, which had the 
shortest genipin reaction times) completely excluded its ingress, thus confirming the 
desired permselectivity property. Note that the microcapsules that allowed IgG ingress 
had a less dense membrane (low crosslinking density). This underscores the importance 
of membrane crosslinking density in providing favorable permselectivity to the 
microcapsules. Moreover, the slowing down of the diffusion rate (increase in τ ) of all 
the three biomolecules with an increase in membrane thickness can be attributed to the 
longer diffusion path length (or increased resistance to diffusion). Our study demonstrates 
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a simple yet effective way to control the membrane thickness by varying the alginate-
chitosan coacervation reaction time.  
 The mass transport behavior of the biomolecules with respect to the microcapsule size 
is intriguing. With an increase in microcapsule size, the tendency to swell resulted in 
increased permeability and diffusion path length. But vitamin B12
τ
 (MW of 1.5 kDa) 
being a small molecule did not experience any effect of the increased permeability. Large 
microcapsules experienced relatively greater swelling in comparison to the small 
microcapsules; hence, the increase in diffusion path length resulted in an increase in . In 
contrast, in case of IgG and CA, the effect of increased permeability due to swelling 
resulted in faster diffusion despite a longer diffusion path length with an increase in 
microcapsule size. This indicates that diffusion of large molecules such as IgG (MW of 
150 kDa) and CA (MW of 30 kDa) is controlled by the membrane permeability and not 
by the microcapsule size. Thus, small microcapsules that resist swelling and possess 
restricted permeability were able to slow down the diffusion of CA and in fact completely 
exclude the ingress of IgG.  These results suggest that small GCA microcapsules are 
better suited both to improve inward diffusion of small nutrient molecules and completely 
exclude ingress of immune-macromolecules such as IgG. In addition, small GCA 
microcapsules have higher permselectivity in comparison to other microcapsules such as 
APA, Ba-alginate and Ba-APA that can allow diffusion of molecules of molecular weight 
up to 300 kDa [Peirone et al., 1998]. 
 
7.3.5 Bio-molecular Egress from GCA Microcapsules 
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 Protein (CA) release from GCA microcapsules into the extra-capsular medium was 
measured and the data were fit to Eq. (7.1) and the characteristic time τ  obtained. Fig. 
7.7 shows representative data for the large LS microcapsules that had diameters in the 
range of 500-600 µm and a chitosan-alginate coacervation reaction time of 15 min. These 
data confirm the similarity in release rate between the egress and the ingress of CA. Table 
7.5 summarizes the τ  values for CA egress from all 12 GCA microcapsules that were 
studied. The egress of CA is observed to slow down (increase inτ ) as the microcapsules 
are subjected to longer genipin crosslinking times. The membrane thickness has a similar 
effect. Irrespective of the membrane density and microcapsule size, an increase in 
membrane thickness decreases the diffusion rate of CA from the microcapsules. Similar 
to CA ingress, the size of the microcapsules has a noticeable effect on the egress. As the 
microcapsule size increases, the diffusion of CA from the microcapsules seems to get 
faster (decrease inτ ). The increase in τ  for large relative to small microcapsules was 
around 9% to 25%. Nonetheless, the magnitude of τ  for CA egress is comparable to that 
of CA ingress. 
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Figure 7.7. Representative plots of egress of IgG into large GCA microcapsules. The points 
are experimental data and the solid curves are the theoretical predictions from Eq. 7.1 for LS-6, 
LS-12, LS-18, microcapsules with correlation coefficient (R2
τ
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 Similar to CA ingress, CA egress from the microcapsules (small and large) is 
decelerated (increase inτ ) with an increase in genipin crosslinking time due to the 
formation of denser crosslinks and reduced permeability. The decrease in τ  as the 
microcapsule size increases is consistent with the CA ingress results, probably due to 
improved permeability resulting from swelling as explained previously. These results 
underscore the importance of small microcapsules that display less swelling and better 
mechanical stability despite slightly reduced egress of CA. Other microcapsules such as 
APA [Rokstad et al., 2002; Li et al., 2006; Zhang et al., 2007; Ross and Chang, 2002] and 
Ba-APA [Peirone et al., 1998] have shown that neither the size nor the type of 
microcapsule affects the product egress significantly, which indicates low 
permselectivity. Two studies have shown that APA microcapsules with additional shell- 
or core-cross-linking [Mazumder et al., 2009] and AP-PMM50 microcapsules [Gardner et 
al., 2010] possess a molecular weight cut-off (MWCO) of around 100-200 kDa by using 
Dextran molecular markers. But the use of Dextrans to assess selectivity is not reflective 
of protein transport across the semi-permeable membrane due to factors such as surface 
charge, size variation for the same molecular weight, and conformation. Also, high 
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MWCO of 300 kDa for APA microcapsules [Awrey et al., 1996] and 150-247 kDa for 
alginate-PLL-pectin-PLL-alginate microcapsules [Ouyang et al., 2009] have been 
demonstrated, but this MWCO is not recommended for immunoisolation since the 
molecular weight of IgG is around 150 kDa.  APA microcapsules treated with growth 
factors and collagen did not improve the selectivity as it partially allowed the ingress of 
proteins of 150 to 300 kDa [Li et al., 2006], whereas only erythropoietin (34 kDa) was 
shown to be secreted from APA microcapsules encapsulating myoblasts [Ding et al., 
2007]. These studies demonstrate poor or no selectivity. APA microcapsules were shown 
to resist the diffusion of IgG, but the study was performed for only 1 hour [Yoshioka et 
al., 2003]. This experimental design and the analysis are erroneous because IgG is a 
macromolecule and its diffusion is slow. Typically, the diffusion should be monitored at 
least for 2 to 3 days to observe the real phenomena. However, one study by Yoshioka et 
al. has proven that APA(Ba) microcapsules completely excluded the ingress of 
components of anti-serum by demonstrating that the encapsulated cells were viable for at 
least 10 days [Yoshioka et al., 2003]. This study shows that the antibodies in the anti-
serum were excluded from ingress, however it lacks a systematic approach to control the 
permeability and to confirm it as compared to our diffusion studies bolstered by the 
mathematical modeling. Also, the GCA microcapsules can be produced with considerable 
control over membrane thickness, density and microcapsule size as demonstrated in this 
study. Since GCA microcapsules exhibit improved permselectivity, they could be better 
bioreactors for protein delivery in biomedical applications. However, this inference needs 
to be validated with the evaluation of GCA microcapsules in the presence of protein 
expressing cells. Also an optimization of GCA microcapsules in terms of protein 
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secretion and long term mechanical stability is warranted. Nevertheless, this study 
provides useful insight into the potential of GCA microcapsules with respect to nutrient 
diffusion, IgG exclusion and protein release in addition to aspects of controlling 
membrane permeability.  
 
7.4 Conclusions 
 In summary, GCA microcapsules were characterized and the effects of size, membrane 
density and thickness on permselectivity to three relevant biomolecules were studied. The 
three-step electrospray process, chitosan-alginate reaction and genipin crosslinking 
reaction were utilized to control the microcapsule size, membrane thickness and density. 
Scaling analysis was implemented to obtain an equation that permitted obtaining the 
diffusion coefficient and rate constant from measurements of the chitosan-alginate 
reaction shell thickness as a function of contact time. The fluoregenic genipin-chitosan 
membrane enabled its vivid characterization in terms of thickness and density of 
crosslinking by the aid of confocal microscopic imaging. Furthermore, biomolecular 
mass transport across the GCA microcapsules was described by the use of mathematical 
models based on the balance of chemical potential of the bio-molecule. Overall, the 
theoretical predictions fit the experimental results very well. GCA microcapsules allowed 
diffusion of small nutrient molecules (vitamin B12) and protein (CA) but completely 
excluded large antibodies (IgG), thereby displaying improved selectivity compared to 
other microcapsule types. Microcapsules with denser and thicker membranes showed 
increased resistance to diffusion of all three bio-molecules. Small microcapsules allowed 
better ingress of vitamin B12, whereas large microcapsules favored the diffusion of IgG 
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and CA due to swelling effects and the resultant increase in membrane permeability. 
Nevertheless, a follow-up study involving encapsulated cells in the alginate core should 
be carried out. This should encompass the detailed study on how membrane 
characteristics and microcapsule size affect protein expression and its subsequent release 
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CHAPTER 8 
CONCLUSIONS AND RECOMMENDATIONS 
8.1 General Conclusions  
 In this thesis, the critical but often overlooked dependence of transport properties of 
the chemotherapeutic drug in tumor tissue and drug release rate from biodegradable 
polymeric implants on treatment efficacy is explored and satisfactorily addressed in the 
instance of treating malignant brain tumors. Specifically, paclitaxel, a drug possessing 
favourable transport properties was successfully encapsulated in PLGA polymer and then 
micro/nano-structured to achieve near constant drug release rate and sufficient drug 
availability at the implant surface to aid effective drug diffusion into the tumor tissue. 
Finally, the effect of the enhanced drug penetration on treating intracranial glioblastoma 
in mice model was evaluated. In another study, the dependence of membrane properties 
and microcapsule size of GCA microcapsules on bio-molecular mass transport was 
studied. This study offers insight into the potential of GCA microcapsules as micro-
bioreactors expressing anti-angiogenic proteins such as PEX to treat malignant brain 
tumors.  
 
 In the first study (Chapter 4) paclitaxel was encapsulated in PLGA and micro/nano-
structured into fibers ranging from micron to nanometre in diameter. Electrospinning 
technique was exploited successfully to fabricate monodisperse fibers with high drug 
encapsulation efficiency. Paclitaxel in the fiber implants was in a molecular dispersion 
state ideal for diffusion from the polymer matrix. The fiber implants provided sustained 
paclitaxel release for more than 80 days with low initial burst which exhibits clear 
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advantage over conventional systemic delivery of Taxol®. Polymer degradation was 
pronounced in the submicrofiber discs/sheets in comparison to microfibers and hence 
exhibited faster release. At a cellular level, paclitaxel release from the fiber implants had 
a significantly stronger cytotoxic effect on C6 glioma cells as against acute Taxol®
 The initial drug burst from conventional polymeric microsphere-based implants has 
always been a concern due to its resultant toxicity. Hence in the context of this study, it 
seems relevant to not only overcome the initial burst, but at the same time to provide 
sufficiently high drug release at a constant rate sustainably. This challenge was met by 
the development of a novel, composite drug delivery implant (Chapter 5) where in the 
conventional PLGA-based paclitaxel-loaded microspheres were entrapped in an alginate 
gel matrix. This strategy was employed to serve twin purposes. Firstly, to inhibit the 
initial drug burst release due to surface bound paclitaxel and secondly, to provide 
implantability in the tumor resection cavity. While EHDA was employed to fabricate 
 
administration due to sustained paclitaxel-induced apoptosis. Similar effect of sustained 
paclitaxel cytotoxicity was demonstrated in mice with subcutaneous C6 glioma tumors. 
To further increase the paclitaxel release rate, the implants were nano-structured into 
nanofibers, but using two different PLGA co-polymers. It was shown that the co-polymer 
had very little effect on drug release rate compared to fiber diameter. But all the six 
dosage forms exhibited near constant drug release rate with small initial burst. Two 
formulations, paclitaxel-loaded PLGA 50:50 nanofiber (F3) and paclitaxel-loaded PLGA 
50:50 microfiber (F2) were screened for further in vivo characterizations owing to their 
favourable release profiles.  
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paclitaxel-loaded PLGA microspheres, the composite implant was fabricated using 
electrospray process in dripping mode followed by gelation process in CaCl2 solution.  
The implants (gel beads) were highly monodisperse with uniform microsphere 
distribution and high loading efficiency, all of these reflecting the efficiency of the 
electrospray process and gelation. Thermal analysis of the implants revealed the 
amorphous state of paclitaxel which could facilitate diffusion from the matrix. Release of 
paclitaxel from the hydrogel implant was controlled initially by the swelling of the 
implant resulting in the disintegration of the alginate matrix releasing the microspheres 
followed by PLGA degradation. Stronger beads produced using higher gelling bath 
concentration and/or gelation time disintegrated slowly. Implants with higher 
microsphere loading disintegrated faster. Hence it is suggestive of the fact that the extent 
of Ca2+ cross-linking controls the disintegration of the bead.  The swelling of the beads 
before disintegration resulted in minimum initial drug burst release because it increases 
the diffusion path length for the surface bound drug which would otherwise diffuse 
quickly from the microsphere surface. Overall, the paclitaxel release was sustainable for 
more than 60 days at a near-constant rate with minimum initial burst. The study also 
revealed that lower microsphere loading leads to easy bead disintegration and higher % 
cumulative paclitaxel release. At cellular level, IC50 study against C6 glioma cells 
showed that the beads could induce a similar cytotoxicity effect as Taxol® that overcomes 
the need for repeated drug administering. The bead implants also exhibited sustained 
paclitaxel-induced apoptosis in C6 glioma cells in vitro in comparison to acute Taxol® 
administration. Furthermore, subcutaneously implanted gel beads could reduce the 
tumour size in nude mice more effectively than Taxol® and the control.  
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 Subsequently, four formulations were screened from the previous studies to 
investigate their efficacies in providing optimal paclitaxel pharmacokinetics in 
brain/tumor tissue and treating intracranial glioblastoma in mice. The four formulations 
were paclitaxel-loaded PLGA microfiber disc (F2), paclitaxel-loaded PLGA 50:50 
nanofiber disc (F3), 80% (w/w) paclitaxel-PLGA microsphere loaded alginate hydrogel 
beads with medium (M80) and high (H80) cross-linking.  
 
 The four formulations, F2, F3, M80, and H80 possessing different paclitaxel release 
profiles were utilized to study the effect of drug release rate on the pharmacokinetics of 
paclitaxel in plasma as well as in the brain/tumor tissue (Chapter 6). The absence of 
paclitaxel in the plasma confirmed that the drug was highly localized at the target site. 
Enhanced, therapeutic paclitaxel penetration (~1 µM) in the mouse brain up to 5 mm 
from the implant site even after 42 days post-implantation from F3 and H80 was 
observed. The comparison of the experimental data with the simulation confirmed that 
the penetration was diffusion/elimination controlled and thus F2 and M80 implants 
possessing low drug release rates could not provide deeper penetration due to insufficient 
drug availability at the implant surface for diffusion. On the other hand, F3 and H80 
demonstrated deeper drug penetration owing to their sustained high drug concentration at 
the implant surface. As a result, F3 and H80 implants showed significant (~30 fold) 
tumor inhibition and significantly low tumor proliferation index after 41 days of 
treatment in comparison to sham and placebo controls. Hence this study elucidates the 
importance of developing local drug delivery devices from the perspective of drug 
transport and drug release rates, and not just on the basis of drug potency against the 
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tumor. Also, we have shown how micro/nano-structuring of polymeric implants could 
improve the drug availability at the implant surface and enhance drug 
diffusion/penetration in the tissue. Thus these micro/nano-structured implants are able to 
demonstrate optimal paclitaxel pharmacokinetics in the brain/tumor with significant 
tumor inhibition in a glioblastoma xenograft model in mice and hence could be 
potentially useful to treat highly recurrent GBM.  
 
 In another study, microcapsules with a calcium cross-linked alginate core and a 
genipin-chitosan membrane shell (GCA) were fabricated using an electrospray process 
followed by chitosan co-acervation and genipin cross-linking (Chapter 7). The primary 
objective however, was analyzing the effects of the membrane characteristics and 
microcapsule size on bio-molecular mass transport across these microcapsules using 
scaling analysis (to predict membrane thickness) and mathematical models based on a 
balance of chemical potential. The fluoregenic genipin-chitosan membrane was 
characterized by using confocal imaging microscopy. Vitamin B12, immunoglobulin 
(IgG) and carbonic anhydrase (CA) constituted the bio-molecules with diverse properties 
and were utilized as markers to study the mass transport phenomena. The models 
predicted the bio-molecular mass transport across the microcapsules well. Compared to 
other microcapsules, the GCA microcapsules possess greater selectivity for they allow 
diffusion of small molecules (vitamin B12) and protein (CA) but completely exclude large 
antibodies (IgG). Denser, thicker membranes resulting from a longer genipin cross-
linking time exhibited increased resistance to diffusion of all three bio-molecules. 
Interestingly, due to swelling effect and resulting increase in permeability, large 
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microcapsules allowed larger bio-molecules (IgG and CA) to diffuse more readily. But, 
in case of vitamin B12, a shorter diffusion path length was more important than the 
increased permeability due to its size and hence small microcapsules allowed better 
ingress of vitamin B12. These results elucidate the implications of controlling membrane 
properties and microcapsule size to realize favourable transport phenomena of bio-
molecules across the GCA microcapsules. 
 
8.2 Future Work and Recommendations 
8.2.1 Local Chemotherapy for GBM   
 Although we have shown enhanced paclitaxel penetration in the brain/tumor tissue 
because of micro/nano-structuring of PLGA based implants, there are a few areas for 
improvement and innovation. Most importantly, the concentration of the drug in the 
extracellular space (ECS) is not necessarily equal to the drug concentration within the 
tumor cells (Siepmann et al., 2006). Drug diffusion in the cell cytoplasm is known to be 
many orders of magnitude lower than in the ECS due to molecular crowding. Hence 
efforts should be made to improve the drug permeability in the cytoplasm. One potential 
method is to increase the lipophilicity of the drug by nano-encapsulation into liposomes 
or polymeric nanoparticles which could easily be uptaken by the tumor cells. This could 
be achieved by entrapping drug-loaded nanoparticles in hydrogel matrix and releasing 
them locally into the tumor tissue. The subsequent nanoparticle uptake by the tumor cells 
not only increases the drug concentration inside the tumor cells but also totally 
overcomes the diffusional limitations of the drug in the ECS, since the drug doesn’t have 
to diffuse from ECS into the cytoplasm.  
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 Secondly, instead of a single-modality therapy, a multi-modality approach such as 
chemo-anti-angiogenic therapy has to be employed since the GBM is inhibited from 
recurring and simultaneously the inhibition of angiogenesis is achieved. However, in 
local chemotherapy using polymeric implants, the danger of drug resistance is often the 
reason for low therapeutic efficacy despite prolonged exposure. This necessitates that a 
multitude of potent drugs targeting different GBM receptors must be released either 
sequentially or parallely. A very promising way to release two or more drugs is to 
encapsulate them co-axially within different polymers. Depending on the co-axial 
arrangement of polymers and drugs, a sequential or parallel drug release could be 
achieved. Dosage forms such as co-axial micro/nanofibers and/or co-axial microspheres 
could be very promising for local therapy involving a cocktail of drugs. EHDA process 
has been employed to achieve co-axial microspheres encapsulating a hydrophobic 
(paclitaxel) and a hydrophilic drug (suramin) and achieved desired release profiles 
(Hemin 2009).    
 
 Thirdly, evaluation of the implants must be done in larger animal models such as 
dogs or monkeys. Survival studies of the animals after treatment using the implants 
should be carried out to investigate the survival benefit. Larger animals are closer to 
human subjects and hence have higher translational relevance. Bio-imaging is one of the 
critical techniques of evaluating treatment efficacy. It can be used to quantify tumor 
volume, metabolism, proliferation and angiogenesis. Various available techniques are 
computerized tomography (CT), positron emission tomography (PET), luciferase imaging 
and magnetic resonance imaging (MRI). Often, any single technique is unable to 
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characterize the GBM with respect to its different aspects. Hence, two or more techniques 
could be fused together to accurately pin point the tumor location, quantify its 
metabolism, proliferation and angiogenesis using different markers. We recently have 
made one such effort by fusing images of mouse glioblastoma from CT and micro-PET 
(using 18F-FDG and 18F-Choline tracers). We showed that glioma-bearing mice showed a 
high tumor-to-background ratio for 18F-FCH (2.89±0.59). However 18
 
Figure 8.1 PET and BLI images of a representative normal mouse (A-D) and glioblastoma-
bearing mice (E-H). A and E: 
F -FCH uptake was 
observed in some sections of the normal brain (Fu et al., 2009).  
 
18F -FDG images; B and F: 18F -FCH images; C and G: fusion 18F -
FCH/18
 In tumor tissues however, their corresponding 
F -FDG images; D and H: BLI images.  T denotes tumor (adapted from Fu et al., 2009).  
 
18F-FDG uptake was also elevated 
(1.63±0.04, 1.47±0.07 and 1.36±0.05 vs. averaged value, 1.00±0.02, in normal mouse 
brains) thus avoiding potential false positives. The use of a dual tracer methodology 
could be used to identify and quantify tumor metabolism in the brain. 18F-FCH identifies 
potential tumors while 18F-FDG confirms the presence of tumor by providing information 
on its increased glucose metabolism. However, larger sample size, broader spectrum of 
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animal models and sensitivity analysis are warranted to evaluate the diagnostic and 
prognostic value of this technique in patients presenting with intracranial masses.  
 
 Fourthly, the above discussed animal studies are highly labour intensive, expensive 
and present high variability. This necessitates the development of highly realistic 
mathematical models that enables the prediction of chemotherapeutic drug 
transport/distribution in human brain tumors. Some improvements to be made on the 
existing models are: 1) anisotropic and spatially varied drug diffusion and convective 
flow due to the heterogeneity of the brain tissue (Linninger et al., 2008) and tumor 
vasculature (Zhao et al., 2007); 2) preferential binding of the drug to the brain tissue; 3) 
effects of the type of formulation (drug loading, size and geometry). Ideally, models with 
these improvements could significantly reduce the number of animals required for in vivo 
studies.  
 
8.2.2 Local Anti-angiogenic Therapy for GBM using PEX Protein 
 In this study, we have done a preliminary evaluation of the GCA microcapsules with 
regards to perm-selectivity and mechanical stability. The logical continuation would thus 
be: 1) encapsulating the PEX producing QM7 cells in GCA microcapsules; 2) evaluate 
the long term mechanical stability; 3) optimize the GCA microcapsules in terms of PEX 
protein expression/release and capsule integrity.  
 
 Recently, we successfully transfected the QM7 cells with pM9PEX plasmid 
(generous gift from Peking University School of Oncology). PEX protein expression in 
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cell lysis solution and supernatant were analysed using western blot and shown in Figure 
8.2. The band represents PEX protein (~ 30 kDa) and it is observed that PEX protein was 
successfully expressed and was extracellular in nature that is ideal for protein therapy 
applications.  
 
Figure 8.2 Western blot analysis of PEX protein in: A) cell lysis (intracellular) solution; B) 
supernatant (extracellular).  
 
 Successful encapsulation of QM7 cells inside of GCA microcapsules was achieved 
through electrospray followed by Ca2+
            
Figure 8.3 Confocal images of GCA microcapsules encapsulating QM7 cells. (A) LS-6; (B) LS-
12; (C) LS-18.  
 
 
 gelation, alginate-chitosan coacervation and 
genipin cross-linking. Figure 8.3 shows that the cells were uniformly dispersed in the 
microcapsules.  
 The cell micro-encapsulated GCA microcapsules were suspended in growth medium 
for ten days to ensure sufficient cell viability before they are subjected to differentiation 
medium to result in terminal differentiation of the cells. Figure 8.3 shows that LS-6 and 
LS-12 microcapsules possessed better cell viability (green fluorescence in the 
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microcapsules) after 21 days in differentiation medium compared to LS-18. This 
confirms that 18 hours of genipin cross-linking reaction might affect the cell viability. 
However, quantification confirmation is needed. Future studies involve the evaluation of 
long term capsular integrity, cell viability and protein release to optimize the GCA 
microcapsules. Specifically the GCA microcapsules will be optimized to achieve optimal 
therapeutic PEX release and capsular integrity.  
 
 A better understanding of the PEX release from GCA microcapsules is intended to be 
obtained through mathematical modelling. It comprises of a micro-scale model of PEX 
release from individual QM7 cells which can then be incorporated into a macro-scale 
model of the GCA microcapsule to predict the PEX release from the microcapsules. Also, 
the effect of microcapsule size and membrane properties on the PEX release could be 
studied. Finally, evaluation of the GCA microcapsules releasing PEX protein on a 
cellular and animal level could be carried out. Specifically, the effect of sustained PEX 
release on inhibition of angiogenesis, glioma invasion and proliferation would be studied. 
Additionally, PEX delivering GCA microcapsules could be implanted along with 
paclitaxel delivering implants (discussed in the thesis) to bring about synergetic effect of 
chemo/anti-angiogenic therapy to inhibit GBM growth, proliferation, invasion and 
recurrence. The GCA microcapsules could also be employed to encapsulate more than 
one type of cell capable of releasing a cocktail of agents to treat GBM.  
 
 Finally, it would be interesting to study the scale-up potential of the EHDA process. 
This would enable to produce drug/protein-loaded polymeric implants in large scale.  
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